🏷

Classifications

ICD-O Morphology

◆

Subtypes

3

Alpha Heavy Chain Disease (IPSID / Mediterranean Lymphoma) MONDO:0015045

The commonest heavy chain disease, secreting a truncated IgA (alpha) heavy chain. It presents as immunoproliferative small intestinal disease (IPSID), an extranodal marginal zone (MALT-type) lymphoma of the proximal small bowel causing chronic diarrhoea, malabsorption, and weight loss in young adults of Mediterranean, North African, and Middle Eastern origin. Chronic enteric infection - Campylobacter jejuni most convincingly - drives the antigen-dependent early phase, which is antibiotic responsive; untreated disease progresses to lymphoplasmacytic and immunoblastic lymphoma invading the bowel wall and mesenteric nodes.

Show evidence (2 references)

PMID:29326807 SUPPORT Human Clinical

"Alpha-HCD is the most common and usually occurs as intestinal malabsorption in a young adult from a country of the Mediterranean area."

Defines alpha-HCD as the commonest subtype with its characteristic malabsorptive presentation and geographic distribution.

PMID:15542584 SUPPORT Human Clinical

"Most untreated IPSID patients progress to lymphoplasmacytic and immunoblastic lymphoma invading the intestinal wall and mesenteric lymph nodes, and may metastasize to a distant organ."

Establishes the progression from antibiotic-responsive early disease to aggressive lymphoma that defines the alpha-HCD natural history.

Gamma Heavy Chain Disease (Franklin Disease) MONDO:0015046

Franklin disease, secreting a truncated IgG (gamma) heavy chain. It is diagnosed at a median age in the seventh decade with a female predominance and is nearly always accompanied by an underlying lymphoplasmacytic neoplasm. Roughly a quarter of patients have a coexisting autoimmune disease - most often rheumatoid arthritis, less often Sjogren syndrome, systemic lupus erythematosus, vasculitis, myasthenia gravis, or autoimmune cytopenias - whose manifestations frequently precede the HCD diagnosis by years. Clinical patterns range from disseminated lymphoma with constitutional symptoms, generalised lymphadenopathy, splenomegaly, and hepatomegaly, to localised medullary or extramedullary (commonly cutaneous) disease. Palatal oedema from involvement of the Waldeyer's ring lymphoid tissue is a classically reported sign.

Show evidence (2 references)

PMID:29326807 SUPPORT Human Clinical

"It is uncommon, with approximately 130 cases reported in the literature, being the age at diagnosis between 51 and 68 years, with a female predominance."

Establishes the rarity, age range, and female predominance that characterise gamma-HCD.

PMID:22301495 SUPPORT Human Clinical

"Gamma heavy-chain disease (gHCD) is defined as a lymphoplasmacytic neoplasm that produces an abnormally truncated immunoglobulin gamma heavy-chain protein that lacks associated light chains."

Pathology-series definition of gamma-HCD as a lymphoplasmacytic neoplasm secreting a truncated, light-chain-free gamma chain.

Mu Heavy Chain Disease MONDO:0015044

The rarest heavy chain disease, with only 30-40 reported cases, secreting a truncated IgM (mu) heavy chain. It occurs predominantly in older men and almost always arises in a marrow lymphoid neoplasm resembling chronic lymphocytic leukaemia / small lymphocytic lymphoma; MYD88 L265P has been reported in individual cases, which has been argued to place at least some of them closer to lymphoplasmacytic lymphoma / Waldenstrom macroglobulinaemia than to CLL. Vacuolated bone marrow plasma cells admixed with small round lymphocytes are the characteristic morphology. Unlike the other subtypes, Bence Jones proteinuria is frequent, because the clone continues to make monoclonal (usually kappa) light chains that cannot assemble with the CH1-deleted heavy chain.

Show evidence (2 references)

PMID:29326807 SUPPORT Human Clinical

"The disease occurs predominantly in Caucasian males, with a median age of 58 years at diagnosis."

Establishes the demographic profile of mu-HCD.

PMID:35932039 SUPPORT Human Clinical

"Mu heavy chain disease is a rare lymphoid neoplasm characterized by vacuolated bone marrow plasma cells and secretion of defective mu immunoglobulin heavy chains."

Defines mu-HCD by its two hallmarks: vacuolated marrow plasma cells and secretion of a defective mu heavy chain.

◈

Mechanistic Hypotheses

1

Antigen-independent BCR signalling by the truncated heavy chain

antigen_independent_bcr_signaling EMERGING

Evidence balance 2 support

The hypothesis that the membrane form of the CH1-deleted heavy chain, as part of the B-cell receptor, aggregates and signals in the absence of antigen, giving the clone a ligand-independent survival advantage. If true, the CH1 lesion is an oncogenic driver rather than only a secretory-escape event, and it would explain progression that continues after eradication of the initiating antigen. Not demonstrated in human HCD tissue.

Pathograph links

Loss of the CH1 Domain and Failure of Light Chain Pairing -> Antigen-Independent B-Cell Receptor Aggregation The same CH1-deleted chain, in its membrane-anchored form, is the substrate proposed to aggregate within the B-cell receptor without antigen.

Antigen-Independent B-Cell Receptor Aggregation -> Clonal Lymphoplasmacytic B-Cell Expansion Antigen-independent BCR signalling is proposed to sustain the clone once the initiating antigen drive is removed.

Show evidence (2 references)

PMID:29326807 SUPPORT Human Clinical

"In addition, recent work suggests that the altered heavy chain, which forms part of the transmembrane B -cell receptor, may facilitate antigen -independent aggregation and"

The review presents the mechanism as suggested rather than established.

PMID:29326807 SUPPORT Human Clinical

"down-stream signaling by the receptor, thereby conferring a growth advantage to neoplastic cells."

The continuation of the same sentence across a PDF page break in the cached review, carrying the growth-advantage claim itself. Quoted as a separate item because the page break makes a single contiguous quote impossible.

?

Discussions and Knowledge Gaps

3

Is the CH1-deleted heavy chain merely a secretory-escape by-product, or is its membrane form an oncogenic driver that sustains the clone through antigen-independent B-cell receptor signalling?

KNOWLEDGE GAP OPEN hcd_ch1_membrane_form_oncogenic_driver

Attached to

pathophysiology#Antigen-Independent B-Cell Receptor Aggregation

The distinction determines whether the CH1 lesion is a diagnostic marker or a therapeutic target, and whether antimicrobial therapy alone can be curative once the lesion is established. It would also explain why a subset of alpha-HCD progresses despite eradication of the driving organism. The proposal currently rests on suggestion in a review rather than direct demonstration in human HCD tissue.

Proposed experiments

Single-cell BCR and transcriptomic profiling of HCD clones

hcd_single_cell_bcr_tonic_signalling

Profile HCD clones at single-cell resolution alongside matched lymphoplasmacytic and MALT lymphoma controls, testing whether the HCD clone shows tonic, ligand-independent BCR pathway activation.

Decision criterion

Selective enrichment of BCR-pathway activation signatures in HCD clones relative to light-chain-competent controls would support the driver model.

Engineered CH1-deleted heavy chain constructs in B-cell lines

hcd_ch1_deleted_construct_aggregation

Express CH1-deleted heavy chain constructs in B-cell lines and assay directly for antigen-independent receptor aggregation and downstream signalling.

Decision criterion

Demonstration of spontaneous receptor clustering and downstream signalling in the absence of antigen would establish the mechanism in a controlled system.

Show evidence (2 references)

PMID:29326807 SUPPORT Human Clinical

"In addition, recent work suggests that the altered heavy chain, which forms part of the transmembrane B -cell receptor, may facilitate antigen -independent aggregation and"

Documents the state of the art: the mechanism is offered as a suggestion, not a demonstration, which is what leaves the gap open.

PMID:29326807 SUPPORT Human Clinical

"down-stream signaling by the receptor, thereby conferring a growth advantage to neoplastic cells."

The continuation of the same sentence across a PDF page break in the cached review, carrying the growth-advantage claim itself. Quoted as a separate item because the page break makes a single contiguous quote impossible.

What is the true population incidence of each heavy chain disease subtype, and how much of the reported geographic and sex skew is ascertainment bias?

KNOWLEDGE GAP OPEN hcd_population_incidence_unknown

Attached to

pathophysiology#Clonal Lymphoplasmacytic B-Cell Expansion

Every published figure is a cumulative literature case count (more than 400 alpha, about 130 gamma, 30-40 mu), not a rate. Mu-HCD is explicitly suspected to be under-ascertained because the truncated chain is missed on serum protein electrophoresis, so its reported median survival of about two years is probably an underestimate. Without denominators, neither prognosis nor treatment effect can be estimated reliably.

Proposed experiments

International HCD registry with centralised confirmation

hcd_international_registry

Establish a multinational registry with centralised mass-spectrometric and immunofixation confirmation of every submitted case and contemporary outcome capture.

Decision criterion

Denominator-based incidence estimates and outcome curves that are stable across contributing regions.

Reflex immunoselection in discordant monoclonal gammopathies

hcd_reflex_immunoselection_ascertainment

Apply systematic reflex immunoselection in laboratories reporting monoclonal gammopathies with discordant heavy-chain and light-chain quantitation, to estimate how many HCD cases current practice misses.

Decision criterion

A measurable yield of previously unrecognised free heavy chains would quantify the ascertainment shortfall.

Show evidence (1 reference)

PMID:29326807 SUPPORT Human Clinical

"It is the most common of the three HCDs, with more than 400 cases described in the literature since its initial description in 1968."

Illustrates that the best available epidemiological figures are cumulative literature case counts rather than population rates.

Is Campylobacter jejuni causal in alpha-HCD/IPSID, or a marker of the poor sanitation and polymicrobial enteric colonisation that constitute the real antigenic drive?

KNOWLEDGE GAP OPEN hcd_campylobacter_causality

Attached to

pathophysiology#Chronic Enteric Antigenic Stimulation

The C. jejuni association is well documented and antibiotic responsiveness is consistent with an antigen-driven mechanism, but reviewers explicitly note controversy about the organism's pathogenetic role, and contemporary cases have found several concomitant enteric pathogens rather than C. jejuni alone. Resolving this determines whether targeted eradication or broad decolonisation is the rational therapy.

Proposed experiments

Metagenomic sequencing of IPSID small-bowel biopsies

hcd_ipsid_metagenomics

Sequence the small-bowel microbiome of IPSID patients and geographically matched controls to test whether C. jejuni is specifically enriched relative to overall enteric microbial burden.

Decision criterion

Specific enrichment of C. jejuni beyond the general increase in enteric burden would support a causal role.

Organism-specific eradication versus histological remission

hcd_targeted_eradication_cohort

Prospectively correlate documented organism-specific eradication with histological remission versus persistence in a multicentre IPSID cohort.

Decision criterion

Remission tracking C. jejuni clearance specifically, rather than broad antimicrobial exposure, would support causality.

Show evidence (1 reference)

PMID:29372346 SUPPORT Human Clinical

"A link between Campylobacter jejuni infection and IPSID has been established, but there is controversy as to the role played by this organism in disease pathogenesis."

States the controversy explicitly, which is the gap this discussion records.

⚙

Pathophysiology

11

Chronic Enteric Antigenic Stimulation

In alpha-HCD/IPSID, persistent bacterial (most convincingly Campylobacter jejuni, sometimes Helicobacter pylori) or parasitic colonisation of the proximal small bowel provides sustained antigenic drive to mucosa-associated lymphoid tissue. The epidemiological concentration of the disease in low-socioeconomic Mediterranean, North African, and Middle Eastern populations, and the responsiveness of early disease to antimicrobials, both support an antigen-driven initiating step. This is the same chronic-infection-driven lymphomagenesis logic as Helicobacter pylori and gastric MALT lymphoma. Neither organism has been shown to be necessary or sufficient in every case.

Inflammatory Response GO:0006954 ↑ INCREASED immunoglobulin production in mucosal tissue GO:0002426 ↑ INCREASED

lamina propria of small intestine UBERON:0001238

Downstream

Clonal Lymphoplasmacytic B-Cell Expansion Sustained mucosal antigen exposure selects and expands an IgA-committed mucosal B-cell/plasma-cell clone.

Show evidence (3 references)

PMID:14724303 SUPPORT Human Clinical

"Analysis of frozen intestinal tissue obtained from an index patient with immunoproliferative small intestinal disease who had a dramatic response to antibiotics revealed the presence of Campylobacter jejuni."

The landmark observation linking C. jejuni to antibiotic-responsive IPSID, establishing chronic enteric infection as the antigenic trigger.

PMID:14724303 SUPPORT Human Clinical

"These results indicate that campylobacter and immunoproliferative small intestinal disease are associated and that C. jejuni should be added to the growing list of human pathogens responsible for immunoproliferative states."

States the association explicitly and places IPSID among the infection-driven immunoproliferative disorders.

PMID:29372346 SUPPORT Human Clinical

"A link between Campylobacter jejuni infection and IPSID has been established, but there is controversy as to the role played by this organism in disease pathogenesis."

Confirms the association while explicitly qualifying its causal weight, which is why this node is modelled as a trigger rather than a necessary cause.

Chronic Autoimmune B-Cell Stimulation

In gamma-HCD, a coexisting autoimmune disease - rheumatoid arthritis most often, then Sjogren syndrome, systemic lupus erythematosus, vasculitis, myasthenia gravis, and autoimmune cytopenias - is present in about a quarter of patients and its manifestations typically precede the HCD diagnosis by years. Chronic autoimmune B-cell stimulation is therefore the plausible gamma-HCD counterpart of the enteric-infection drive in alpha-HCD, but the temporal ordering is not proof of causation and the direction of the relationship remains formally unresolved.

Inflammatory Response GO:0006954 ↑ INCREASED positive regulation of B cell proliferation GO:0030890 ↑ INCREASED

Downstream

Clonal Lymphoplasmacytic B-Cell Expansion Chronic autoimmune B-cell stimulation is proposed to favour emergence of the lymphoplasmacytic clone; directionality is not established.

Rheumatoid Arthritis Rheumatoid arthritis is the commonest clinical expression of the autoimmune context in gamma-HCD.

Show evidence (2 references)

PMID:29326807 SUPPORT Human Clinical

"The manifestations of the associated autoimmune disease often herald the diagnosis of γ -HCD by many years."

Documents that autoimmune manifestations typically precede the gamma-HCD diagnosis, motivating the trigger role assigned to this node.

PMID:22301495 SUPPORT Human Clinical

"Clinically, patients showed a female predominance (85%) with frequent occurrence of autoimmune disease (69%)."

Quantifies the autoimmune association in a dedicated gamma-HCD pathology series.

Clonal Lymphoplasmacytic B-Cell Expansion

A mature B-cell/plasmacytic clone expands in the small-intestinal lamina propria (alpha-HCD), in marrow, spleen, lymph nodes, and extranodal sites (gamma-HCD), or in the bone marrow as a CLL/SLL-like or lymphoplasmacytic neoplasm (mu-HCD). The expanding clone is the substrate within which the heavy-chain gene lesion is acquired and selected.

plasma cell CL:0000786 neoplastic B cell CL:0000236

MYD88 hgnc:7562

positive regulation of B cell proliferation GO:0030890 ↑ INCREASED immunoglobulin production GO:0002377 ↑ INCREASED

Downstream

Somatic Immunoglobulin Heavy Chain Gene Deletion Somatic hypermutation acting on the expanding clone generates the CH1-disrupting IGH lesion.

Lymphoplasmacytic Tissue Infiltration The expanding clone infiltrates gut lamina propria, marrow, spleen, and lymph nodes.

Show evidence (2 references)

PMID:29326807 SUPPORT Human Clinical

"The heavy chain diseases (HCDs) are rare B-cell malignancies characterized by the production of a monoclonal immunoglobulin heavy chain without an associated light chain."

Establishes that HCD is a clonal B-cell neoplasm secreting the abnormal heavy chain, i.e. that a neoplastic clone is the cell of origin.

PMID:15542584 SUPPORT Human Clinical

"Cytogenetic studies demonstrated clonal rearrangements involving predominantly the heavy and light chain genes, including t(9;14) translocation involving the PAX5 gene."

Demonstrates clonality of the proliferating population in alpha-HCD/IPSID.

Somatic Immunoglobulin Heavy Chain Gene Deletion

Deletions, insertions, and point mutations acquired somatically during somatic hypermutation of the rearranged IGH locus (14q32.33) remove a large portion of the sequence encoding the first constant (CH1) domain, and in alpha-HCD frequently the variable (VH) region as well. These are clone-specific somatic structural lesions of the rearranged immunoglobulin genes, not constitutional pathogenic variants; no germline predisposing variant is established for HCD. Terminology caveat: GO:0016446 is defined for hypermutation of the rearranged V regions, whereas the HCD lesion falls in the CH1 constant domain. The term is used here for the somatic hypermutation machinery that the source identifies as the origin of the lesion, not to assert that the mutations lie in V.

IGHA1 hgnc:5478 IGHG1 hgnc:5525 IGHM hgnc:5541

somatic hypermutation of immunoglobulin genes GO:0016446 ⚠ ABNORMAL

Downstream

Loss of the CH1 Domain and Failure of Light Chain Pairing Deletion of CH1-encoding sequence yields a heavy chain protein lacking the light-chain-binding domain.

Show evidence (2 references)

PMID:29326807 SUPPORT Human Clinical

"The altered heavy chains contain deletions, insertions, and point mutations that are acquired during somatic hypermutation."

Identifies somatic hypermutation of the rearranged IGH locus as the origin of the structural lesion.

PMID:15542584 SUPPORT Human Clinical

"The encoding gene sequence reveals a deletion of V region and parts of C(H)1 domain."

Direct sequence-level demonstration that the CH1-encoding region is deleted in the alpha-HCD clone.

Loss of the CH1 Domain and Failure of Light Chain Pairing

CH1 is the heavy-chain constant domain that pairs with the light-chain constant (CL) domain, and the two are covalently joined by an interchain disulfide bond. CH1 is unusual among immunoglobulin domains in being intrinsically unfolded in isolation: it acquires structure only on association with a folded CL domain, in a reaction rate-limited by isomerisation of a conserved proline. A heavy chain that has lost CH1 has therefore lost the only interface through which it can engage light chain, and the resulting molecule is a light-chain-free heavy chain - the defining lesion shared by all three HCD subtypes.

Antigen-independent BCR signalling by the truncated heavy chain

endoplasmic reticulum lumen GO:0005788

Downstream

Escape from BiP-Dependent ER Quality Control Without CH1 there is no stably unfolded domain for BiP to hold, so the chain is no longer retained.

Antigen-Independent B-Cell Receptor Aggregation The same CH1-deleted chain, in its membrane-anchored form, is the substrate proposed to aggregate within the B-cell receptor without antigen.

Show evidence (3 references)

PMID:29326807 SUPPORT Human Clinical

"These structural abnormalities typically result in loss of a large portion of the constant -1 (CH1) domain of the Ig heavy chain molecule responsible for LC binding"

States that CH1 loss is the typical structural abnormality and that CH1 is the domain responsible for light-chain binding.

PMID:33596645 SUPPORT Human Clinical

"Normal immunoglobulin is composed of two heavy chains and two light chains joined by disulfide bonds at the heavy chain constant domain 1 (CH1)."

Establishes CH1 as the heavy-chain/light-chain pairing interface whose loss abolishes assembly.

PMID:19524537 SUPPORT In Vitro

"In vivo experiments demonstrate that requirements identified for folding the C(H)1 domain in vitro, including association with a folded C(L) domain and isomerization of a conserved proline residue, are essential for antibody assembly and secretion in the cell."

Biophysical and cell-biological demonstration that CH1 folds only on association with CL, explaining why CH1 loss abolishes pairing.

Escape from BiP-Dependent ER Quality Control

Normally, an unpaired heavy chain is trapped in the endoplasmic reticulum: the unfolded CH1 domain permanently exposes chaperone-binding sites, the Hsp70 chaperone BiP/GRP78 binds it stably (its ATPase cycle stalled until light chain arrives), and the retained chain is routed to proteasomal degradation, which is why free heavy chains are never found in normal serum or urine. A CH1-deleted chain presents no such binding surface. It binds neither light chain nor BiP, bypasses ER retention and degradation, and enters the secretory pathway. This is the mechanistic core of every heavy chain disease.

protein folding in endoplasmic reticulum GO:0034975 ⚠ ABNORMAL ERAD pathway GO:0036503 ↓ DECREASED

BiP chaperone binding by the unpaired heavy chain GO:0051087 ↓ DECREASED

endoplasmic reticulum lumen GO:0005788

Downstream

Secretion of Truncated Light Chain Free Heavy Chain Having escaped retention and degradation, the truncated chain transits the secretory pathway and reaches serum and urine.

Show evidence (6 references)

PMID:33596645 SUPPORT Human Clinical

"In the absence of light chains, the heat shock protein BiP binds to CH1 and retains the heavy chain in the endoplasmic reticulum."

States the normal BiP/CH1 retention mechanism that the HCD lesion subverts.

PMID:33596645 SUPPORT Human Clinical

"In HCD various mutations are responsible of splicing error leading to complete or partial deletion of CH1 and preventing therefore the binding of heavy chains to light chains as well as BiP."

States the disease lesion directly: CH1 deletion prevents binding of both light chain and BiP.

PMID:29326807 SUPPORT Human Clinical

"Regular heavy chains unassociated with LCs are therefore never detected in serum or urine."

Establishes the normal outcome (no free heavy chain in body fluids) whose failure defines HCD.

+ 3 more references

Secretion of Truncated Light Chain Free Heavy Chain

The CH1-deleted heavy chain is exported into serum and urine as a monoclonal paraprotein that reacts with isotype-specific anti-IgA, anti-IgG, or anti-mu antiserum but with neither anti-kappa nor anti-lambda antiserum. This light-chain-free monoclonal heavy chain is the pathognomonic and diagnosis-defining finding of heavy chain disease. Because the truncated chain is small and may fail to form a discrete band, serum protein electrophoresis is frequently normal or shows only a broad band, so immunofixation with immunoselection - not electrophoresis - is the diagnostic test.

plasma cell CL:0000786

protein secretion GO:0009306 ↑ INCREASED

Downstream

IgA Heavy Chain Paraproteinemia Alpha-HCD secretes a truncated IgA heavy chain.

IgG Heavy Chain Paraproteinemia Gamma-HCD secretes a truncated IgG heavy chain.

IgM Heavy Chain Paraproteinemia Mu-HCD secretes a truncated IgM heavy chain.

Unassembled Free Light Chain Excess In mu-HCD the clone keeps producing light chains that the truncated heavy chain cannot assemble with, leaving them free.

Show evidence (2 references)

PMID:29326807 SUPPORT Human Clinical

"the altered structure of the CH1 domain prevents the heavy chain from binding both the LC and HSP78"

States the escape-and-secretion step. Note the review's "HSP78" is a naming slip for the ER chaperone BiP/GRP78 (HSPA5); the BiP identity is taken from the primary sources cited on the upstream node.

PMID:16026747 SUPPORT Human Clinical

"Diagnosis of HCD requires documentation of a deleted immunoglobulin heavy chain without a bound light chain in the serum or urine."

Confirms the secreted light-chain-free truncated heavy chain as the diagnosis-defining finding.

Antigen-Independent B-Cell Receptor Aggregation

A proposed self-reinforcing arm: the membrane-anchored form of the truncated heavy chain, incorporated into the B-cell receptor, has been suggested to aggregate and signal without antigen, conferring a ligand-independent growth and survival advantage on the clone. This would make the CH1 lesion not just a secretory-escape event but an oncogenic driver in its own right, and would explain why disease can progress after the initiating antigen (for example C. jejuni) has been eradicated. The proposal is not established in human HCD tissue and is recorded here as an emerging hypothesis.

Antigen-independent BCR signalling by the truncated heavy chain

B cell receptor signaling pathway GO:0050853 ↑ INCREASED

Downstream

Clonal Lymphoplasmacytic B-Cell Expansion Antigen-independent BCR signalling is proposed to sustain the clone once the initiating antigen drive is removed.

Show evidence (2 references)

PMID:29326807 SUPPORT Human Clinical

"In addition, recent work suggests that the altered heavy chain, which forms part of the transmembrane B -cell receptor, may facilitate antigen -independent aggregation and"

The review flags this as suggested by recent work rather than established, which is why the node is marked HYPOTHETICAL.

PMID:29326807 SUPPORT Human Clinical

"down-stream signaling by the receptor, thereby conferring a growth advantage to neoplastic cells."

The continuation of the same sentence across a PDF page break in the cached review, carrying the growth-advantage claim itself. Quoted as a separate item because the page break makes a single contiguous quote impossible.

Lymphoplasmacytic Tissue Infiltration

The neoplastic clone infiltrates tissue in a subtype-specific distribution. In alpha-HCD a dense plasma-cell-rich lymphoplasmacytic infiltrate fills the lamina propria of the duodenum and jejunum, admixed with marginal-zone-like small lymphocytes and sometimes lymphoepithelial lesions; the infiltrate causes villous atrophy and hence malabsorption. In gamma-HCD the infiltrate involves bone marrow, spleen, lymph nodes, and extranodal sites including skin and the Waldeyer's ring lymphoid tissue. In mu-HCD marrow infiltration by a CLL/SLL-like population with vacuolated plasma cells produces cytopenias, with splenomegaly and hepatomegaly.

IgA plasma cell CL:0000987 marginal zone-like B cell CL:0000845

lamina propria of small intestine UBERON:0001238 duodenum UBERON:0002114 jejunum UBERON:0002115

Downstream

Villous Atrophy The lamina propria infiltrate flattens the small-bowel villi.

Malabsorption Villous atrophy and mucosal infiltration impair nutrient absorption.

Ascites Advanced disease with profound hypoalbuminaemia produces ascites.

Anasarca The hypoalbuminaemia of advanced malabsorptive disease produces anasarca.

Chronic Diarrhea Mucosal infiltration and malabsorption produce chronic diarrhoea.

Abdominal Pain Bowel wall infiltration causes abdominal discomfort and pain.

Weight Loss Malabsorption and mucosal disease drive progressive weight loss.

Growth Delay Chronic malabsorption in adolescents and young adults retards growth.

Lymphadenopathy Nodal infiltration produces mesenteric and generalised lymphadenopathy.

Splenomegaly Splenic infiltration produces splenomegaly.

Hepatomegaly Hepatic and portal infiltration produces hepatomegaly.

Anemia Marrow infiltration plus malabsorptive iron and vitamin deficiency produces anaemia.

Autoimmune Hemolytic Anemia In gamma-HCD, marrow infiltration is accompanied by Coombs-positive autoimmune haemolytic anaemia and other autoimmune cytopenias.

Thrombocytopenia Marrow infiltration and the autoimmune diathesis of gamma-HCD produce thrombocytopenia alongside the anaemias.

Palatal Edema Infiltration of the Waldeyer's ring lymphoid tissue produces oedema of the soft palate in gamma-HCD.

Recurrent Respiratory Infections Marrow replacement and failure of normal immunoglobulin production predispose to recurrent respiratory infection in mu-HCD.

Transformation to Aggressive Lymphoma Untreated mucosal disease progresses to transmural and disseminated high-grade lymphoma.

Show evidence (3 references)

PMID:29326807 SUPPORT Human Clinical

"A lymphoplasmacytic infiltrate rich in plasma cells can be detected in the lamina propria of the bowel, and lymphoepithelial lesions may also be present."

Describes the lamina propria infiltrate that constitutes the tissue lesion of alpha-HCD.

PMID:29326807 SUPPORT Human Clinical

"villous atrophy and is admixed with small lymphocytes, resembling marginal zone B cells."

Links the infiltrate to villous atrophy and identifies the marginal-zone-like component.

PMID:15542584 SUPPORT Human Clinical

"IPSID is a variant of the B-cell lymphoma of mucosa-associated lymphoid tissue (MALT), which involves mainly the proximal small intestine resulting in malabsorption, diarrhea, and abdominal pain."

Directly links proximal small-intestinal involvement to the malabsorption, diarrhoea, and abdominal pain phenotypes wired downstream of this node.

Unassembled Free Light Chain Excess

A mu-HCD-specific and superficially paradoxical consequence of the same lesion. The clone continues to synthesise monoclonal light chains, usually kappa, but the CH1-deleted mu chain cannot assemble with them. The unassembled light chains are secreted freely, filtered at the glomerulus, and appear in the urine as Bence Jones protein - so a disease defined by a heavy-chain defect commonly presents with light-chain proteinuria, sometimes with cast nephropathy or amyloidosis. This does not occur in alpha-HCD, where Bence Jones proteinuria has never been reported.

Downstream

Bence Jones Proteinuria Free unassembled monoclonal light chains are filtered and excreted as Bence Jones protein.

Show evidence (2 references)

PMID:29326807 SUPPORT Human Clinical

"the neoplastic cells also produce monoclonal LCs, usually of kappa type, that fail to assemble with the truncated heavy chain"

States the mechanism: light chains are still made but cannot assemble with the truncated heavy chain, so they are excreted free.

PMID:29326807 SUPPORT Human Clinical

"as well as in urine in only small amounts, but Bence Jones proteinuria has never been detected."

Establishes the contrast with alpha-HCD, in which free light chains are not excreted.

Transformation to Aggressive Lymphoma

IPSID is generally regarded as a pre-lymphomatous condition. Untreated or antibiotic-refractory alpha-HCD progresses from an antigen-dependent mucosal lesion to lymphoplasmacytic and immunoblastic lymphoma invading the bowel wall and mesenteric nodes, with distant spread; the same transformation accounts for constitutional symptoms and for death from obstruction, perforation, cachexia, and infection. Gamma-HCD shows an analogous spectrum, with disseminated lymphoma and constitutional symptoms in roughly two-thirds of patients. Recent reports of longstanding non-progressive IPSID show the transformation is not obligate.

Downstream

Fever Disseminated lymphoma produces constitutional symptoms including fever.

Intestinal Obstruction Enlargement of the lymphomatous mass obstructs the small bowel, and may also perforate or intussuscept.

Show evidence (2 references)

PMID:15542584 SUPPORT Human Clinical

"Most untreated IPSID patients progress to lymphoplasmacytic and immunoblastic lymphoma invading the intestinal wall and mesenteric lymph nodes, and may metastasize to a distant organ."

Documents the transformation step and its anatomic pattern.

PMID:29372346 SUPPORT Human Clinical

"IPSID is typically regarded as a pre-lymphomatous condition with eventual progression to frank lymphoma; however, recent reports of longstanding non-progressive cases have expanded its clinical spectrum."

Supports the pre-lymphomatous framing while establishing that transformation is not obligate.

✶

Histopathology

4

Lamina Propria Lymphoplasmacytic Infiltrate

A dense plasma-cell-rich lymphoplasmacytic infiltrate expands the lamina propria of the duodenum and jejunum, admixed with small lymphocytes resembling marginal zone B cells, with lymphoepithelial lesions in some cases. The infiltrating plasma cells and marginal zone cells express monoclonal cytoplasmic alpha chain without light chains, which is the immunohistochemical confirmation of the diagnosis.

Show evidence (1 reference)

PMID:29326807 SUPPORT Human Clinical

"A lymphoplasmacytic infiltrate rich in plasma cells can be detected in the lamina propria of the bowel, and lymphoepithelial lesions may also be present."

Describes the diagnostic histology of alpha-HCD/IPSID.

Villous Atrophy

The lamina propria infiltrate flattens the small-bowel villi. Villous atrophy is the histological substrate of malabsorption in alpha-HCD and is the shared feature that makes celiac disease the principal differential diagnosis on biopsy.

Show evidence (1 reference)

PMID:29326807 SUPPORT Human Clinical

"villous atrophy and is admixed with small lymphocytes, resembling marginal zone B cells."

States that the infiltrate causes villous atrophy and describes its composition.

Vacuolated Bone Marrow Plasma Cells

Bone marrow smears and touch preparations show plasma cells with prominent cytoplasmic vacuoles admixed with small round lymphocytes. This is the characteristic - and in practice the most useful - morphological clue to mu-HCD, prompting the immunoselection studies that establish the diagnosis.

Show evidence (2 references)

PMID:29326807 SUPPORT Human Clinical

"Bone marrow smears and touch preparations show characteristic plasma cells with prominent cytoplasmic vacuoles admixed with small, round lymphocytes."

Describes the pathognomonic marrow morphology of mu-HCD.

PMID:33596645 SUPPORT Human Clinical

"the presence of vacuolated plasma cells in the bone marrow was highly suggestive of"

Confirms the diagnostic value of the vacuolated plasma cell morphology in practice.

Polymorphous Lymphoplasmacytic Neoplasm

Gamma-HCD is most often associated with a polymorphous neoplasm of small lymphocytes, plasmacytoid lymphocytes, and plasma cells that is hard to classify with certainty and overlaps with "vaguely nodular, polymorphous" lymphoplasmacytic lymphoma; a minority of cases show the features of another defined WHO entity. Immunoblasts, eosinophils, histiocytes, and occasional Reed-Sternberg-like cells may be present, which is why Hodgkin lymphoma and peripheral T-cell lymphoma enter the differential.

Show evidence (1 reference)

PMID:22301495 SUPPORT Human Clinical

"Histologically, 8 cases (61%) contained a morphologically similar neoplasm of small lymphocytes, plasmacytoid lymphocytes, and plasma cells that was difficult to classify with certainty, whereas the remaining 5 cases (39%) showed the typical features of one of several other well-defined entities..."

Defines the morphological spectrum of the gamma-HCD-associated neoplasm.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

23

Blood 3

Anemia FREQUENT HP:0001903

Show evidence (1 reference)

PMID:29326807 SUPPORT Human Clinical

"Common laboratory abnormalities include mild -to-moderate hypochromic anemia, deficiency of vitamins and minerals"

Names hypochromic anaemia as a "common" laboratory abnormality of alpha-HCD. Per the frequency-evidence guidelines the qualitative term "common" maps to FREQUENT (30-79%).

Thrombocytopenia HP:0001873

Show evidence (1 reference)

PMID:29326807 SUPPORT Human Clinical

"These comprise cytopenias, in particular, normochromic normocytic anemia, Coombs-positive autoimmune hemolytic anemia, and thrombocytopenia."

Names thrombocytopenia among the cytopenias detected during diagnostic work-up of gamma-HCD.

Autoimmune Hemolytic Anemia HP:0001890

Show evidence (1 reference)

PMID:29326807 SUPPORT Human Clinical

"These comprise cytopenias, in particular, normochromic normocytic anemia, Coombs-positive autoimmune hemolytic anemia, and thrombocytopenia."

Names Coombs-positive autoimmune haemolytic anaemia among the cytopenias detected during diagnostic work-up of gamma-HCD.

Cardiovascular 2

Lymphadenopathy FREQUENT HP:0002716

Show evidence (2 references)

PMID:29326807 SUPPORT Human Clinical

"Palpable, superficial lymphadenopathy can be identified in 40% of the patients."

Quantifies lymphadenopathy in mu-HCD, supporting the FREQUENT band.

PMID:12861101 SUPPORT Human Clinical

"At the time of diagnosis, lymphadenopathy was present in 8 patients, splenomegaly in 7, and hepatomegaly in 1."

Direct case counts for lymphadenopathy in a 23-patient gamma-HCD series.

Splenomegaly FREQUENT HP:0001744

Show evidence (2 references)

PMID:29326807 SUPPORT Human Clinical

"Splenomegaly is frequent, and hepatomegaly can be found in about 25%."

States splenomegaly as frequent in mu-HCD, supporting the FREQUENT band.

PMID:12861101 SUPPORT Human Clinical

"At the time of diagnosis, lymphadenopathy was present in 8 patients, splenomegaly in 7, and hepatomegaly in 1."

Case counts for splenomegaly in a gamma-HCD series.

Digestive 5

Chronic Diarrhea VERY_FREQUENT HP:0002028

Temporal: CHRONIC

Show evidence (2 references)

PMID:15542584 SUPPORT Human Clinical

"IPSID is a variant of the B-cell lymphoma of mucosa-associated lymphoid tissue (MALT), which involves mainly the proximal small intestine resulting in malabsorption, diarrhea, and abdominal pain."

Lists diarrhoea among the defining consequences of proximal small intestinal involvement.

PMID:29326807 SUPPORT Human Clinical

"Malabsorption syndrome with weight loss that can cause growth retardation, amenorrhea, alopecia, diarrhea, and abdominal discomfort are the typical symptoms of gastrointestinal"

Names diarrhoea among the typical symptoms of gastrointestinal alpha-HCD, supporting the VERY_FREQUENT band.

Malabsorption VERY_FREQUENT HP:0002024

Show evidence (2 references)

PMID:29326807 SUPPORT Human Clinical

"Alpha-HCD is the most common and usually occurs as intestinal malabsorption in a young adult from a country of the Mediterranean area."

Malabsorption is stated as the usual presenting syndrome of alpha-HCD, supporting the VERY_FREQUENT band.

PMID:15542584 SUPPORT Human Clinical

"which involves mainly the proximal small intestine resulting in malabsorption, diarrhea, and abdominal pain"

Links malabsorption mechanistically to proximal small bowel disease.

Hepatomegaly OCCASIONAL HP:0002240

Show evidence (1 reference)

PMID:29326807 SUPPORT Human Clinical

"Splenomegaly is frequent, and hepatomegaly can be found in about 25%."

Quantifies hepatomegaly at about 25% in mu-HCD, supporting the OCCASIONAL band.

Ascites HP:0001541

Show evidence (1 reference)

PMID:29326807 SUPPORT Human Clinical

"HCD, ascites and anasarca can be detected at the physical examination."

Names ascites as a physical finding of advanced gastrointestinal alpha-HCD.

Intestinal Obstruction HP:0005214

Show evidence (1 reference)

PMID:29326807 SUPPORT Human Clinical

"Small bowel obstruction, perforat ion, and intussusception that can be fatal are the dreadful local complications of enlargement of the lymphomatous tissue."

Names small bowel obstruction as a fatal local complication of the enlarging lymphomatous mass.

Immune 1

Recurrent Respiratory Infections VERY_RARE HP:0002205

Temporal: RECURRENT

Show evidence (1 reference)

PMID:29326807 SUPPORT Human Clinical

"Rare associations of µ-HCD with recurrent pulmonary infections"

The review explicitly calls this a "rare" association, which per the frequency-evidence guidelines maps to VERY_RARE (1-4%).

Metabolism 1

Fever FREQUENT HP:0001945

Show evidence (1 reference)

PMID:29326807 SUPPORT Human Clinical

"In 57% to 66% of patients, a disseminated lymphoma associated with constitutional symptoms (i.e., fever, malaise, and weight loss) is present."

Quantifies the constitutional syndrome, including fever, at 57-66% of gamma-HCD patients, supporting the FREQUENT band.

Constitutional 1

Abdominal Pain FREQUENT HP:0002027

Show evidence (1 reference)

PMID:15542584 SUPPORT Human Clinical

"which involves mainly the proximal small intestine resulting in malabsorption, diarrhea, and abdominal pain"

Names abdominal pain as one of the three cardinal consequences of small intestinal involvement.

Growth 2

Weight Loss FREQUENT HP:0001824

Course: PROGRESSIVE

Show evidence (2 references)

PMID:29326807 SUPPORT Human Clinical

"Malabsorption syndrome with weight loss that can cause growth retardation, amenorrhea, alopecia, diarrhea, and abdominal discomfort are the typical symptoms of gastrointestinal"

Names weight loss as a typical symptom of gastrointestinal alpha-HCD.

PMID:29326807 SUPPORT Human Clinical

"In 57% to 66% of patients, a disseminated lymphoma associated with constitutional symptoms (i.e., fever, malaise, and weight loss) is present."

Quantifies weight loss as part of the constitutional syndrome of disseminated gamma-HCD.

Growth Delay HP:0001510

Show evidence (1 reference)

PMID:29326807 SUPPORT Human Clinical

"Malabsorption syndrome with weight loss that can cause growth retardation, amenorrhea, alopecia, diarrhea, and abdominal discomfort are the typical symptoms of gastrointestinal"

Attributes growth retardation directly to the malabsorption syndrome of alpha-HCD.

Other 8

IgA Heavy Chain Paraproteinemia HP:0020194

Show evidence (2 references)

PMID:14724303 SUPPORT Human Clinical

"Immunoproliferative small intestinal disease (also known as alpha chain disease) is a form of lymphoma that arises in small intestinal mucosa-associated lymphoid tissue (MALT) and is associated with the expression of a monotypic truncated immunoglobulin alpha heavy chain without an associated..."

Defines the alpha-HCD paraprotein as a monotypic truncated alpha heavy chain without light chain.

PMID:15542584 SUPPORT Human Clinical

"IPSID lymphomas reveal excessive plasma cell differentiation and produce truncated alpha heavy chain proteins lacking the light chains as well as the first constant domain."

Ties the paraprotein directly to loss of the first constant (CH1) domain.

IgG Heavy Chain Paraproteinemia HP:0020195

Show evidence (2 references)

PMID:12861101 SUPPORT Human Clinical

"gamma-Heavy chain was documented by immunofixation in the serum of all patients"

In a 23-patient series the gamma heavy chain was demonstrable by serum immunofixation in every case, establishing it as the defining laboratory finding.

PMID:12861101 SUPPORT Human Clinical

"gamma-Heavy chain was present in the urine in 19 of 22 patients."

Quantifies urinary excretion of the truncated gamma chain in the same series.

IgM Heavy Chain Paraproteinemia HP:0020196

Show evidence (2 references)

PMID:33596645 SUPPORT Human Clinical

"Serum immuno-selection confirmed the presence of m-heavy chain"

Demonstrates the immunoselection technique required to detect the free mu heavy chain in mu-HCD. The cached full text renders the Greek mu as "m".

PMID:35932039 SUPPORT Human Clinical

"Identification of the truncated mu immunoglobulin was facilitated by mass spectrometric analysis of the patient's serum."

Confirms the truncated mu chain as the analyte and illustrates a modern detection approach.

Villous Atrophy FREQUENT HP:0011473

Show evidence (1 reference)

PMID:29326807 SUPPORT Human Clinical

"villous atrophy and is admixed with small lymphocytes, resembling marginal zone B cells."

States that the lamina propria infiltrate causes villous atrophy. The FREQUENT band reflects that the review presents villous atrophy as a characteristic but not invariable consequence of the infiltrate.

Anasarca HP:0012050

Show evidence (1 reference)

PMID:29326807 SUPPORT Human Clinical

"HCD, ascites and anasarca can be detected at the physical examination."

Names anasarca as a physical finding of advanced gastrointestinal alpha-HCD.

Rheumatoid Arthritis OCCASIONAL HP:0001370

Show evidence (2 references)

PMID:29326807 SUPPORT Human Clinical

"An autoimmune disease such as rheumatoid arthritis (the most common), Sjögren syndrome,"

Names rheumatoid arthritis as the most common autoimmune association of gamma-HCD.

PMID:22301495 SUPPORT Human Clinical

"Clinically, patients showed a female predominance (85%) with frequent occurrence of autoimmune disease (69%)."

Quantifies the autoimmune association in a 13-case gamma-HCD pathology series.

Bence Jones Proteinuria FREQUENT HP:0030156

Show evidence (2 references)

PMID:29326807 SUPPORT Human Clinical

"Bence Jones proteinuria is frequently detected"

States directly that Bence Jones proteinuria is frequent in mu-HCD, supporting the FREQUENT band.

PMID:33596645 SUPPORT Human Clinical

"Urine protein immuno-electrophoresis revealed Bence Jones proteinuria."

A case in which light-chain proteinuria was the presenting abnormality that ultimately revealed mu-HCD.

Palatal Edema Abnormal soft palate morphology HP:0100736

Show evidence (1 reference)

PMID:29472805 SUPPORT Human Clinical

"We describe a case of a challenging diagnosis of γ-HCD due to the absence of clinical signs frequently reported in the disease (anaemia and palatal oedema among others)."

Attests that palatal oedema is a frequently reported clinical sign of gamma-HCD. Marked PARTIAL because the attestation is incidental - the reported case in fact lacked the sign - and no quantitative series was located.

🧬

Genetic Associations

5

IGHA1

Gene: IGHA1 hgnc:5478 relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC

Show evidence (1 reference)

PMID:15542584 SUPPORT Human Clinical

"The corresponding mRNA lacks the variable heavy chain (V(H)) and the constant heavy chain 1 (C(H)1) sequences and contains deletions as well as insertions of unknown origin."

Transcript-level demonstration of the VH and CH1 deletion in the alpha heavy chain gene.

IGHG1

Gene: IGHG1 hgnc:5525 relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC

Show evidence (1 reference)

PMID:22301495 SUPPORT Human Clinical

"Gamma heavy-chain disease (gHCD) is defined as a lymphoplasmacytic neoplasm that produces an abnormally truncated immunoglobulin gamma heavy-chain protein that lacks associated light chains."

Establishes the truncated gamma heavy chain protein as the product of the lesioned gamma heavy chain gene.

IGHM

Gene: IGHM hgnc:5541 relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC

Show evidence (1 reference)

PMID:35932039 SUPPORT Human Clinical

"Mu heavy chain disease is a rare lymphoid neoplasm characterized by vacuolated bone marrow plasma cells and secretion of defective mu immunoglobulin heavy chains."

Establishes the defective mu heavy chain as the gene product defining the subtype.

MYD88

Gene: MYD88 hgnc:7562 relationship_type: COOPERATING variant_origin: SOMATIC

Show evidence (2 references)

PMID:35932039 SUPPORT Human Clinical

"We report a case of mu heavy chain disease with MYD88 L265P mutation and deletion of 6q, genetic aberrations that are both strongly associated with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia."

Documents MYD88 L265P in mu-HCD and its implication for classifying the underlying clone.

PMID:33596645 SUPPORT Human Clinical

"The screening for L265P mutation of MYD88 was positive."

Independent confirmation of MYD88 L265P in a mu-HCD case with an underlying Waldenstrom macroglobulinaemia clone.

PAX5

Gene: PAX5 hgnc:8619 relationship_type: DISPUTED variant_origin: SOMATIC

Show evidence (2 references)

PMID:15542584 SUPPORT Human Clinical

"Cytogenetic studies demonstrated clonal rearrangements involving predominantly the heavy and light chain genes, including t(9;14) translocation involving the PAX5 gene."

Documents the t(9;14)/PAX5 rearrangement in IPSID.

PMID:29372346 SUPPORT Human Clinical

"While cytogenetic abnormalities involving various immunoglobulin loci and PAX5 have been reported, these have been described in rare, single cases, limiting their ability to shed further light on disease pathogenesis."

Qualifies the PAX5 finding as a rare single-case observation, which is why it is typed DISPUTED rather than a driver.

💊

Medical Actions

9

Antimicrobial Therapy for Early Alpha-HCD

Action: antibiotic therapy Ontology label: Antibiotic Therapy NCIT:C15620

Agent: metronidazole CHEBI:6909 ampicillin CHEBI:28971 tetracycline CHEBI:27902

First-line treatment of early-stage alpha-HCD/IPSID, and the therapeutic expression of its antigen-driven pathogenesis. Any documented bacterial or parasitic gastrointestinal infection is eradicated; empirical treatment with metronidazole, ampicillin, or tetracycline is commonly given even without a demonstrated organism. A six-month course is recommended, since shorter courses relapse. Clinical, laboratory, and histological remission is achieved in 33-71% of early-stage patients, though recurrence is frequent. These are historical regimen choices and require contemporary susceptibility, safety, and antimicrobial-stewardship review.

Mechanism Target:

INHIBITS Chronic Enteric Antigenic Stimulation — Eradicating the driving enteric organism removes the antigenic stimulus sustaining the clone, which is why early antigen-dependent disease regresses.

Show evidence (2 references)

PMID:29326807 SUPPORT Human Clinical

"Metronidazole, ampicillin, or tetracycline are the antibiotics of choice for this empiric therapy."

Names the empirical antimicrobial regimens used in alpha-HCD.

PMID:15542584 SUPPORT Human Clinical

"Early-stage IPSID responds to antibiotics (30%-70% complete remission)."

Quantifies the complete remission rate of early-stage IPSID with antibiotics.

Doxorubicin-Containing Combination Chemotherapy

Action: chemotherapy Ontology label: Chemotherapy NCIT:C15632 Regimen: CHOP regimen Ontology label: CHOP Regimen NCIT:C9549

Agent: cyclophosphamide CHEBI:4027 doxorubicin CHEBI:28748 vincristine CHEBI:28445 prednisone CHEBI:8382

For alpha-HCD that is refractory to antimicrobials, bulky, or transformed, and for aggressive gamma-HCD. CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) is the standard backbone, with rituximab added in CD20-positive disease; CHVP and ABV are historical alternatives. Total abdominal radiation is an alternative for refractory alpha-HCD. There is no randomised trial evidence in HCD; regimens are adapted from infection-associated MALT lymphoma and other B-cell neoplasms.

Mechanism Target:

INHIBITS Transformation to Aggressive Lymphoma — Cytotoxic chemotherapy is directed at the transformed high-grade lymphoma that antimicrobial therapy cannot control.

Show evidence (2 references)

PMID:29326807 SUPPORT Human Clinical

"Refractory disease is treated with either total abdominal radiation"

Establishes the escalation pathway for antimicrobial-refractory alpha-HCD.

PMID:29326807 SUPPORT Human Clinical

"CHOP regimen (with rituximab in CD20 - positive cases) shows the best results in aggressive/refractory patients."

Identifies CHOP with rituximab as the best-performing regimen in aggressive or refractory gamma-HCD.

Rituximab-Based Immunotherapy

Action: monoclonal antibody therapy Ontology label: Monoclonal Antibody Therapy NCIT:C15490

Agent: rituximab NCIT:C1702

Anti-CD20 monoclonal antibody therapy for CD20-positive gamma-HCD, used alone or with chemotherapy. Fludarabine plus rituximab has been reported effective in gamma-HCD complicated by pancytopenia.

Mechanism Target:

INHIBITS Clonal Lymphoplasmacytic B-Cell Expansion — Anti-CD20 depletes the CD20-positive neoplastic B-cell clone.

Show evidence (1 reference)

PMID:29326807 SUPPORT Human Clinical

"Chlorambucil, or melphalan and prednisone, or bortezomib and prednisone , and rituximab in CD20 -positive disease are the treatment of choice for plasma cell"

Identifies rituximab as treatment of choice for CD20-positive plasma-cell-predominant gamma-HCD.

Alkylator and Proteasome-Inhibitor Therapy for Plasma-Cell-Predominant Gamma-HCD

Action: chemotherapy Ontology label: Chemotherapy NCIT:C15632

Agent: chlorambucil CHEBI:28830 melphalan CHEBI:28876 prednisone CHEBI:8382 bortezomib CHEBI:52717

For gamma-HCD in which the underlying neoplasm is plasma-cell predominant rather than a disseminated aggressive lymphoma, the treatments of choice are chlorambucil, melphalan plus prednisone, or bortezomib plus prednisone. A single-institution series has also reported responses to modern myeloma- and lymphoma-derived regimens including CRd (cyclophosphamide, lenalidomide, dexamethasone), CyBorD, R-CVP, bendamustine-rituximab, and V-EPOCH.

Mechanism Target:

INHIBITS Clonal Lymphoplasmacytic B-Cell Expansion — Alkylator and proteasome-inhibitor therapy is directed at the plasma-cell-predominant clone rather than at an antigenic trigger.

Show evidence (2 references)

PMID:29326807 SUPPORT Human Clinical

"Chlorambucil, or melphalan and prednisone, or bortezomib and prednisone , and rituximab in CD20 -positive disease are the treatment of choice for plasma cell"

Names the alkylator and proteasome-inhibitor options as treatment of choice for plasma-cell-predominant gamma-HCD.

PMID:32245744 SUPPORT Human Clinical

"Herein we present a review of the literature and 5 consecutive cases at a single institution of gamma heavy chain disease and heavy chain deposition disease treated with novel agents including regimens of CRd (cyclophosphamide, lenalidomide, and dexamethasone), CyBorD (cyclophosphamide,..."

A contemporary single-institution series enumerating the novel-agent regimens actually used in gamma-HCD.

Autologous Hematopoietic Stem Cell Transplantation

Action: hematopoietic stem cell transplantation Ontology label: Hematopoietic Cell Transplantation NCIT:C15431

High-dose therapy with autologous haematopoietic stem cell transplantation should be considered for refractory or relapsing disease. Evidence is limited to case-level experience; there is no trial-level support in any HCD subtype.

Mechanism Target:

INHIBITS Clonal Lymphoplasmacytic B-Cell Expansion — High-dose conditioning is intended to eradicate the refractory clone, with autologous rescue.

Show evidence (1 reference)

PMID:29326807 SUPPORT Human Clinical

"For patients with a refractory or relapsing disease, high -dose therapy with autologous hematopoietic stem cell transplantation should be considered."

Recommends autologous HSCT for refractory or relapsing disease. Marked PARTIAL because the recommendation is expert opinion without trial-level support.

Radiation Therapy

Action: radiation therapy Ontology label: Radiation Therapy NCIT:C15313

Radiotherapy has two distinct roles in HCD. In alpha-HCD it is used as total abdominal radiation for disease refractory to antimicrobials, as an alternative to doxorubicin-containing chemotherapy. In gamma-HCD it is used as local radiation for localised extranodal disease, where surgical resection is the other option. As with every HCD treatment, the evidence is case-level and adapted from related B-cell neoplasms.

Mechanism Target:

INHIBITS Lymphoplasmacytic Tissue Infiltration — Radiation is directed at the bulk of infiltrating neoplastic tissue, whether diffusely in the abdomen or at a localised extranodal site.

Show evidence (2 references)

PMID:29326807 SUPPORT Human Clinical

"Refractory disease is treated with either total abdominal radiation"

Establishes total abdominal radiation as an option for antimicrobial-refractory alpha-HCD.

PMID:29326807 SUPPORT Human Clinical

"While surgical resection or radiation therapy have been successfully employed in patients with localized extra-nodal disease"

Establishes local radiation as a successful option for localised extranodal gamma-HCD.

Surgical Resection and Management of Bowel Complications

Action: surgical procedure Ontology label: Surgical Procedure NCIT:C15329

Surgery has two roles. In localised extranodal gamma-HCD, surgical resection is a definitive option alongside radiation. In alpha-HCD it is complication-directed rather than disease-directed: small bowel obstruction, perforation, and intussusception arising from enlargement of the lymphomatous tissue are the dreadful and potentially fatal local complications that require operative management.

Mechanism Target:

INHIBITS Lymphoplasmacytic Tissue Infiltration — In localised extranodal gamma-HCD, resection removes the infiltrating neoplastic tissue itself and can be definitive.

INHIBITS Transformation to Aggressive Lymphoma — In alpha-HCD, surgery is complication-directed: it relieves the mechanical bowel complications produced by the enlarging lymphomatous mass.

Show evidence (2 references)

PMID:29326807 SUPPORT Human Clinical

"While surgical resection or radiation therapy have been successfully employed in patients with localized extra-nodal disease"

Establishes surgical resection as a successful option for localised extranodal gamma-HCD.

PMID:29326807 SUPPORT Human Clinical

"Small bowel obstruction, perforat ion, and intussusception that can be fatal are the dreadful local complications of enlargement of the lymphomatous tissue."

Names the mechanical bowel complications of alpha-HCD that require operative management.

Observation and Watchful Waiting

Appropriate for asymptomatic gamma-HCD without an overt lymphoma, and for asymptomatic mu-HCD in which a monoclonal mu chain is detected incidentally. Some gamma-HCD patients without overt lymphoma undergo spontaneous remission and survive for prolonged periods untreated; in the Mayo series, treatment was judged unnecessary in five of 23 patients, and median survival in that series was 7.4 years.

Show evidence (2 references)

PMID:12861101 SUPPORT Human Clinical

"For 5 patients, treatment was not felt to be necessary; 2 patients were thought to be too sick for treatment."

Documents that a subset of gamma-HCD patients are appropriately managed without treatment.

PMID:12861101 SUPPORT Human Clinical

"Median survival was 7.4 years."

Provides the survival benchmark against which observation is judged reasonable in gamma-HCD.

Nutritional and Supportive Care

Action: dietary intervention Ontology label: Dietary Intervention NCIT:C15447

Correction of malnutrition, electrolyte disturbance (hypocalcaemia, hypokalaemia, hypomagnesaemia), hypoalbuminaemia, and vitamin and mineral deficiency is essential in alpha-HCD, in which severe malnutrition and cachexia are recognised causes of death alongside infection and mechanical bowel complications.

Show evidence (1 reference)

PMID:29326807 SUPPORT Human Clinical

"Other potential causes of death are severe malnutrition and subsequent cachexia, as well as infectious complications."

Establishes malnutrition and cachexia as causes of death, motivating nutritional support as a treatment component.

🌍

Environmental Factors

2

Chronic Campylobacter jejuni infection

Persistent small-bowel colonisation by Campylobacter jejuni is the best-supported environmental factor in alpha-HCD/IPSID. It was identified by PCR, sequencing, FISH, and immunohistochemistry in an index patient with a dramatic response to antibiotics and in four of six further archival cases, and persistent colonisation has since been documented in contemporary cases. Its causal weight remains debated and it is neither necessary nor sufficient in every case.

Show evidence (2 references)

PMID:14724303 SUPPORT Human Clinical

"A follow-up retrospective analysis of archival intestinal-biopsy specimens disclosed campylobacter species in four of six additional patients with immunoproliferative small intestinal disease."

Quantifies detection of campylobacter in an IPSID case series beyond the index patient.

PMID:39176219 SUPPORT Human Clinical

"We report a rare case of GI αHCD with 5 concomitant pathogens identified on a GI multiplex real-time polymerase chain reaction panel, featured by persistent Campylobacter jejuni colonization and refractory giardiasis."

A contemporary case documenting persistent C. jejuni colonisation in alpha-HCD alongside other enteric pathogens.

Mechanism Target:

TRIGGERS Chronic Enteric Antigenic Stimulation — The node names this organism as the most convincingly implicated source of the sustained antigenic drive it describes, so colonisation by it is the node's own content. Both items are graded partial rather than supporting, and the exposure's own description gives the reason better than the grade can: the causal weight remains debated, and the organism is neither necessary nor sufficient in every case. What the evidence establishes is detection and persistence, not causation. The triggering effect and the directness are therefore inherited from the node, which names this organism as the antigenic drive it describes, rather than asserted by any cited sentence.

Show evidence (4 references)

PMID:14724303 SUPPORT Human Clinical

"A follow-up retrospective analysis of archival intestinal-biopsy specimens disclosed campylobacter species in four of six additional patients with immunoproliferative small intestinal disease."

Retrospective analysis finding the organism in four of six further archival cases beyond the index patient. Detection in a small series, which is the evidential ceiling for this exposure.

PMID:14724303 SUPPORT Human Clinical

"These results indicate that campylobacter and immunoproliferative small intestinal disease are associated and that C. jejuni should be added to the growing list of human pathogens responsible for immunoproliferative states"

The study's own conclusion, which is the strongest wording it offers: the organism and the disease are associated, and it should be added to the list of pathogens responsible for immunoproliferative states. Associated is the operative word, and it is why this is partial.

PMID:29372346 SUPPORT Human Clinical

"A link between Campylobacter jejuni infection and IPSID has been established, but there is controversy as to the role played by this organism in disease pathogenesis"

Carried on this link so that the dispute travels with the claim rather than sitting apart from it: the link is established, and the organism's role in pathogenesis is contested. That is the honest state of this exposure and the reason no item here is graded supporting.

+ 1 more reference

Low socioeconomic conditions and poor sanitation

Alpha-HCD is strikingly concentrated in Mediterranean, North African, and Middle Eastern populations of low socioeconomic background, an epidemiological pattern that itself argues for an environmental, probably infectious, pathogenetic mechanism. Improved sanitation is biologically plausible as primary prevention but has never been shown prospectively to prevent HCD.

Show evidence (1 reference)

PMID:29326807 SUPPORT Human Clinical

"particularly those of low socio-economic background, suggesting an environmental, possibly infectious, pathogenetic mechanism."

States the socioeconomic association and its interpretation as evidence for an environmental/infectious mechanism.

Mechanism Target:

PREDISPOSES Chronic Enteric Antigenic Stimulation — Graded below the organism link into this same node, which is the right order but worth stating plainly: this exposure is an epidemiological pattern rather than an agent. Its value is that the pattern itself argues for an environmental and probably infectious mechanism, which is what makes it a claim about this node at all rather than only about who gets the disease. The entry is candid that improved sanitation has never been shown prospectively to prevent it.

Show evidence (1 reference)

PMID:29326807 SUPPORT Human Clinical

"particularly those of low socio-economic background, suggesting an environmental, possibly infectious, pathogenetic mechanism."

States the socioeconomic concentration of the disease and reads it as suggesting an environmental, possibly infectious, mechanism. The inference to this node is the source's own, and it is offered as a suggestion.

🔬

Biochemical Markers

3

Light Chain Free Monoclonal Heavy Chain on Immunofixation

Show evidence (2 references)

PMID:16026747 SUPPORT Human Clinical

"Diagnosis of HCD requires documentation of a deleted immunoglobulin heavy chain without a bound light chain in the serum or urine."

States the diagnostic requirement that defines this biochemical marker.

PMID:33596645 SUPPORT Human Clinical

"In order to detect heavy chains devoid of light chains on immuno-electrophoresis, immuno-selection techniques and the use of specific anti-light chains anti-serum are required."

Explains why immunoselection rather than routine electrophoresis is required to make the diagnosis.

Elevated Serum Free Light Chains

Show evidence (1 reference)

PMID:33596645 SUPPORT Human Clinical

"The dissociation between the sFLC level and the absence of a peak on SPEP was unusual."

Describes the free-light-chain/electrophoresis dissociation that characterises mu-HCD.

Malabsorptive Biochemical Deficit

Show evidence (1 reference)

PMID:29326807 SUPPORT Human Clinical

"electrolytic disorders (i.e., hypoalbuminemia, hypocalcemia, hypokalemia, and hypomagnesemia)."

Lists the biochemical deficits produced by malabsorption in alpha-HCD.

🔬

Diagnosis

2

Immunofixation with immunoselection of serum and urine

The diagnostic cornerstone. Serum protein electrophoresis is performed first but can be entirely normal, hypogammaglobulinaemic, or show only a broad band in the alpha-2/beta region, and therefore cannot exclude HCD. The diagnosis requires demonstrating isotype-specific heavy chain reactivity (anti-IgA, anti-IgG, or anti-mu) with no corresponding kappa or lambda reactivity in serum or urine, using immunoselection or two-dimensional immunoelectrophoresis. Mass spectrometry of serum is a modern alternative for identifying the truncated chain.

Show evidence (2 references)

PMID:16026747 SUPPORT Human Clinical

"Diagnosis of HCD requires documentation of a deleted immunoglobulin heavy chain without a bound light chain in the serum or urine."

States the diagnostic criterion.

PMID:29326807 SUPPORT Human Clinical

"dimensional immunoelectrophoresis has been shown to be a useful diagnostic tool for all three types of HCD."

Establishes two-dimensional immunoelectrophoresis as a diagnostic tool across subtypes.

Upper endoscopy with multiple duodenal and jejunal biopsies

Required in suspected alpha-HCD, because the disease is centred on the proximal small bowel. Endoscopy shows one of five patterns - infiltrative, nodular, ulcerative, mosaic, or isolated mucosal fold thickening - of which the infiltrative and nodular patterns are the most sensitive and characteristic. Biopsies should also be examined and cultured for bacteria and parasites.

Show evidence (1 reference)

PMID:29326807 SUPPORT Human Clinical

"endoscopy is mandatory and can reveal five different patterns: i) infiltrative, ii) nodular, iii) ulcerations, iv) mosaic, v) isolated mucosal fold thickening."

Establishes endoscopy as mandatory and enumerates the diagnostic patterns.

📈

Progression

4

Early antigen-dependent phase

Alpha-HCD

Mucosal, non-bulky disease with a plasma-cell-rich lamina propria infiltrate. This is the therapeutic window: 33-71% of early-stage patients achieve clinical, laboratory, and histological remission on prolonged antimicrobial therapy.

Show evidence (1 reference)

PMID:15542584 SUPPORT Human Clinical

"Early-stage IPSID responds to antibiotics (30%-70% complete remission)."

Defines the antibiotic-responsive early phase and quantifies its remission rate.

Transformed lymphomatous phase

Alpha-HCD

Progression to lymphoplasmacytic and immunoblastic lymphoma invading the bowel wall and mesenteric nodes, with possible distant metastasis. Requires chemotherapy or radiation; death results from progressive lymphoma, obstruction, perforation, intussusception, cachexia, or infection.

Show evidence (1 reference)

PMID:15542584 SUPPORT Human Clinical

"Most untreated IPSID patients progress to lymphoplasmacytic and immunoblastic lymphoma invading the intestinal wall and mesenteric lymph nodes, and may metastasize to a distant organ."

Defines the transformed phase and its anatomic extent.

Heterogeneous gamma-HCD course

Gamma-HCD

Prognosis is highly variable and depends on the associated neoplasm. Occasional spontaneous remissions occur in patients with no overt lymphoma, who may survive for long periods untreated; treated localised lymphoma usually achieves sustained complete clinical and immunologic remission; gamma-HCD with systemic lymphoma may be either aggressive and rapidly progressive or indolent. Median survival in the Mayo series was 7.4 years.

Show evidence (2 references)

PMID:29326807 SUPPORT Human Clinical

"Occasional spontaneous remissions have been reported in patients with no overt lymphoma, who are nonetheless expec ted to undergo a prolonged survival without treatment."

Documents the indolent, sometimes spontaneously remitting end of the gamma-HCD spectrum.

PMID:12861101 SUPPORT Human Clinical

"Median survival was 7.4 years."

Provides the survival benchmark for gamma-HCD from the largest published single-institution series.

Mu-HCD course

Mu-HCD

Reported median overall survival is approximately two years, with a very wide range. This figure is probably an underestimate, because the truncated mu chain is frequently missed on serum protein electrophoresis and indolent cases go unrecognised.

Show evidence (1 reference)

PMID:29326807 SUPPORT Human Clinical

"Reported median overall survival is approximately two years"

Provides the survival benchmark for mu-HCD.

📊

Prevalence

3

Worldwide cumulative literature reports, concentrated in Mediterranean, North African, and Middle Eastern populations

Cases In Literature Ultra Rare Alpha-HCD

More than 400 cases reported since the 1968 first description. This is a cumulative literature case count, not a population rate; no reliable population incidence or prevalence estimate for any HCD subtype exists.

Show evidence (1 reference)

PMID:29326807 SUPPORT Human Clinical

"It is the most common of the three HCDs, with more than 400 cases described in the literature since its initial description in 1968."

Source of the cumulative alpha-HCD literature case count and of its rank as the commonest subtype.

Worldwide cumulative literature reports

Cases In Literature Ultra Rare Gamma-HCD

Approximately 130 reported cases. Cumulative literature case count, not a population rate.

Show evidence (1 reference)

PMID:29326807 SUPPORT Human Clinical

"It is uncommon, with approximately 130 cases reported in the literature, being the age at diagnosis between 51 and 68 years, with a female predominance."

Source of the cumulative gamma-HCD literature case count.

Worldwide cumulative literature reports

Cases In Literature Ultra Rare Mu-HCD

Only 30-40 reported cases, making mu-HCD the rarest subtype. Cumulative literature case count, not a population rate; the true figure is probably an underestimate because the monoclonal mu chain is frequently missed on serum protein electrophoresis.

Show evidence (1 reference)

PMID:29326807 SUPPORT Human Clinical

"It is the rarest of the HCDs, with only 30 to 40 cases reported"

Source of the cumulative mu-HCD literature case count.

🌍

Epidemiology

1

Geographic and demographic distribution

Alpha-HCD is concentrated in Mediterranean, North African, and Middle Eastern populations of low socioeconomic background and presents in the second and third decades with a slight male predominance. Gamma-HCD presents between 51 and 68 years with a marked female predominance. Mu-HCD occurs predominantly in older Caucasian men, with a median age of 58 years. These distributions may partly reflect ascertainment and publication bias; no modern population-based incidence estimate exists for any subtype.

Show evidence (2 references)

PMID:29326807 SUPPORT Human Clinical

"is most prevalent during the second and third decades of life, with a slight male predominance, typically affects the gastrointestinal system and rarely the respiratory tract."

Documents the age distribution and sex ratio of alpha-HCD and its organ tropism.

PMID:29326807 SUPPORT Human Clinical

"The disease occurs predominantly in Caucasian males, with a median age of 58 years at diagnosis."

Documents the demographic distribution of mu-HCD.

🦠

Infectious Agent

2

Campylobacter jejuni

The bacterial species most convincingly associated with alpha-HCD/IPSID. Helicobacter pylori and intestinal parasites (including Giardia) have also been reported. No organism has been shown to be necessary or sufficient.

Campylobacter jejuni NCBITaxon:197

Show evidence (1 reference)

PMID:14724303 SUPPORT Human Clinical

"These results indicate that campylobacter and immunoproliferative small intestinal disease are associated and that C. jejuni should be added to the growing list of human pathogens responsible for immunoproliferative states."

Establishes C. jejuni as the infectious agent associated with alpha-HCD/IPSID.

Helicobacter pylori

A second bacterium reported in association with alpha-HCD/IPSID, by analogy with its established role in gastric MALT lymphoma. The evidence is weaker than for C. jejuni and amounts to co-detection rather than a demonstrated causal role.

Helicobacter pylori NCBITaxon:210

Show evidence (1 reference)

PMID:29326807 SUPPORT Human Clinical

"Campylobacter jejuni or Helicobacter pylori) can be associated."

Names H. pylori alongside C. jejuni as an organism that "can be associated" with alpha-HCD. Marked PARTIAL because the phrasing asserts association only, with no case counts or causal claim.

🔀

Differential Diagnoses

7

Conditions with similar clinical presentations that must be differentiated from Heavy Chain Disease:

MALT Lymphoma MONDO:0007650

Overlapping Features Alpha-HCD is itself a variant of extranodal marginal zone (MALT) lymphoma and shares its antigen-driven pathogenesis, indolent early course, and antibiotic responsiveness - the same logic as Helicobacter pylori and gastric MALT lymphoma. Conventional MALT lymphoma of the gut is therefore the closest neighbour rather than a distant mimic.

Distinguishing Features

Only alpha-HCD secretes a truncated, light-chain-free alpha heavy chain; conventional MALT lymphoma expresses a complete, light-chain-restricted immunoglobulin.
Alpha-HCD is centred on the proximal small bowel with diffuse plasmacytic lamina propria infiltration and villous atrophy, whereas the stomach is the commonest conventional MALT lymphoma site.
Conventional MALT lymphoma carries recurrent NF-kB-activating translocations such as t(11;18)/BIRC3::MALT1 that are not features of alpha-HCD.

Show evidence (1 reference)

PMID:15542584 SUPPORT Human Clinical

"IPSID lymphoma shares clinical, morphologic, and molecular features with MALT lymphoma, lymphoplasmacytic lymphoma, and plasma cell neoplasms."

States the overlap with MALT lymphoma, lymphoplasmacytic lymphoma, and plasma cell neoplasms that generates this differential.

Waldenstrom Macroglobulinemia MONDO:0100280

Overlapping Features Mu-HCD overlaps Waldenstrom macroglobulinaemia closely: both are IgM-secreting marrow lymphoplasmacytic neoplasms, both may carry MYD88 L265P, and mu-HCD has been reported as an atypical presentation of Waldenstrom macroglobulinaemia. Gamma-HCD may likewise arise during the course of Waldenstrom macroglobulinaemia.

Distinguishing Features

Waldenstrom macroglobulinaemia secretes an intact monoclonal IgM with an assembled light chain; mu-HCD secretes a free truncated mu chain demonstrable only by immunoselection.
Vacuolated marrow plasma cells and the dissociation between very high serum free light chains and an absent or trivial SPEP peak favour mu-HCD.
Hyperviscosity, cryoglobulinaemia, and anti-MAG neuropathy favour Waldenstrom macroglobulinaemia.

Show evidence (1 reference)

PMID:33596645 SUPPORT Human Clinical

"Waldenström macroglobulinemia (WM) is a lymphoplasmacytic lymphoma secreting monoclonal IgM, mainly κ, which is strongly associated with the MYD88 L265P somatic mutation."

Defines Waldenstrom macroglobulinaemia and the shared MYD88 L265P association that makes the distinction difficult.

Multiple Myeloma MONDO:0009693

Overlapping Features Both are monoclonal gammopathies of the plasma-cell/lymphoplasmacytic lineage, and mu-HCD in particular can be mistaken for light-chain myeloma because it presents with hypogammaglobulinaemia, very high serum free light chains, and Bence Jones proteinuria.

Distinguishing Features

Multiple myeloma secretes an intact monoclonal immunoglobulin or free light chains from a marrow plasma-cell clone; HCD secretes a truncated heavy chain with no bound light chain.
Lytic bone lesions, hypercalcaemia, and the other CRAB features are myeloma findings that HCD does not produce.
The underlying HCD neoplasm is lymphoplasmacytic or MALT-type rather than a plasma cell myeloma.

Show evidence (1 reference)

PMID:33596645 SUPPORT Human Clinical

"Free light chain multiple myeloma was suspected and bone marrow aspiration was performed"

A worked example in which mu-HCD was initially mistaken for free light-chain myeloma.

Monoclonal Gammopathy of Undetermined Significance Not Yet Curated MONDO:0004225

Overlapping Features Gamma- and mu-HCD patients without an overt lymphoma may be labelled as MGUS, and asymptomatic mu-HCD is managed by watchful waiting exactly as MGUS is.

Distinguishing Features

MGUS involves an intact monoclonal immunoglobulin with normal light-chain pairing, whereas the HCD paraprotein is a truncated heavy chain with no bound light chain, demonstrable only by immunoselection.
Making the distinction matters because HCD carries a defined risk of progression to overt lymphoma.

Show evidence (1 reference)

PMID:29326807 SUPPORT Human Clinical

"These patients may occasionally be diagnosed with a monoclonal gammopathy of undetermined significance (MGUS)."

States directly that HCD patients may be misclassified as MGUS.

Chronic Lymphocytic Leukemia MONDO:0003864

Overlapping Features Mu-HCD almost always arises in a marrow lymphoid neoplasm with CLL/SLL features and has historically been described as CLL-like, so CLL/SLL is the default alternative diagnosis. A systematic review of published mu-HCD cases nevertheless found lymphocytosis to be uncommon, and recurrent MYD88 mutation points many cases toward lymphoplasmacytic lymphoma instead.

Distinguishing Features

CLL/SLL shows peripheral lymphocytosis with a CD5-positive, CD23-positive clone and no free heavy chain.
Mu-HCD shows vacuolated marrow plasma cells, frequent Bence Jones proteinuria, usually no lymphocytosis, and a free truncated mu chain on immunoselection.

Show evidence (1 reference)

PMID:35932039 SUPPORT Human Clinical

"Mu heavy chain disease has been described as similar to chronic lymphocytic leukemia; however, the frequency of lymphocytosis in mu heavy chain disease has not been previously reported. We reviewed all previously published mu heavy chain disease reports and found that lymphocytosis is uncommon..."

Establishes both the historical CLL comparison and the evidence that distinguishes the two.

Celiac Disease MONDO:0005130

Overlapping Features The principal non-neoplastic differential for the alpha-HCD malabsorption presentation. Both cause chronic diarrhoea, malabsorption, weight loss, and small-bowel villous atrophy with a lamina propria lymphoid infiltrate, and both involve chronic mucosal antigenic stimulation with an increased risk of lymphoid malignancy; celiac disease predominates in Northwestern Europe and North America where IPSID is rare, and vice versa.

Distinguishing Features

Celiac disease responds to gluten withdrawal, whereas alpha-HCD does not respond to a gluten-free diet.
Celiac disease shows serological markers (anti-tissue transglutaminase, anti-endomysial antibodies) and HLA-DQ2/DQ8, with a polyclonal plasma-cell population and intraepithelial lymphocytosis.
Alpha-HCD shows a monoclonal alpha-chain-positive, light-chain-negative plasma-cell population on immunohistochemistry and is confirmed by anti-IgA immunofixation.

Show evidence (2 references)

PMID:10235185 SUPPORT Human Clinical

"In Middle-Eastern and Mediterranean countries immunoproliferative small intestinal disease is endemic, whereas in other parts of the world (including Northwestern Europe and North America) celiac sprue, and other sprue-like syndromes refractory to dietary gluten withdrawal, predominate."

Frames celiac sprue and IPSID as the geographically complementary causes of the same malabsorption syndrome.

PMID:10235185 SUPPORT Human Clinical

"All of these syndromes appear to involve chronic stimulation of intestinal mucosa-associated lymphoid tissue and are associated with a heightened risk of malignant transformation."

Identifies the shared mechanism (chronic MALT stimulation) that makes the distinction mechanistically as well as clinically important.

Heavy Chain Deposition Disease Not Yet Curated MONDO:0019728

Overlapping Features The most commonly confused entity, and a genuinely distinct one. Heavy chain deposition disease shares the CH1-deleted truncated heavy chain but the abnormal chain deposits in tissue - typically producing nodular glomerulosclerosis - rather than circulating as a detectable serum or urine paraprotein.

Distinguishing Features

In heavy chain disease the truncated chain is demonstrable in serum or urine; in heavy chain deposition disease and heavy chain amyloidosis it is demonstrable in tissue.
The clinical picture of heavy chain deposition disease is a monoclonal immunoglobulin deposition nephropathy rather than a lymphoproliferative syndrome.

Show evidence (1 reference)

PMID:32245744 SUPPORT Human Clinical

"These disorders share the pathognomonic finding of a truncated immunoglobulin heavy chain without an associated light chain in the serum or urine in the case of heavy chain disease or in the tissues in the case of heavy chain deposition disease and heavy chain amyloidosis but are clinically..."

States precisely the serum/urine versus tissue distinction that separates heavy chain disease from heavy chain deposition disease.

{ }

Source YAML

click to show

name: Heavy Chain Disease
creation_date: "2026-08-01T05:30:00Z"
description: >-
  Heavy chain disease (HCD) is a group of three rare acquired B-cell
  lymphoplasmacytic neoplasms unified by a single molecular lesion: the clone
  secretes a structurally abnormal, truncated immunoglobulin heavy chain that
  cannot bind light chain. Somatic deletions, insertions, and point mutations
  acquired during somatic hypermutation of the rearranged IGH locus remove most
  or all of the first constant (CH1) domain. CH1 is the domain that normally
  keeps an unpaired heavy chain out of the circulation: it is intrinsically
  unfolded until it pairs with the light-chain constant (CL) domain, and while
  unfolded it is held in the endoplasmic reticulum by the chaperone BiP/GRP78 and
  routed to degradation. A CH1-deleted heavy chain can bind neither light chain
  nor BiP, escapes ER quality control, and is secreted into serum and urine as a
  light-chain-free paraprotein - the diagnostic hallmark. The three subtypes are
  defined by the isotype of the truncated chain and are clinically distinct:
  alpha-HCD (IgA), the commonest, presents as immunoproliferative small
  intestinal disease (IPSID) / Mediterranean lymphoma, is associated with
  Campylobacter jejuni and other chronic enteric infection, responds to
  antibiotics in early stages, and transforms to aggressive lymphoma if
  untreated; gamma-HCD (IgG, Franklin disease) accompanies a lymphoplasmacytic
  neoplasm and frequently coexists with autoimmune disease, especially rheumatoid
  arthritis and Sjogren syndrome; mu-HCD (IgM), the rarest, arises in a
  CLL/SLL-like or lymphoplasmacytic marrow neoplasm, shows vacuolated marrow
  plasma cells, and - despite the heavy-chain assembly defect - is frequently
  accompanied by Bence Jones proteinuria because unassembled free light chains
  are still produced.
categories:
- Hematologic Malignancy
- B-cell Neoplasm
- Lymphoplasmacytic Neoplasm
- Monoclonal Gammopathy
parents:
- plasma cell neoplasm
- B-cell non-Hodgkin lymphoma
disease_term:
  preferred_term: heavy chain disease
  term:
    id: MONDO:0019464
    label: heavy chain disease
synonyms:
- HCD
- heavy-chain disease
- Franklin disease
- alpha chain disease
- immunoproliferative small intestinal disease
- Mediterranean lymphoma
classifications:
  icdo_morphology:
    classification_value: Lymphoma
    notes: >-
      MONDO:0019464 carries the ICD-O morphology xref ICDO:9762/3 (heavy chain
      disease), which has no dedicated value in this repository's closed
      ICDOMorphologyEnum. `Lymphoma` (ICDO:9590/3) is the closest correct parent
      and is supported by the primary literature, which classifies the HCDs as
      variant types of non-Hodgkin lymphoma. `Multiple Myeloma` (ICDO:9732/3)
      was deliberately NOT used: it would mis-assert a plasma-cell-myeloma
      morphology that HCD does not have.
    evidence:
    - reference: PMID:16026747
      reference_title: Heavy chain diseases.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        HCDs can be thought of as variant types of non-Hodgkin lymphoma:
        alpha-HCD presents as an extranodal marginal-zone lymphoma of
        mucosa-associated lymph-node tissue, gamma-HCD as lymphoplasmacytoid
        non-Hodgkin lymphoma, and mu-HCD as small lymphocytic non-Hodgkin
        lymphoma or chronic lymphocytic leukemia.
      explanation: >-
        Supports assigning HCD to the lymphoma morphology axis rather than to a
        plasma-cell-myeloma morphology.
references:
- reference: PMID:29326807
  title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
- reference: PMID:16026747
  title: Heavy chain diseases.
has_subtypes:
- name: Alpha-HCD
  display_name: Alpha Heavy Chain Disease (IPSID / Mediterranean Lymphoma)
  subtype_term:
    preferred_term: alpha-heavy chain disease
    term:
      id: MONDO:0015045
      label: alpha-heavy chain disease
  description: >-
    The commonest heavy chain disease, secreting a truncated IgA (alpha) heavy
    chain. It presents as immunoproliferative small intestinal disease (IPSID),
    an extranodal marginal zone (MALT-type) lymphoma of the proximal small bowel
    causing chronic diarrhoea, malabsorption, and weight loss in young adults of
    Mediterranean, North African, and Middle Eastern origin. Chronic enteric
    infection - Campylobacter jejuni most convincingly - drives the
    antigen-dependent early phase, which is antibiotic responsive; untreated
    disease progresses to lymphoplasmacytic and immunoblastic lymphoma invading
    the bowel wall and mesenteric nodes.
  geography:
  - Mediterranean basin
  - North Africa
  - Middle East
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Alpha-HCD is the most common and usually occurs as intestinal
      malabsorption in a young adult from a country of the Mediterranean area.
    explanation: >-
      Defines alpha-HCD as the commonest subtype with its characteristic
      malabsorptive presentation and geographic distribution.
  - reference: PMID:15542584
    reference_title: "Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Most untreated IPSID patients progress to lymphoplasmacytic and
      immunoblastic lymphoma invading the intestinal wall and mesenteric lymph
      nodes, and may metastasize to a distant organ.
    explanation: >-
      Establishes the progression from antibiotic-responsive early disease to
      aggressive lymphoma that defines the alpha-HCD natural history.
- name: Gamma-HCD
  display_name: Gamma Heavy Chain Disease (Franklin Disease)
  subtype_term:
    preferred_term: gamma-heavy chain disease
    term:
      id: MONDO:0015046
      label: gamma-heavy chain disease
  description: >-
    Franklin disease, secreting a truncated IgG (gamma) heavy chain. It is
    diagnosed at a median age in the seventh decade with a female predominance
    and is nearly always accompanied by an underlying lymphoplasmacytic neoplasm.
    Roughly a quarter of patients have a coexisting autoimmune disease - most
    often rheumatoid arthritis, less often Sjogren syndrome, systemic lupus
    erythematosus, vasculitis, myasthenia gravis, or autoimmune cytopenias -
    whose manifestations frequently precede the HCD diagnosis by years. Clinical
    patterns range from disseminated lymphoma with constitutional symptoms,
    generalised lymphadenopathy, splenomegaly, and hepatomegaly, to localised
    medullary or extramedullary (commonly cutaneous) disease. Palatal oedema from
    involvement of the Waldeyer's ring lymphoid tissue is a classically reported
    sign.
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It is uncommon, with approximately 130 cases reported in the literature,
      being the age at diagnosis between 51 and 68 years, with a female
      predominance.
    explanation: >-
      Establishes the rarity, age range, and female predominance that
      characterise gamma-HCD.
  - reference: PMID:22301495
    reference_title: "Gamma heavy-chain disease: defining the spectrum of associated lymphoproliferative disorders through analysis of 13 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Gamma heavy-chain disease (gHCD) is defined as a lymphoplasmacytic
      neoplasm that produces an abnormally truncated immunoglobulin gamma
      heavy-chain protein that lacks associated light chains.
    explanation: >-
      Pathology-series definition of gamma-HCD as a lymphoplasmacytic neoplasm
      secreting a truncated, light-chain-free gamma chain.
- name: Mu-HCD
  display_name: Mu Heavy Chain Disease
  subtype_term:
    preferred_term: mu-heavy chain disease
    term:
      id: MONDO:0015044
      label: mu-heavy chain disease
  description: >-
    The rarest heavy chain disease, with only 30-40 reported cases, secreting a
    truncated IgM (mu) heavy chain. It occurs predominantly in older men and
    almost always arises in a marrow lymphoid neoplasm resembling chronic
    lymphocytic leukaemia / small lymphocytic lymphoma; MYD88 L265P has been
    reported in individual cases, which has been argued to place at least some
    of them closer to lymphoplasmacytic lymphoma / Waldenstrom
    macroglobulinaemia than to CLL.
    Vacuolated bone marrow plasma cells admixed with small round lymphocytes are
    the characteristic morphology. Unlike the other subtypes, Bence Jones
    proteinuria is frequent, because the clone continues to make monoclonal
    (usually kappa) light chains that cannot assemble with the CH1-deleted heavy
    chain.
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The disease occurs predominantly in Caucasian males, with a median age of
      58 years at diagnosis.
    explanation: Establishes the demographic profile of mu-HCD.
  - reference: PMID:35932039
    reference_title: "Mu heavy chain disease with MYD88 L265P mutation: an unusual manifestation of lymphoplasmacytic lymphoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Mu heavy chain disease is a rare lymphoid neoplasm characterized by
      vacuolated bone marrow plasma cells and secretion of defective mu
      immunoglobulin heavy chains.
    explanation: >-
      Defines mu-HCD by its two hallmarks: vacuolated marrow plasma cells and
      secretion of a defective mu heavy chain.
prevalence:
- subtype: Alpha-HCD
  population: >-
    Worldwide cumulative literature reports, concentrated in Mediterranean,
    North African, and Middle Eastern populations
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    More than 400 cases reported since the 1968 first description. This is a
    cumulative literature case count, not a population rate; no reliable
    population incidence or prevalence estimate for any HCD subtype exists.
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It is the most common of the three HCDs, with more than 400 cases
      described in the literature since its initial description in 1968.
    explanation: >-
      Source of the cumulative alpha-HCD literature case count and of its rank
      as the commonest subtype.
- subtype: Gamma-HCD
  population: Worldwide cumulative literature reports
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    Approximately 130 reported cases. Cumulative literature case count, not a
    population rate.
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It is uncommon, with approximately 130 cases reported in the literature,
      being the age at diagnosis between 51 and 68 years, with a female
      predominance.
    explanation: Source of the cumulative gamma-HCD literature case count.
- subtype: Mu-HCD
  population: Worldwide cumulative literature reports
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    Only 30-40 reported cases, making mu-HCD the rarest subtype. Cumulative
    literature case count, not a population rate; the true figure is probably
    an underestimate because the monoclonal mu chain is frequently missed on
    serum protein electrophoresis.
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It is the rarest of the HCDs, with only 30 to 40 cases reported"
    explanation: Source of the cumulative mu-HCD literature case count.
pathophysiology:
- name: Chronic Enteric Antigenic Stimulation
  conforms_to: "tumor_promoting_inflammation#Chronic Inflammatory Stimulus"
  role: trigger
  biological_scale: ORGANISM
  subtypes:
  - Alpha-HCD
  description: >-
    In alpha-HCD/IPSID, persistent bacterial (most convincingly Campylobacter
    jejuni, sometimes Helicobacter pylori) or parasitic colonisation of the
    proximal small bowel provides sustained antigenic drive to mucosa-associated
    lymphoid tissue. The epidemiological concentration of the disease in
    low-socioeconomic Mediterranean, North African, and Middle Eastern
    populations, and the responsiveness of early disease to antimicrobials, both
    support an antigen-driven initiating step. This is the same
    chronic-infection-driven lymphomagenesis logic as Helicobacter pylori and
    gastric MALT lymphoma. Neither organism has been shown to be necessary or
    sufficient in every case.
  locations:
  - preferred_term: lamina propria of small intestine
    term:
      id: UBERON:0001238
      label: lamina propria of small intestine
  biological_processes:
  - preferred_term: Inflammatory Response
    modifier: INCREASED
    term:
      id: GO:0006954
      label: inflammatory response
  - preferred_term: immunoglobulin production in mucosal tissue
    modifier: INCREASED
    term:
      id: GO:0002426
      label: immunoglobulin production in mucosal tissue
  downstream:
  - target: Clonal Lymphoplasmacytic B-Cell Expansion
    description: >-
      Sustained mucosal antigen exposure selects and expands an IgA-committed
      mucosal B-cell/plasma-cell clone.
  evidence:
  - reference: PMID:14724303
    reference_title: Immunoproliferative small intestinal disease associated with Campylobacter jejuni.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Analysis of frozen intestinal tissue obtained from an index patient with
      immunoproliferative small intestinal disease who had a dramatic response
      to antibiotics revealed the presence of Campylobacter jejuni.
    explanation: >-
      The landmark observation linking C. jejuni to antibiotic-responsive IPSID,
      establishing chronic enteric infection as the antigenic trigger.
  - reference: PMID:14724303
    reference_title: Immunoproliferative small intestinal disease associated with Campylobacter jejuni.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These results indicate that campylobacter and immunoproliferative small
      intestinal disease are associated and that C. jejuni should be added to
      the growing list of human pathogens responsible for immunoproliferative
      states.
    explanation: >-
      States the association explicitly and places IPSID among the
      infection-driven immunoproliferative disorders.
  - reference: PMID:29372346
    reference_title: Heavy Chain Disease of the Small Bowel.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A link between Campylobacter jejuni infection and IPSID has been
      established, but there is controversy as to the role played by this
      organism in disease pathogenesis.
    explanation: >-
      Confirms the association while explicitly qualifying its causal weight,
      which is why this node is modelled as a trigger rather than a necessary
      cause.
- name: Chronic Autoimmune B-Cell Stimulation
  conforms_to: "tumor_promoting_inflammation#Chronic Inflammatory Stimulus"
  role: trigger
  biological_scale: ORGANISM
  subtypes:
  - Gamma-HCD
  mechanism_confidence: PROVISIONAL
  description: >-
    In gamma-HCD, a coexisting autoimmune disease - rheumatoid arthritis most
    often, then Sjogren syndrome, systemic lupus erythematosus, vasculitis,
    myasthenia gravis, and autoimmune cytopenias - is present in about a quarter
    of patients and its manifestations typically precede the HCD diagnosis by
    years. Chronic autoimmune B-cell stimulation is therefore the plausible
    gamma-HCD counterpart of the enteric-infection drive in alpha-HCD, but the
    temporal ordering is not proof of causation and the direction of the
    relationship remains formally unresolved.
  biological_processes:
  - preferred_term: Inflammatory Response
    modifier: INCREASED
    term:
      id: GO:0006954
      label: inflammatory response
  - preferred_term: positive regulation of B cell proliferation
    modifier: INCREASED
    term:
      id: GO:0030890
      label: positive regulation of B cell proliferation
  downstream:
  - target: Clonal Lymphoplasmacytic B-Cell Expansion
    description: >-
      Chronic autoimmune B-cell stimulation is proposed to favour emergence of
      the lymphoplasmacytic clone; directionality is not established.
  - target: Rheumatoid Arthritis
    description: >-
      Rheumatoid arthritis is the commonest clinical expression of the
      autoimmune context in gamma-HCD.
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The manifestations of the associated autoimmune disease often herald the
      diagnosis of γ -HCD by many years.
    explanation: >-
      Documents that autoimmune manifestations typically precede the gamma-HCD
      diagnosis, motivating the trigger role assigned to this node.
  - reference: PMID:22301495
    reference_title: "Gamma heavy-chain disease: defining the spectrum of associated lymphoproliferative disorders through analysis of 13 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinically, patients showed a female predominance (85%) with frequent
      occurrence of autoimmune disease (69%).
    explanation: >-
      Quantifies the autoimmune association in a dedicated gamma-HCD pathology
      series.
- name: Clonal Lymphoplasmacytic B-Cell Expansion
  role: driver
  biological_scale: CELLULAR
  description: >-
    A mature B-cell/plasmacytic clone expands in the small-intestinal lamina
    propria (alpha-HCD), in marrow, spleen, lymph nodes, and extranodal sites
    (gamma-HCD), or in the bone marrow as a CLL/SLL-like or lymphoplasmacytic
    neoplasm (mu-HCD). The expanding clone is the substrate within which the
    heavy-chain gene lesion is acquired and selected.
  cell_types:
  - preferred_term: plasma cell
    term:
      id: CL:0000786
      label: plasma cell
  - preferred_term: neoplastic B cell
    term:
      id: CL:0000236
      label: B cell
  genes:
  - preferred_term: MYD88
    term:
      id: hgnc:7562
      label: MYD88
  biological_processes:
  - preferred_term: positive regulation of B cell proliferation
    modifier: INCREASED
    term:
      id: GO:0030890
      label: positive regulation of B cell proliferation
  - preferred_term: immunoglobulin production
    modifier: INCREASED
    term:
      id: GO:0002377
      label: immunoglobulin production
  downstream:
  - target: Somatic Immunoglobulin Heavy Chain Gene Deletion
    description: >-
      Somatic hypermutation acting on the expanding clone generates the
      CH1-disrupting IGH lesion.
  - target: Lymphoplasmacytic Tissue Infiltration
    description: >-
      The expanding clone infiltrates gut lamina propria, marrow, spleen, and
      lymph nodes.
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The heavy chain diseases (HCDs) are rare B-cell malignancies
      characterized by the production of a monoclonal immunoglobulin heavy chain
      without an associated light chain.
    explanation: >-
      Establishes that HCD is a clonal B-cell neoplasm secreting the abnormal
      heavy chain, i.e. that a neoplastic clone is the cell of origin.
  - reference: PMID:15542584
    reference_title: "Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cytogenetic studies demonstrated clonal rearrangements involving
      predominantly the heavy and light chain genes, including t(9;14)
      translocation involving the PAX5 gene.
    explanation: >-
      Demonstrates clonality of the proliferating population in alpha-HCD/IPSID.
- name: Somatic Immunoglobulin Heavy Chain Gene Deletion
  role: central_effector
  biological_scale: MOLECULAR
  description: >-
    Deletions, insertions, and point mutations acquired somatically during
    somatic hypermutation of the rearranged IGH locus (14q32.33) remove a large
    portion of the sequence encoding the first constant (CH1) domain, and in
    alpha-HCD frequently the variable (VH) region as well. These are
    clone-specific somatic structural lesions of the rearranged immunoglobulin
    genes, not constitutional pathogenic variants; no germline predisposing
    variant is established for HCD. Terminology caveat: GO:0016446 is defined
    for hypermutation of the rearranged V regions, whereas the HCD lesion falls
    in the CH1 constant domain. The term is used here for the somatic
    hypermutation machinery that the source identifies as the origin of the
    lesion, not to assert that the mutations lie in V.
  genes:
  - preferred_term: IGHA1
    term:
      id: hgnc:5478
      label: IGHA1
  - preferred_term: IGHG1
    term:
      id: hgnc:5525
      label: IGHG1
  - preferred_term: IGHM
    term:
      id: hgnc:5541
      label: IGHM
  biological_processes:
  - preferred_term: somatic hypermutation of immunoglobulin genes
    modifier: ABNORMAL
    term:
      id: GO:0016446
      label: somatic hypermutation of immunoglobulin genes
  downstream:
  - target: Loss of the CH1 Domain and Failure of Light Chain Pairing
    description: >-
      Deletion of CH1-encoding sequence yields a heavy chain protein lacking the
      light-chain-binding domain.
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The altered heavy chains contain deletions, insertions, and point
      mutations that are acquired during somatic hypermutation.
    explanation: >-
      Identifies somatic hypermutation of the rearranged IGH locus as the origin
      of the structural lesion.
  - reference: PMID:15542584
    reference_title: "Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The encoding gene sequence reveals a deletion of V region and parts of
      C(H)1 domain.
    explanation: >-
      Direct sequence-level demonstration that the CH1-encoding region is
      deleted in the alpha-HCD clone.
- name: Loss of the CH1 Domain and Failure of Light Chain Pairing
  role: central_effector
  biological_scale: MOLECULAR
  description: >-
    CH1 is the heavy-chain constant domain that pairs with the light-chain
    constant (CL) domain, and the two are covalently joined by an interchain
    disulfide bond. CH1 is unusual among immunoglobulin domains in being
    intrinsically unfolded in isolation: it acquires structure only on
    association with a folded CL domain, in a reaction rate-limited by
    isomerisation of a conserved proline. A heavy chain that has lost CH1 has
    therefore lost the only interface through which it can engage light chain,
    and the resulting molecule is a light-chain-free heavy chain - the defining
    lesion shared by all three HCD subtypes.
  cellular_components:
  - preferred_term: endoplasmic reticulum lumen
    term:
      id: GO:0005788
      label: endoplasmic reticulum lumen
  downstream:
  - target: Escape from BiP-Dependent ER Quality Control
    description: >-
      Without CH1 there is no stably unfolded domain for BiP to hold, so the
      chain is no longer retained.
  - target: Antigen-Independent B-Cell Receptor Aggregation
    description: >-
      The same CH1-deleted chain, in its membrane-anchored form, is the
      substrate proposed to aggregate within the B-cell receptor without
      antigen.
    hypothesis_groups:
    - antigen_independent_bcr_signaling
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These structural abnormalities typically result in loss of a large
      portion of the constant -1 (CH1) domain of the Ig heavy chain molecule
      responsible for LC binding
    explanation: >-
      States that CH1 loss is the typical structural abnormality and that CH1 is
      the domain responsible for light-chain binding.
  - reference: PMID:33596645
    reference_title: "Light chain proteinuria revealing mu-heavy chain disease: an atypical presentation of Waldenström macroglobulinemia in two cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Normal immunoglobulin is composed of two heavy chains and two light chains
      joined by disulfide bonds at the heavy chain constant domain 1 (CH1).
    explanation: >-
      Establishes CH1 as the heavy-chain/light-chain pairing interface whose
      loss abolishes assembly.
  - reference: PMID:19524537
    reference_title: An unfolded CH1 domain controls the assembly and secretion of IgG antibodies.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      In vivo experiments demonstrate that requirements identified for folding
      the C(H)1 domain in vitro, including association with a folded C(L)
      domain and isomerization of a conserved proline residue, are essential for
      antibody assembly and secretion in the cell.
    explanation: >-
      Biophysical and cell-biological demonstration that CH1 folds only on
      association with CL, explaining why CH1 loss abolishes pairing.
- name: Escape from BiP-Dependent ER Quality Control
  role: mediator
  biological_scale: CELLULAR
  description: >-
    Normally, an unpaired heavy chain is trapped in the endoplasmic reticulum:
    the unfolded CH1 domain permanently exposes chaperone-binding sites, the
    Hsp70 chaperone BiP/GRP78 binds it stably (its ATPase cycle stalled until
    light chain arrives), and the retained chain is routed to proteasomal
    degradation, which is why free heavy chains are never found in normal serum
    or urine. A CH1-deleted chain presents no such binding surface. It binds
    neither light chain nor BiP, bypasses ER retention and degradation, and
    enters the secretory pathway. This is the mechanistic core of every heavy
    chain disease.
  cellular_components:
  - preferred_term: endoplasmic reticulum lumen
    term:
      id: GO:0005788
      label: endoplasmic reticulum lumen
  molecular_functions:
  - preferred_term: BiP chaperone binding by the unpaired heavy chain
    modifier: DECREASED
    term:
      id: GO:0051087
      label: protein-folding chaperone binding
  biological_processes:
  - preferred_term: protein folding in endoplasmic reticulum
    modifier: ABNORMAL
    term:
      id: GO:0034975
      label: protein folding in endoplasmic reticulum
  - preferred_term: ERAD pathway
    modifier: DECREASED
    term:
      id: GO:0036503
      label: ERAD pathway
  downstream:
  - target: Secretion of Truncated Light Chain Free Heavy Chain
    description: >-
      Having escaped retention and degradation, the truncated chain transits the
      secretory pathway and reaches serum and urine.
  evidence:
  - reference: PMID:33596645
    reference_title: "Light chain proteinuria revealing mu-heavy chain disease: an atypical presentation of Waldenström macroglobulinemia in two cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In the absence of light chains, the heat shock protein BiP binds to CH1
      and retains the heavy chain in the endoplasmic reticulum.
    explanation: >-
      States the normal BiP/CH1 retention mechanism that the HCD lesion
      subverts.
  - reference: PMID:33596645
    reference_title: "Light chain proteinuria revealing mu-heavy chain disease: an atypical presentation of Waldenström macroglobulinemia in two cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In HCD various mutations are responsible of splicing error leading to
      complete or partial deletion of CH1 and preventing therefore the binding
      of heavy chains to light chains as well as BiP.
    explanation: >-
      States the disease lesion directly: CH1 deletion prevents binding of both
      light chain and BiP.
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Regular heavy chains unassociated with LCs are therefore never detected in
      serum or urine.
    explanation: >-
      Establishes the normal outcome (no free heavy chain in body fluids) whose
      failure defines HCD.
  - reference: PMID:11485742
    reference_title: Unassembled Ig heavy chains do not cycle from BiP in vivo but require light chains to trigger their release.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Unassembled Ig heavy chains are retained in the ER via the binding of BiP
      to the C(H)1 domain, which remains unoxidized.
    explanation: >-
      Direct experimental demonstration that ER retention of unassembled heavy
      chains is mediated by BiP binding to CH1.
  - reference: PMID:19524537
    reference_title: An unfolded CH1 domain controls the assembly and secretion of IgG antibodies.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      If deleted or replaced with another antibody domain, isolated heavy chains
      can be secreted, as occurs in the case of the rare heavy chain diseases
    explanation: >-
      Explicitly connects experimental CH1 deletion to heavy-chain secretion and
      names heavy chain disease as the human instance of that lesion.
  - reference: PMID:15705573
    reference_title: Cysteines in CH1 underlie retention of unassembled Ig heavy chains.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Unassembled immunoglobulin heavy chains are retained intracellularly by
      delayed folding of the C(H)1 domain and irreversible interaction of BiP
      with this domain.
    explanation: >-
      Independent experimental confirmation that retention depends on delayed
      CH1 folding plus an irreversible BiP interaction with that domain - the
      two properties a CH1-deleted chain lacks.
- name: Secretion of Truncated Light Chain Free Heavy Chain
  role: consequence
  biological_scale: ORGANISM
  description: >-
    The CH1-deleted heavy chain is exported into serum and urine as a monoclonal
    paraprotein that reacts with isotype-specific anti-IgA, anti-IgG, or anti-mu
    antiserum but with neither anti-kappa nor anti-lambda antiserum. This
    light-chain-free monoclonal heavy chain is the pathognomonic and
    diagnosis-defining finding of heavy chain disease. Because the truncated
    chain is small and may fail to form a discrete band, serum protein
    electrophoresis is frequently normal or shows only a broad band, so
    immunofixation with immunoselection - not electrophoresis - is the diagnostic
    test.
  cell_types:
  - preferred_term: plasma cell
    term:
      id: CL:0000786
      label: plasma cell
  biological_processes:
  - preferred_term: protein secretion
    modifier: INCREASED
    term:
      id: GO:0009306
      label: protein secretion
  downstream:
  - target: IgA Heavy Chain Paraproteinemia
    description: Alpha-HCD secretes a truncated IgA heavy chain.
  - target: IgG Heavy Chain Paraproteinemia
    description: Gamma-HCD secretes a truncated IgG heavy chain.
  - target: IgM Heavy Chain Paraproteinemia
    description: Mu-HCD secretes a truncated IgM heavy chain.
  - target: Unassembled Free Light Chain Excess
    description: >-
      In mu-HCD the clone keeps producing light chains that the truncated heavy
      chain cannot assemble with, leaving them free.
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the altered structure of the CH1 domain prevents the heavy chain from
      binding both the LC and HSP78
    explanation: >-
      States the escape-and-secretion step. Note the review's "HSP78" is a
      naming slip for the ER chaperone BiP/GRP78 (HSPA5); the BiP identity is
      taken from the primary sources cited on the upstream node.
  - reference: PMID:16026747
    reference_title: Heavy chain diseases.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Diagnosis of HCD requires documentation of a deleted immunoglobulin heavy
      chain without a bound light chain in the serum or urine.
    explanation: >-
      Confirms the secreted light-chain-free truncated heavy chain as the
      diagnosis-defining finding.
- name: Antigen-Independent B-Cell Receptor Aggregation
  role: amplifier
  biological_scale: MOLECULAR
  mechanism_confidence: HYPOTHETICAL
  description: >-
    A proposed self-reinforcing arm: the membrane-anchored form of the truncated
    heavy chain, incorporated into the B-cell receptor, has been suggested to
    aggregate and signal without antigen, conferring a ligand-independent growth
    and survival advantage on the clone. This would make the CH1 lesion not just
    a secretory-escape event but an oncogenic driver in its own right, and would
    explain why disease can progress after the initiating antigen (for example
    C. jejuni) has been eradicated. The proposal is not established in human HCD
    tissue and is recorded here as an emerging hypothesis.
  biological_processes:
  - preferred_term: B cell receptor signaling pathway
    modifier: INCREASED
    term:
      id: GO:0050853
      label: B cell receptor signaling pathway
  downstream:
  - target: Clonal Lymphoplasmacytic B-Cell Expansion
    description: >-
      Antigen-independent BCR signalling is proposed to sustain the clone once
      the initiating antigen drive is removed.
    hypothesis_groups:
    - antigen_independent_bcr_signaling
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In addition, recent work suggests that the altered heavy chain, which
      forms part of the transmembrane B -cell receptor, may facilitate antigen
      -independent aggregation and
    explanation: >-
      The review flags this as suggested by recent work rather than established,
      which is why the node is marked HYPOTHETICAL.
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      down-stream signaling by the receptor, thereby conferring a growth
      advantage to neoplastic cells.
    explanation: >-
      The continuation of the same sentence across a PDF page break in the
      cached review, carrying the growth-advantage claim itself. Quoted as a
      separate item because the page break makes a single contiguous quote
      impossible.
- name: Lymphoplasmacytic Tissue Infiltration
  role: effector
  biological_scale: TISSUE
  description: >-
    The neoplastic clone infiltrates tissue in a subtype-specific distribution.
    In alpha-HCD a dense plasma-cell-rich lymphoplasmacytic infiltrate fills the
    lamina propria of the duodenum and jejunum, admixed with marginal-zone-like
    small lymphocytes and sometimes lymphoepithelial lesions; the infiltrate
    causes villous atrophy and hence malabsorption. In gamma-HCD the infiltrate
    involves bone marrow, spleen, lymph nodes, and extranodal sites including
    skin and the Waldeyer's ring lymphoid tissue. In mu-HCD marrow infiltration
    by a CLL/SLL-like population with vacuolated plasma cells produces
    cytopenias, with splenomegaly and hepatomegaly.
  cell_types:
  - preferred_term: IgA plasma cell
    term:
      id: CL:0000987
      label: IgA plasma cell
  - preferred_term: marginal zone-like B cell
    term:
      id: CL:0000845
      label: marginal zone B cell of spleen
  locations:
  - preferred_term: lamina propria of small intestine
    term:
      id: UBERON:0001238
      label: lamina propria of small intestine
  - preferred_term: duodenum
    term:
      id: UBERON:0002114
      label: duodenum
  - preferred_term: jejunum
    term:
      id: UBERON:0002115
      label: jejunum
  downstream:
  - target: Villous Atrophy
    description: The lamina propria infiltrate flattens the small-bowel villi.
  - target: Malabsorption
    description: >-
      Villous atrophy and mucosal infiltration impair nutrient absorption.
  - target: Ascites
    description: >-
      Advanced disease with profound hypoalbuminaemia produces ascites.
  - target: Anasarca
    description: >-
      The hypoalbuminaemia of advanced malabsorptive disease produces anasarca.
  - target: Chronic Diarrhea
    description: Mucosal infiltration and malabsorption produce chronic diarrhoea.
  - target: Abdominal Pain
    description: Bowel wall infiltration causes abdominal discomfort and pain.
  - target: Weight Loss
    description: Malabsorption and mucosal disease drive progressive weight loss.
  - target: Growth Delay
    description: >-
      Chronic malabsorption in adolescents and young adults retards growth.
  - target: Lymphadenopathy
    description: >-
      Nodal infiltration produces mesenteric and generalised lymphadenopathy.
  - target: Splenomegaly
    description: Splenic infiltration produces splenomegaly.
  - target: Hepatomegaly
    description: Hepatic and portal infiltration produces hepatomegaly.
  - target: Anemia
    description: >-
      Marrow infiltration plus malabsorptive iron and vitamin deficiency
      produces anaemia.
  - target: Autoimmune Hemolytic Anemia
    description: >-
      In gamma-HCD, marrow infiltration is accompanied by Coombs-positive
      autoimmune haemolytic anaemia and other autoimmune cytopenias.
  - target: Thrombocytopenia
    description: >-
      Marrow infiltration and the autoimmune diathesis of gamma-HCD produce
      thrombocytopenia alongside the anaemias.
  - target: Palatal Edema
    description: >-
      Infiltration of the Waldeyer's ring lymphoid tissue produces oedema of the
      soft palate in gamma-HCD.
  - target: Recurrent Respiratory Infections
    description: >-
      Marrow replacement and failure of normal immunoglobulin production
      predispose to recurrent respiratory infection in mu-HCD.
  - target: Transformation to Aggressive Lymphoma
    description: >-
      Untreated mucosal disease progresses to transmural and disseminated
      high-grade lymphoma.
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A lymphoplasmacytic infiltrate rich in plasma cells can be detected in the
      lamina propria of the bowel, and lymphoepithelial lesions may also be
      present.
    explanation: >-
      Describes the lamina propria infiltrate that constitutes the tissue lesion
      of alpha-HCD.
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      villous atrophy and is admixed with small lymphocytes, resembling marginal
      zone B cells.
    explanation: >-
      Links the infiltrate to villous atrophy and identifies the
      marginal-zone-like component.
  - reference: PMID:15542584
    reference_title: "Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      IPSID is a variant of the B-cell lymphoma of mucosa-associated lymphoid
      tissue (MALT), which involves mainly the proximal small intestine
      resulting in malabsorption, diarrhea, and abdominal pain.
    explanation: >-
      Directly links proximal small-intestinal involvement to the malabsorption,
      diarrhoea, and abdominal pain phenotypes wired downstream of this node.
- name: Unassembled Free Light Chain Excess
  role: consequence
  biological_scale: MOLECULAR
  subtypes:
  - Mu-HCD
  description: >-
    A mu-HCD-specific and superficially paradoxical consequence of the same
    lesion. The clone continues to synthesise monoclonal light chains, usually
    kappa, but the CH1-deleted mu chain cannot assemble with them. The
    unassembled light chains are secreted freely, filtered at the glomerulus, and
    appear in the urine as Bence Jones protein - so a disease defined by a
    heavy-chain defect commonly presents with light-chain proteinuria, sometimes
    with cast nephropathy or amyloidosis. This does not occur in alpha-HCD, where
    Bence Jones proteinuria has never been reported.
  downstream:
  - target: Bence Jones Proteinuria
    description: >-
      Free unassembled monoclonal light chains are filtered and excreted as
      Bence Jones protein.
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the neoplastic cells also produce monoclonal LCs, usually of kappa type,
      that fail to assemble with the truncated heavy chain
    explanation: >-
      States the mechanism: light chains are still made but cannot assemble with
      the truncated heavy chain, so they are excreted free.
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      as well as in urine in only small amounts, but Bence Jones proteinuria has
      never been detected.
    explanation: >-
      Establishes the contrast with alpha-HCD, in which free light chains are
      not excreted.
- name: Transformation to Aggressive Lymphoma
  role: outcome
  biological_scale: ORGANISM
  description: >-
    IPSID is generally regarded as a pre-lymphomatous condition. Untreated or
    antibiotic-refractory alpha-HCD progresses from an antigen-dependent mucosal
    lesion to lymphoplasmacytic and immunoblastic lymphoma invading the bowel
    wall and mesenteric nodes, with distant spread; the same transformation
    accounts for constitutional symptoms and for death from obstruction,
    perforation, cachexia, and infection. Gamma-HCD shows an analogous spectrum,
    with disseminated lymphoma and constitutional symptoms in roughly two-thirds
    of patients. Recent reports of longstanding non-progressive IPSID show the
    transformation is not obligate.
  downstream:
  - target: Fever
    description: >-
      Disseminated lymphoma produces constitutional symptoms including fever.
  - target: Intestinal Obstruction
    description: >-
      Enlargement of the lymphomatous mass obstructs the small bowel, and may
      also perforate or intussuscept.
  evidence:
  - reference: PMID:15542584
    reference_title: "Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Most untreated IPSID patients progress to lymphoplasmacytic and
      immunoblastic lymphoma invading the intestinal wall and mesenteric lymph
      nodes, and may metastasize to a distant organ.
    explanation: Documents the transformation step and its anatomic pattern.
  - reference: PMID:29372346
    reference_title: Heavy Chain Disease of the Small Bowel.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      IPSID is typically regarded as a pre-lymphomatous condition with eventual
      progression to frank lymphoma; however, recent reports of longstanding
      non-progressive cases have expanded its clinical spectrum.
    explanation: >-
      Supports the pre-lymphomatous framing while establishing that
      transformation is not obligate.
mechanistic_hypotheses:
- hypothesis_group_id: antigen_independent_bcr_signaling
  hypothesis_label: Antigen-independent BCR signalling by the truncated heavy chain
  status: EMERGING
  description: >-
    The hypothesis that the membrane form of the CH1-deleted heavy chain, as part
    of the B-cell receptor, aggregates and signals in the absence of antigen,
    giving the clone a ligand-independent survival advantage. If true, the CH1
    lesion is an oncogenic driver rather than only a secretory-escape event, and
    it would explain progression that continues after eradication of the
    initiating antigen. Not demonstrated in human HCD tissue.
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In addition, recent work suggests that the altered heavy chain, which
      forms part of the transmembrane B -cell receptor, may facilitate antigen
      -independent aggregation and
    explanation: >-
      The review presents the mechanism as suggested rather than established.
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      down-stream signaling by the receptor, thereby conferring a growth
      advantage to neoplastic cells.
    explanation: >-
      The continuation of the same sentence across a PDF page break in the
      cached review, carrying the growth-advantage claim itself. Quoted as a
      separate item because the page break makes a single contiguous quote
      impossible.
phenotypes:
- category: Laboratory
  name: IgA Heavy Chain Paraproteinemia
  subtype: Alpha-HCD
  diagnostic: true
  description: >-
    A monoclonal truncated IgA (alpha) heavy chain without associated light chain
    in serum, and in small amounts in jejunal or gastric fluid and urine. Serum
    protein electrophoresis may be normal, hypogammaglobulinaemic, or show only a
    broad band in the alpha-2/beta region, so positivity of anti-IgA
    immunofixation is required to confirm the diagnosis.
  phenotype_term:
    preferred_term: IgA heavy chain paraproteinemia
    term:
      id: HP:0020194
      label: IgA heavy chain paraproteinemia
  evidence:
  - reference: PMID:14724303
    reference_title: Immunoproliferative small intestinal disease associated with Campylobacter jejuni.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Immunoproliferative small intestinal disease (also known as alpha chain
      disease) is a form of lymphoma that arises in small intestinal
      mucosa-associated lymphoid tissue (MALT) and is associated with the
      expression of a monotypic truncated immunoglobulin alpha heavy chain
      without an associated light chain.
    explanation: >-
      Defines the alpha-HCD paraprotein as a monotypic truncated alpha heavy
      chain without light chain.
  - reference: PMID:15542584
    reference_title: "Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      IPSID lymphomas reveal excessive plasma cell differentiation and produce
      truncated alpha heavy chain proteins lacking the light chains as well as
      the first constant domain.
    explanation: >-
      Ties the paraprotein directly to loss of the first constant (CH1) domain.
- category: Laboratory
  name: IgG Heavy Chain Paraproteinemia
  subtype: Gamma-HCD
  diagnostic: true
  description: >-
    A monoclonal truncated IgG (gamma) heavy chain without associated light
    chain, typically migrating in the beta region and, because of its low
    molecular weight and tendency to dimerise, often detectable in urine as well
    as serum. Anti-IgG immunofixation positivity without kappa or lambda
    reactivity is required for diagnosis.
  phenotype_term:
    preferred_term: IgG heavy chain paraproteinemia
    term:
      id: HP:0020195
      label: IgG heavy chain paraproteinemia
  evidence:
  - reference: PMID:12861101
    reference_title: "Gamma-heavy chain disease: review of 23 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      gamma-Heavy chain was documented by immunofixation in the serum of all
      patients
    explanation: >-
      In a 23-patient series the gamma heavy chain was demonstrable by serum
      immunofixation in every case, establishing it as the defining laboratory
      finding.
  - reference: PMID:12861101
    reference_title: "Gamma-heavy chain disease: review of 23 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "gamma-Heavy chain was present in the urine in 19 of 22 patients."
    explanation: >-
      Quantifies urinary excretion of the truncated gamma chain in the same
      series.
- category: Laboratory
  name: IgM Heavy Chain Paraproteinemia
  subtype: Mu-HCD
  diagnostic: true
  description: >-
    A monoclonal truncated IgM (mu) heavy chain without associated light chain.
    Serum protein electrophoresis is generally normal or shows only a broad band,
    and the abnormal immunoglobulin is missed on electrophoresis in most cases;
    immunofixation positive with anti-mu but negative with anti-kappa and
    anti-lambda antiserum, using immunoselection, confirms the diagnosis.
  phenotype_term:
    preferred_term: IgM heavy chain paraproteinemia
    term:
      id: HP:0020196
      label: IgM heavy chain paraproteinemia
  evidence:
  - reference: PMID:33596645
    reference_title: "Light chain proteinuria revealing mu-heavy chain disease: an atypical presentation of Waldenström macroglobulinemia in two cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Serum immuno-selection confirmed the presence of m-heavy chain"
    explanation: >-
      Demonstrates the immunoselection technique required to detect the free mu
      heavy chain in mu-HCD. The cached full text renders the Greek mu as "m".
  - reference: PMID:35932039
    reference_title: "Mu heavy chain disease with MYD88 L265P mutation: an unusual manifestation of lymphoplasmacytic lymphoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Identification of the truncated mu immunoglobulin was facilitated by mass
      spectrometric analysis of the patient's serum.
    explanation: >-
      Confirms the truncated mu chain as the analyte and illustrates a modern
      detection approach.
- category: Gastrointestinal
  name: Chronic Diarrhea
  subtype: Alpha-HCD
  frequency: VERY_FREQUENT
  description: >-
    Chronic diarrhoea is one of the cardinal presenting features of
    alpha-HCD/IPSID, reflecting extensive lymphoplasmacytic infiltration of the
    proximal small-bowel mucosa with villous atrophy.
  phenotype_term:
    preferred_term: Chronic diarrhea
    term:
      id: HP:0002028
      label: Chronic diarrhea
    temporality: CHRONIC
  evidence:
  - reference: PMID:15542584
    reference_title: "Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      IPSID is a variant of the B-cell lymphoma of mucosa-associated lymphoid
      tissue (MALT), which involves mainly the proximal small intestine
      resulting in malabsorption, diarrhea, and abdominal pain.
    explanation: >-
      Lists diarrhoea among the defining consequences of proximal small
      intestinal involvement.
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Malabsorption syndrome with weight loss that can cause growth retardation,
      amenorrhea, alopecia, diarrhea, and abdominal discomfort are the typical
      symptoms of gastrointestinal
    explanation: >-
      Names diarrhoea among the typical symptoms of gastrointestinal alpha-HCD,
      supporting the VERY_FREQUENT band.
- category: Gastrointestinal
  name: Villous Atrophy
  subtype: Alpha-HCD
  frequency: FREQUENT
  description: >-
    Flattening of the small-bowel villi produced by the expanding lamina propria
    lymphoplasmacytic infiltrate. It is the histological substrate of the
    malabsorption syndrome and the feature that makes celiac disease the
    principal biopsy differential. It is also recorded under `histopathology` as
    the microscopic finding; it is curated here as well so that it is a node in
    the causal graph downstream of mucosal infiltration.
  phenotype_term:
    preferred_term: Villous atrophy
    term:
      id: HP:0011473
      label: Villous atrophy
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      villous atrophy and is admixed with small lymphocytes, resembling marginal
      zone B cells.
    explanation: >-
      States that the lamina propria infiltrate causes villous atrophy. The
      FREQUENT band reflects that the review presents villous atrophy as a
      characteristic but not invariable consequence of the infiltrate.
- category: Gastrointestinal
  name: Malabsorption
  subtype: Alpha-HCD
  frequency: VERY_FREQUENT
  description: >-
    A malabsorption syndrome is the defining clinical presentation of
    alpha-HCD/IPSID, producing hypoalbuminaemia, hypocalcaemia, hypokalaemia,
    hypomagnesaemia, and vitamin and mineral deficiency, and driving weight loss
    and growth retardation.
  phenotype_term:
    preferred_term: Malabsorption
    term:
      id: HP:0002024
      label: Malabsorption
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Alpha-HCD is the most common and usually occurs as intestinal
      malabsorption in a young adult from a country of the Mediterranean area.
    explanation: >-
      Malabsorption is stated as the usual presenting syndrome of alpha-HCD,
      supporting the VERY_FREQUENT band.
  - reference: PMID:15542584
    reference_title: "Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      which involves mainly the proximal small intestine resulting in
      malabsorption, diarrhea, and abdominal pain
    explanation: >-
      Links malabsorption mechanistically to proximal small bowel disease.
- category: Gastrointestinal
  name: Abdominal Pain
  subtype: Alpha-HCD
  frequency: FREQUENT
  description: >-
    Abdominal pain and discomfort accompany the mucosal and, later, transmural
    bowel involvement of alpha-HCD.
  phenotype_term:
    preferred_term: Abdominal pain
    term:
      id: HP:0002027
      label: Abdominal pain
  evidence:
  - reference: PMID:15542584
    reference_title: "Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      which involves mainly the proximal small intestine resulting in
      malabsorption, diarrhea, and abdominal pain
    explanation: >-
      Names abdominal pain as one of the three cardinal consequences of small
      intestinal involvement.
- category: Constitutional
  name: Weight Loss
  frequency: FREQUENT
  description: >-
    Progressive weight loss results from malabsorption in alpha-HCD and from
    constitutional symptoms of disseminated lymphoma in gamma-HCD. Severe
    malnutrition and cachexia are recognised causes of death in advanced
    alpha-HCD.
  phenotype_term:
    preferred_term: Weight loss
    term:
      id: HP:0001824
      label: Weight loss
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Malabsorption syndrome with weight loss that can cause growth retardation,
      amenorrhea, alopecia, diarrhea, and abdominal discomfort are the typical
      symptoms of gastrointestinal
    explanation: >-
      Names weight loss as a typical symptom of gastrointestinal alpha-HCD.
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In 57% to 66% of patients, a disseminated lymphoma associated with
      constitutional symptoms (i.e., fever, malaise, and weight loss) is present.
    explanation: >-
      Quantifies weight loss as part of the constitutional syndrome of
      disseminated gamma-HCD.
- category: Growth
  name: Growth Delay
  subtype: Alpha-HCD
  description: >-
    Growth retardation follows chronic malabsorption in the adolescents and young
    adults in whom alpha-HCD typically presents; amenorrhoea and alopecia occur
    in the same context. No frequency band is asserted: the source says only
    that malabsorption "can cause" growth retardation, which gives no
    quantitative or qualitative frequency signal.
  phenotype_term:
    preferred_term: Growth delay
    term:
      id: HP:0001510
      label: Growth delay
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Malabsorption syndrome with weight loss that can cause growth retardation,
      amenorrhea, alopecia, diarrhea, and abdominal discomfort are the typical
      symptoms of gastrointestinal
    explanation: >-
      Attributes growth retardation directly to the malabsorption syndrome of
      alpha-HCD.
- category: Hematologic
  name: Lymphadenopathy
  frequency: FREQUENT
  description: >-
    Generalised lymphadenopathy is present in about half of gamma-HCD patients
    and palpable superficial lymphadenopathy in 40% of mu-HCD patients;
    mesenteric nodal involvement is characteristic of advancing alpha-HCD.
  phenotype_term:
    preferred_term: Lymphadenopathy
    term:
      id: HP:0002716
      label: Lymphadenopathy
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Palpable, superficial lymphadenopathy can be identified in 40% of the
      patients.
    explanation: >-
      Quantifies lymphadenopathy in mu-HCD, supporting the FREQUENT band.
  - reference: PMID:12861101
    reference_title: "Gamma-heavy chain disease: review of 23 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      At the time of diagnosis, lymphadenopathy was present in 8 patients,
      splenomegaly in 7, and hepatomegaly in 1.
    explanation: >-
      Direct case counts for lymphadenopathy in a 23-patient gamma-HCD series.
- category: Hematologic
  name: Splenomegaly
  frequency: FREQUENT
  description: >-
    Splenomegaly is frequent in mu-HCD and occurs in roughly half of gamma-HCD
    patients with disseminated disease.
  phenotype_term:
    preferred_term: Splenomegaly
    term:
      id: HP:0001744
      label: Splenomegaly
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Splenomegaly is frequent, and hepatomegaly can be found in about 25%."
    explanation: >-
      States splenomegaly as frequent in mu-HCD, supporting the FREQUENT band.
  - reference: PMID:12861101
    reference_title: "Gamma-heavy chain disease: review of 23 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      At the time of diagnosis, lymphadenopathy was present in 8 patients,
      splenomegaly in 7, and hepatomegaly in 1.
    explanation: Case counts for splenomegaly in a gamma-HCD series.
- category: Hepatic
  name: Hepatomegaly
  frequency: OCCASIONAL
  description: >-
    Hepatomegaly occurs in about a quarter of mu-HCD patients and less commonly
    in gamma-HCD.
  phenotype_term:
    preferred_term: Hepatomegaly
    term:
      id: HP:0002240
      label: Hepatomegaly
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Splenomegaly is frequent, and hepatomegaly can be found in about 25%."
    explanation: >-
      Quantifies hepatomegaly at about 25% in mu-HCD, supporting the OCCASIONAL
      band.
- category: Hematologic
  name: Anemia
  frequency: FREQUENT
  description: >-
    Mild-to-moderate hypochromic anaemia is a common laboratory abnormality in
    alpha-HCD, reflecting malabsorptive iron and vitamin deficiency;
    hypoproliferative anaemia is the commonest laboratory abnormality in mu-HCD
    and reflects marrow infiltration.
  phenotype_term:
    preferred_term: Anemia
    term:
      id: HP:0001903
      label: Anemia
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Common laboratory abnormalities include mild -to-moderate hypochromic
      anemia, deficiency of vitamins and minerals
    explanation: >-
      Names hypochromic anaemia as a "common" laboratory abnormality of
      alpha-HCD. Per the frequency-evidence guidelines the qualitative term
      "common" maps to FREQUENT (30-79%).
- category: Gastrointestinal
  name: Ascites
  subtype: Alpha-HCD
  description: >-
    Ascites is a feature of advanced gastrointestinal alpha-HCD, detectable on
    physical examination together with anasarca. No frequency band is asserted:
    the source describes it as a finding of advanced disease without
    quantifying it.
  phenotype_term:
    preferred_term: Ascites
    term:
      id: HP:0001541
      label: Ascites
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      HCD, ascites and anasarca can be detected at the physical examination.
    explanation: >-
      Names ascites as a physical finding of advanced gastrointestinal
      alpha-HCD.
- category: Constitutional
  name: Anasarca
  subtype: Alpha-HCD
  description: >-
    Anasarca accompanies ascites in advanced gastrointestinal alpha-HCD,
    reflecting the profound hypoalbuminaemia of the malabsorption syndrome. No
    frequency band is asserted for the same reason as ascites.
  phenotype_term:
    preferred_term: Anasarca
    term:
      id: HP:0012050
      label: Anasarca
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      HCD, ascites and anasarca can be detected at the physical examination.
    explanation: >-
      Names anasarca as a physical finding of advanced gastrointestinal
      alpha-HCD.
- category: Gastrointestinal
  name: Intestinal Obstruction
  subtype: Alpha-HCD
  description: >-
    Small bowel obstruction, together with perforation and intussusception, is a
    potentially fatal local complication of the enlarging lymphomatous mass in
    alpha-HCD, and one of the recognised causes of death. It is the principal
    indication for surgery in this disease.
  phenotype_term:
    preferred_term: Small bowel obstruction
    term:
      id: HP:0005214
      label: Intestinal obstruction
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Small bowel obstruction, perforat ion, and intussusception that can be
      fatal are the dreadful local complications of enlargement of the
      lymphomatous tissue.
    explanation: >-
      Names small bowel obstruction as a fatal local complication of the
      enlarging lymphomatous mass.
- category: Hematologic
  name: Thrombocytopenia
  subtype: Gamma-HCD
  description: >-
    Thrombocytopenia occurs alongside normochromic normocytic anaemia and
    Coombs-positive autoimmune haemolytic anaemia as laboratory evidence of
    autoimmune disease or marrow infiltration in gamma-HCD. No frequency band is
    asserted because the source lists these cytopenias without quantifying them.
  phenotype_term:
    preferred_term: Thrombocytopenia
    term:
      id: HP:0001873
      label: Thrombocytopenia
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These comprise cytopenias, in particular, normochromic normocytic anemia,
      Coombs-positive autoimmune hemolytic anemia, and thrombocytopenia.
    explanation: >-
      Names thrombocytopenia among the cytopenias detected during diagnostic
      work-up of gamma-HCD.
- category: Hematologic
  name: Autoimmune Hemolytic Anemia
  subtype: Gamma-HCD
  description: >-
    Coombs-positive autoimmune haemolytic anaemia is a distinctive gamma-HCD
    cytopenia, occurring alongside normochromic normocytic anaemia and
    thrombocytopenia as laboratory evidence of the autoimmune diathesis and
    marrow infiltration. No frequency band is asserted because the source lists
    these cytopenias without quantifying them.
  phenotype_term:
    preferred_term: Coombs-positive autoimmune hemolytic anemia
    term:
      id: HP:0001890
      label: Autoimmune hemolytic anemia
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These comprise cytopenias, in particular, normochromic normocytic anemia,
      Coombs-positive autoimmune hemolytic anemia, and thrombocytopenia.
    explanation: >-
      Names Coombs-positive autoimmune haemolytic anaemia among the cytopenias
      detected during diagnostic work-up of gamma-HCD.
- category: Immunologic
  name: Rheumatoid Arthritis
  subtype: Gamma-HCD
  frequency: OCCASIONAL
  description: >-
    Rheumatoid arthritis is the commonest of the autoimmune diseases that
    accompany gamma-HCD, found together with Sjogren syndrome, systemic lupus
    erythematosus, vasculitis, myasthenia gravis, and autoimmune cytopenias in
    about 25% of patients - a figure reaching 69% in a dedicated pathology
    series. Its manifestations often precede the HCD diagnosis by years.
  phenotype_term:
    preferred_term: Rheumatoid arthritis
    term:
      id: HP:0001370
      label: Rheumatoid arthritis
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      An autoimmune disease such as rheumatoid arthritis (the most common),
      Sjögren syndrome,
    explanation: >-
      Names rheumatoid arthritis as the most common autoimmune association of
      gamma-HCD.
  - reference: PMID:22301495
    reference_title: "Gamma heavy-chain disease: defining the spectrum of associated lymphoproliferative disorders through analysis of 13 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinically, patients showed a female predominance (85%) with frequent
      occurrence of autoimmune disease (69%).
    explanation: >-
      Quantifies the autoimmune association in a 13-case gamma-HCD pathology
      series.
- category: Laboratory
  name: Bence Jones Proteinuria
  subtype: Mu-HCD
  frequency: FREQUENT
  description: >-
    Bence Jones proteinuria is frequent in mu-HCD despite the heavy-chain
    assembly defect, because the clone continues to produce monoclonal (usually
    kappa) light chains that cannot assemble with the truncated mu chain and are
    therefore excreted free. It only rarely causes renal complications, but cast
    nephropathy and amyloidosis are reported. It has never been described in
    alpha-HCD.
  phenotype_term:
    preferred_term: Bence Jones Proteinuria
    term:
      id: HP:0030156
      label: Bence Jones Proteinuria
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bence Jones proteinuria is frequently detected"
    explanation: >-
      States directly that Bence Jones proteinuria is frequent in mu-HCD,
      supporting the FREQUENT band.
  - reference: PMID:33596645
    reference_title: "Light chain proteinuria revealing mu-heavy chain disease: an atypical presentation of Waldenström macroglobulinemia in two cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Urine protein immuno-electrophoresis revealed Bence Jones proteinuria."
    explanation: >-
      A case in which light-chain proteinuria was the presenting abnormality
      that ultimately revealed mu-HCD.
- category: Immunologic
  name: Recurrent Respiratory Infections
  subtype: Mu-HCD
  frequency: VERY_RARE
  description: >-
    Recurrent pulmonary infection is a recognised but explicitly rare
    association of mu-HCD, attributable to marrow replacement and failure of
    normal polyclonal immunoglobulin production.
  phenotype_term:
    preferred_term: Recurrent respiratory infections
    term:
      id: HP:0002205
      label: Recurrent respiratory infections
    temporality: RECURRENT
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Rare associations of µ-HCD with recurrent pulmonary infections"
    explanation: >-
      The review explicitly calls this a "rare" association, which per the
      frequency-evidence guidelines maps to VERY_RARE (1-4%).
- category: Constitutional
  name: Fever
  subtype: Gamma-HCD
  frequency: FREQUENT
  description: >-
    Fever, malaise, and weight loss constitute the constitutional syndrome that
    accompanies disseminated lymphoma in 57-66% of gamma-HCD patients.
  phenotype_term:
    preferred_term: Fever
    term:
      id: HP:0001945
      label: Fever
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In 57% to 66% of patients, a disseminated lymphoma associated with
      constitutional symptoms (i.e., fever, malaise, and weight loss) is present.
    explanation: >-
      Quantifies the constitutional syndrome, including fever, at 57-66% of
      gamma-HCD patients, supporting the FREQUENT band.
- category: Head and Neck
  name: Palatal Edema
  subtype: Gamma-HCD
  description: >-
    Oedema of the soft palate and uvula, attributed to lymphoid infiltration of
    the Waldeyer's ring tissue, is a classically reported sign of gamma-HCD. No
    HPO term exists for palatal oedema specifically; the entry is bound to the
    nearest correct parent, Abnormal soft palate morphology, with the specific
    finding retained in preferred_term. No frequency is asserted because no
    quantitative estimate was found.
  phenotype_term:
    preferred_term: Palatal oedema
    term:
      id: HP:0100736
      label: Abnormal soft palate morphology
  evidence:
  - reference: PMID:29472805
    reference_title: "Gamma heavy-chain disease accompanied with follicular lymphoma: a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We describe a case of a challenging diagnosis of γ-HCD due to the absence
      of clinical signs frequently reported in the disease (anaemia and palatal
      oedema among others).
    explanation: >-
      Attests that palatal oedema is a frequently reported clinical sign of
      gamma-HCD. Marked PARTIAL because the attestation is incidental - the
      reported case in fact lacked the sign - and no quantitative series was
      located.
histopathology:
- name: Lamina Propria Lymphoplasmacytic Infiltrate
  subtype: Alpha-HCD
  diagnostic: true
  description: >-
    A dense plasma-cell-rich lymphoplasmacytic infiltrate expands the lamina
    propria of the duodenum and jejunum, admixed with small lymphocytes
    resembling marginal zone B cells, with lymphoepithelial lesions in some
    cases. The infiltrating plasma cells and marginal zone cells express
    monoclonal cytoplasmic alpha chain without light chains, which is the
    immunohistochemical confirmation of the diagnosis.
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A lymphoplasmacytic infiltrate rich in plasma cells can be detected in the
      lamina propria of the bowel, and lymphoepithelial lesions may also be
      present.
    explanation: Describes the diagnostic histology of alpha-HCD/IPSID.
- name: Villous Atrophy
  subtype: Alpha-HCD
  finding_term:
    preferred_term: Villous atrophy
    term:
      id: NCIT:C38731
      label: Villous Atrophy
  description: >-
    The lamina propria infiltrate flattens the small-bowel villi. Villous atrophy
    is the histological substrate of malabsorption in alpha-HCD and is the shared
    feature that makes celiac disease the principal differential diagnosis on
    biopsy.
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      villous atrophy and is admixed with small lymphocytes, resembling marginal
      zone B cells.
    explanation: >-
      States that the infiltrate causes villous atrophy and describes its
      composition.
- name: Vacuolated Bone Marrow Plasma Cells
  subtype: Mu-HCD
  diagnostic: true
  description: >-
    Bone marrow smears and touch preparations show plasma cells with prominent
    cytoplasmic vacuoles admixed with small round lymphocytes. This is the
    characteristic - and in practice the most useful - morphological clue to
    mu-HCD, prompting the immunoselection studies that establish the diagnosis.
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Bone marrow smears and touch preparations show characteristic plasma cells
      with prominent cytoplasmic vacuoles admixed with small, round lymphocytes.
    explanation: Describes the pathognomonic marrow morphology of mu-HCD.
  - reference: PMID:33596645
    reference_title: "Light chain proteinuria revealing mu-heavy chain disease: an atypical presentation of Waldenström macroglobulinemia in two cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the presence of vacuolated plasma cells in the bone marrow was highly
      suggestive of
    explanation: >-
      Confirms the diagnostic value of the vacuolated plasma cell morphology in
      practice.
- name: Polymorphous Lymphoplasmacytic Neoplasm
  subtype: Gamma-HCD
  description: >-
    Gamma-HCD is most often associated with a polymorphous neoplasm of small
    lymphocytes, plasmacytoid lymphocytes, and plasma cells that is hard to
    classify with certainty and overlaps with "vaguely nodular, polymorphous"
    lymphoplasmacytic lymphoma; a minority of cases show the features of another
    defined WHO entity. Immunoblasts, eosinophils, histiocytes, and occasional
    Reed-Sternberg-like cells may be present, which is why Hodgkin lymphoma and
    peripheral T-cell lymphoma enter the differential.
  evidence:
  - reference: PMID:22301495
    reference_title: "Gamma heavy-chain disease: defining the spectrum of associated lymphoproliferative disorders through analysis of 13 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Histologically, 8 cases (61%) contained a morphologically similar neoplasm
      of small lymphocytes, plasmacytoid lymphocytes, and plasma cells that was
      difficult to classify with certainty, whereas the remaining 5 cases (39%)
      showed the typical features of one of several other well-defined entities
      in the 2008 WHO classification.
    explanation: >-
      Defines the morphological spectrum of the gamma-HCD-associated neoplasm.
biochemical:
- name: Light Chain Free Monoclonal Heavy Chain on Immunofixation
  notes: >-
    The diagnosis-defining laboratory finding across all three subtypes: an
    isotype-specific monoclonal heavy chain (anti-IgA, anti-IgG, or anti-mu
    reactive) with no corresponding kappa or lambda reactivity, demonstrated in
    serum or urine. Immunoselection - electrophoresis through agar containing
    anti-kappa and anti-lambda antibodies to trap free light chains and intact
    immunoglobulin - is required, because serum protein electrophoresis alone can
    be entirely normal and therefore cannot exclude HCD. Two-dimensional
    immunoelectrophoresis is a useful tool for all three types.
  specificity: Pathognomonic for heavy chain disease
  assays:
  - preferred_term: serum and urine immunofixation with immunoselection
  evidence:
  - reference: PMID:16026747
    reference_title: Heavy chain diseases.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Diagnosis of HCD requires documentation of a deleted immunoglobulin heavy
      chain without a bound light chain in the serum or urine.
    explanation: >-
      States the diagnostic requirement that defines this biochemical marker.
  - reference: PMID:33596645
    reference_title: "Light chain proteinuria revealing mu-heavy chain disease: an atypical presentation of Waldenström macroglobulinemia in two cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In order to detect heavy chains devoid of light chains on
      immuno-electrophoresis, immuno-selection techniques and the use of
      specific anti-light chains anti-serum are required.
    explanation: >-
      Explains why immunoselection rather than routine electrophoresis is
      required to make the diagnosis.
- name: Elevated Serum Free Light Chains
  subtype: Mu-HCD
  notes: >-
    In mu-HCD the unassembled monoclonal light chains accumulate as markedly
    elevated serum free light chains with a skewed kappa/lambda ratio, often in
    striking dissociation from an absent or trivial serum protein electrophoresis
    peak. That dissociation - high free light chains with no or a tiny M-spike -
    is the clue that should prompt immunoselection for a free heavy chain.
  evidence:
  - reference: PMID:33596645
    reference_title: "Light chain proteinuria revealing mu-heavy chain disease: an atypical presentation of Waldenström macroglobulinemia in two cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The dissociation between the sFLC level and the absence of a peak on SPEP
      was unusual.
    explanation: >-
      Describes the free-light-chain/electrophoresis dissociation that
      characterises mu-HCD.
- name: Malabsorptive Biochemical Deficit
  subtype: Alpha-HCD
  notes: >-
    Common laboratory abnormalities in alpha-HCD reflect the malabsorption
    syndrome rather than the paraprotein: hypochromic anaemia, vitamin and
    mineral deficiency, raised intestinal alkaline phosphatase, hypoalbuminaemia,
    hypocalcaemia, hypokalaemia, and hypomagnesaemia. Serum protein
    electrophoresis may show hypogammaglobulinaemia rather than a monoclonal
    spike.
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      electrolytic disorders (i.e., hypoalbuminemia, hypocalcemia, hypokalemia,
      and hypomagnesemia).
    explanation: >-
      Lists the biochemical deficits produced by malabsorption in alpha-HCD.
genetic:
- name: IGHA1
  notes: >-
    In alpha-HCD the rearranged IGHA1/IGHA2 alpha heavy chain constant gene
    carries clone-specific somatic deletions removing the variable region and
    part of the CH1 domain, with additional insertions of unknown origin. These
    are acquired, clone-restricted structural lesions of a rearranged
    immunoglobulin gene - not constitutional variants - so germline allele
    frequency and ACMG variant classification do not apply.
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  subtype: Alpha-HCD
  gene_term:
    preferred_term: IGHA1
    term:
      id: hgnc:5478
      label: IGHA1
  evidence:
  - reference: PMID:15542584
    reference_title: "Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The corresponding mRNA lacks the variable heavy chain (V(H)) and the
      constant heavy chain 1 (C(H)1) sequences and contains deletions as well as
      insertions of unknown origin.
    explanation: >-
      Transcript-level demonstration of the VH and CH1 deletion in the alpha
      heavy chain gene.
- name: IGHG1
  notes: >-
    In gamma-HCD the rearranged gamma heavy chain constant gene carries somatic
    deletions and point mutations removing the CH1 domain, yielding the truncated
    light-chain-free gamma chain. As with the other subtypes, the lesion is
    clone-specific and somatic.
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  subtype: Gamma-HCD
  gene_term:
    preferred_term: IGHG1
    term:
      id: hgnc:5525
      label: IGHG1
  evidence:
  - reference: PMID:22301495
    reference_title: "Gamma heavy-chain disease: defining the spectrum of associated lymphoproliferative disorders through analysis of 13 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Gamma heavy-chain disease (gHCD) is defined as a lymphoplasmacytic
      neoplasm that produces an abnormally truncated immunoglobulin gamma
      heavy-chain protein that lacks associated light chains.
    explanation: >-
      Establishes the truncated gamma heavy chain protein as the product of the
      lesioned gamma heavy chain gene.
- name: IGHM
  notes: >-
    In mu-HCD the rearranged mu heavy chain constant gene carries somatic lesions
    disrupting CH1. The clone continues to secrete monoclonal light chains that
    cannot assemble with the truncated chain.
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  subtype: Mu-HCD
  gene_term:
    preferred_term: IGHM
    term:
      id: hgnc:5541
      label: IGHM
  evidence:
  - reference: PMID:35932039
    reference_title: "Mu heavy chain disease with MYD88 L265P mutation: an unusual manifestation of lymphoplasmacytic lymphoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Mu heavy chain disease is a rare lymphoid neoplasm characterized by
      vacuolated bone marrow plasma cells and secretion of defective mu
      immunoglobulin heavy chains.
    explanation: >-
      Establishes the defective mu heavy chain as the gene product defining the
      subtype.
- name: MYD88
  notes: >-
    MYD88 L265P, the hallmark mutation of lymphoplasmacytic lymphoma /
    Waldenstrom macroglobulinaemia, has been reported in mu-HCD together with 6q
    deletion. This is a co-occurring somatic driver of the underlying clone
    rather than the cause of the heavy-chain defect. It has been argued to place
    at least some mu-HCD closer to lymphoplasmacytic lymphoma than to CLL,
    though the evidence is two case reports rather than a series.
  relationship_type: COOPERATING
  variant_origin: SOMATIC
  subtype: Mu-HCD
  gene_term:
    preferred_term: MYD88
    term:
      id: hgnc:7562
      label: MYD88
  evidence:
  - reference: PMID:35932039
    reference_title: "Mu heavy chain disease with MYD88 L265P mutation: an unusual manifestation of lymphoplasmacytic lymphoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report a case of mu heavy chain disease with MYD88 L265P mutation and
      deletion of 6q, genetic aberrations that are both strongly associated with
      lymphoplasmacytic lymphoma/Waldenström macroglobulinemia.
    explanation: >-
      Documents MYD88 L265P in mu-HCD and its implication for classifying the
      underlying clone.
  - reference: PMID:33596645
    reference_title: "Light chain proteinuria revealing mu-heavy chain disease: an atypical presentation of Waldenström macroglobulinemia in two cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The screening for L265P mutation of MYD88 was positive."
    explanation: >-
      Independent confirmation of MYD88 L265P in a mu-HCD case with an
      underlying Waldenstrom macroglobulinaemia clone.
- name: PAX5
  notes: >-
    A t(9;14) translocation involving PAX5 has been reported among the clonal
    cytogenetic rearrangements of alpha-HCD/IPSID. No recurrent, disease-defining
    translocation has been established for any HCD subtype; the reported
    abnormalities come from rare single cases.
  relationship_type: DISPUTED
  variant_origin: SOMATIC
  subtype: Alpha-HCD
  gene_term:
    preferred_term: PAX5
    term:
      id: hgnc:8619
      label: PAX5
  evidence:
  - reference: PMID:15542584
    reference_title: "Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cytogenetic studies demonstrated clonal rearrangements involving
      predominantly the heavy and light chain genes, including t(9;14)
      translocation involving the PAX5 gene.
    explanation: Documents the t(9;14)/PAX5 rearrangement in IPSID.
  - reference: PMID:29372346
    reference_title: Heavy Chain Disease of the Small Bowel.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      While cytogenetic abnormalities involving various immunoglobulin loci and
      PAX5 have been reported, these have been described in rare, single cases,
      limiting their ability to shed further light on disease pathogenesis.
    explanation: >-
      Qualifies the PAX5 finding as a rare single-case observation, which is why
      it is typed DISPUTED rather than a driver.
environmental:
- name: Chronic Campylobacter jejuni infection
  influences_mechanisms:
  - target: Chronic Enteric Antigenic Stimulation
    environmental_effect: TRIGGERS
    causal_link_type: DIRECT
    description: >-
      The node names this organism as the most convincingly implicated source
      of the sustained antigenic drive it describes, so colonisation by it is
      the node's own content. Both items are graded partial rather than
      supporting, and the exposure's own description gives the reason better
      than the grade can: the causal weight remains debated, and the organism
      is neither necessary nor sufficient in every case. What the evidence
      establishes is detection and persistence, not causation. The triggering
      effect and the directness are therefore inherited from the node, which
      names this organism as the antigenic drive it describes, rather than
      asserted by any cited sentence.
    evidence:
    - reference: PMID:14724303
      reference_title: "Immunoproliferative small intestinal disease associated with Campylobacter jejuni."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "A follow-up retrospective analysis of archival intestinal-biopsy specimens disclosed campylobacter species in four of six additional patients with immunoproliferative small intestinal disease."
      explanation: >-
        Retrospective analysis finding the organism in four of six further
        archival cases beyond the index patient. Detection in a small series,
        which is the evidential ceiling for this exposure.
    - reference: PMID:14724303
      reference_title: "Immunoproliferative small intestinal disease associated with Campylobacter jejuni."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "These results indicate that campylobacter and immunoproliferative small intestinal disease are associated and that C. jejuni should be added to the growing list of human pathogens responsible for immunoproliferative states"
      explanation: >-
        The study's own conclusion, which is the strongest wording it offers:
        the organism and the disease are associated, and it should be added to
        the list of pathogens responsible for immunoproliferative states.
        Associated is the operative word, and it is why this is partial.
    - reference: PMID:29372346
      reference_title: "Heavy Chain Disease of the Small Bowel."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "A link between Campylobacter jejuni infection and IPSID has been established, but there is controversy as to the role played by this organism in disease pathogenesis"
      explanation: >-
        Carried on this link so that the dispute travels with the claim rather
        than sitting apart from it: the link is established, and the
        organism's role in pathogenesis is contested. That is the honest state
        of this exposure and the reason no item here is graded supporting.
    - reference: PMID:39176219
      reference_title: "Gastrointestinal Alpha Heavy Chain Disease With Persistent Campylobacter Jejuni Colonization and Refractory Giardiasis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "We report a rare case of GI αHCD with 5 concomitant pathogens identified on a GI multiplex real-time polymerase chain reaction panel, featured by persistent Campylobacter jejuni colonization and refractory giardiasis."
      explanation: >-
        A contemporary case documenting persistent colonisation alongside
        other enteric pathogens. One patient, and the co-pathogens make
        attribution to this organism harder rather than easier.
  presence: Positive
  description: >-
    Persistent small-bowel colonisation by Campylobacter jejuni is the
    best-supported environmental factor in alpha-HCD/IPSID. It was identified by
    PCR, sequencing, FISH, and immunohistochemistry in an index patient with a
    dramatic response to antibiotics and in four of six further archival cases,
    and persistent colonisation has since been documented in contemporary cases.
    Its causal weight remains debated and it is neither necessary nor sufficient
    in every case.
  evidence:
  - reference: PMID:14724303
    reference_title: Immunoproliferative small intestinal disease associated with Campylobacter jejuni.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A follow-up retrospective analysis of archival intestinal-biopsy specimens
      disclosed campylobacter species in four of six additional patients with
      immunoproliferative small intestinal disease.
    explanation: >-
      Quantifies detection of campylobacter in an IPSID case series beyond the
      index patient.
  - reference: PMID:39176219
    reference_title: "Gastrointestinal Alpha Heavy Chain Disease With Persistent Campylobacter Jejuni Colonization and Refractory Giardiasis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report a rare case of GI αHCD with 5 concomitant pathogens identified
      on a GI multiplex real-time polymerase chain reaction panel, featured by
      persistent Campylobacter jejuni colonization and refractory giardiasis.
    explanation: >-
      A contemporary case documenting persistent C. jejuni colonisation in
      alpha-HCD alongside other enteric pathogens.
- name: Low socioeconomic conditions and poor sanitation
  exposure_term:
    preferred_term: exposure to adverse socioeconomic factors
    term:
      id: ECTO:6000028
      label: exposure to socioeconomic factors
  influences_mechanisms:
  - target: Chronic Enteric Antigenic Stimulation
    environmental_effect: PREDISPOSES
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Graded below the organism link into this same node, which is the right
      order but worth stating plainly: this exposure is an epidemiological
      pattern rather than an agent. Its value is that the pattern itself
      argues for an environmental and probably infectious mechanism, which is
      what makes it a claim about this node at all rather than only about who
      gets the disease. The entry is candid that improved sanitation has never
      been shown prospectively to prevent it.
    evidence:
    - reference: PMID:29326807
      reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "particularly those of low socio-economic background, suggesting an environmental, possibly infectious, pathogenetic mechanism."
      explanation: >-
        States the socioeconomic concentration of the disease and reads it as
        suggesting an environmental, possibly infectious, mechanism. The
        inference to this node is the source's own, and it is offered as a
        suggestion.
  presence: Positive
  description: >-
    Alpha-HCD is strikingly concentrated in Mediterranean, North African, and
    Middle Eastern populations of low socioeconomic background, an
    epidemiological pattern that itself argues for an environmental, probably
    infectious, pathogenetic mechanism. Improved sanitation is biologically
    plausible as primary prevention but has never been shown prospectively to
    prevent HCD.
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      particularly those of low socio-economic background, suggesting an
      environmental, possibly infectious, pathogenetic mechanism.
    explanation: >-
      States the socioeconomic association and its interpretation as evidence
      for an environmental/infectious mechanism.
infectious_agent:
- name: Campylobacter jejuni
  description: >-
    The bacterial species most convincingly associated with alpha-HCD/IPSID.
    Helicobacter pylori and intestinal parasites (including Giardia) have also
    been reported. No organism has been shown to be necessary or sufficient.
  infectious_agent_term:
    preferred_term: Campylobacter jejuni
    term:
      id: NCBITaxon:197
      label: Campylobacter jejuni
  evidence:
  - reference: PMID:14724303
    reference_title: Immunoproliferative small intestinal disease associated with Campylobacter jejuni.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These results indicate that campylobacter and immunoproliferative small
      intestinal disease are associated and that C. jejuni should be added to
      the growing list of human pathogens responsible for immunoproliferative
      states.
    explanation: >-
      Establishes C. jejuni as the infectious agent associated with
      alpha-HCD/IPSID.
- name: Helicobacter pylori
  description: >-
    A second bacterium reported in association with alpha-HCD/IPSID, by analogy
    with its established role in gastric MALT lymphoma. The evidence is weaker
    than for C. jejuni and amounts to co-detection rather than a demonstrated
    causal role.
  infectious_agent_term:
    preferred_term: Helicobacter pylori
    term:
      id: NCBITaxon:210
      label: Helicobacter pylori
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Campylobacter jejuni or Helicobacter pylori) can be associated."
    explanation: >-
      Names H. pylori alongside C. jejuni as an organism that "can be
      associated" with alpha-HCD. Marked PARTIAL because the phrasing asserts
      association only, with no case counts or causal claim.
diagnosis:
- name: Immunofixation with immunoselection of serum and urine
  description: >-
    The diagnostic cornerstone. Serum protein electrophoresis is performed first
    but can be entirely normal, hypogammaglobulinaemic, or show only a broad band
    in the alpha-2/beta region, and therefore cannot exclude HCD. The diagnosis
    requires demonstrating isotype-specific heavy chain reactivity (anti-IgA,
    anti-IgG, or anti-mu) with no corresponding kappa or lambda reactivity in
    serum or urine, using immunoselection or two-dimensional
    immunoelectrophoresis. Mass spectrometry of serum is a modern alternative for
    identifying the truncated chain.
  evidence:
  - reference: PMID:16026747
    reference_title: Heavy chain diseases.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Diagnosis of HCD requires documentation of a deleted immunoglobulin heavy
      chain without a bound light chain in the serum or urine.
    explanation: States the diagnostic criterion.
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      dimensional immunoelectrophoresis has been shown to be a useful diagnostic
      tool for all three types of HCD.
    explanation: >-
      Establishes two-dimensional immunoelectrophoresis as a diagnostic tool
      across subtypes.
- name: Upper endoscopy with multiple duodenal and jejunal biopsies
  description: >-
    Required in suspected alpha-HCD, because the disease is centred on the
    proximal small bowel. Endoscopy shows one of five patterns - infiltrative,
    nodular, ulcerative, mosaic, or isolated mucosal fold thickening - of which
    the infiltrative and nodular patterns are the most sensitive and
    characteristic. Biopsies should also be examined and cultured for bacteria
    and parasites.
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      endoscopy is mandatory and can reveal five different patterns: i)
      infiltrative, ii) nodular, iii) ulcerations, iv) mosaic, v) isolated
      mucosal fold thickening.
    explanation: >-
      Establishes endoscopy as mandatory and enumerates the diagnostic patterns.
differential_diagnoses:
- name: MALT Lymphoma
  disease_term:
    preferred_term: MALT lymphoma
    term:
      id: MONDO:0007650
      label: MALT lymphoma
  description: >-
    Alpha-HCD is itself a variant of extranodal marginal zone (MALT) lymphoma and
    shares its antigen-driven pathogenesis, indolent early course, and antibiotic
    responsiveness - the same logic as Helicobacter pylori and gastric MALT
    lymphoma. Conventional MALT lymphoma of the gut is therefore the closest
    neighbour rather than a distant mimic.
  distinguishing_features:
  - >-
    Only alpha-HCD secretes a truncated, light-chain-free alpha heavy chain;
    conventional MALT lymphoma expresses a complete, light-chain-restricted
    immunoglobulin.
  - >-
    Alpha-HCD is centred on the proximal small bowel with diffuse plasmacytic
    lamina propria infiltration and villous atrophy, whereas the stomach is the
    commonest conventional MALT lymphoma site.
  - >-
    Conventional MALT lymphoma carries recurrent NF-kB-activating translocations
    such as t(11;18)/BIRC3::MALT1 that are not features of alpha-HCD.
  evidence:
  - reference: PMID:15542584
    reference_title: "Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      IPSID lymphoma shares clinical, morphologic, and molecular features with
      MALT lymphoma, lymphoplasmacytic lymphoma, and plasma cell neoplasms.
    explanation: >-
      States the overlap with MALT lymphoma, lymphoplasmacytic lymphoma, and
      plasma cell neoplasms that generates this differential.
- name: Waldenstrom Macroglobulinemia
  disease_term:
    preferred_term: Waldenstrom macroglobulinemia
    term:
      id: MONDO:0100280
      label: Waldenstrom macroglobulinemia
  description: >-
    Mu-HCD overlaps Waldenstrom macroglobulinaemia closely: both are
    IgM-secreting marrow lymphoplasmacytic neoplasms, both may carry MYD88 L265P,
    and mu-HCD has been reported as an atypical presentation of Waldenstrom
    macroglobulinaemia. Gamma-HCD may likewise arise during the course of
    Waldenstrom macroglobulinaemia.
  distinguishing_features:
  - >-
    Waldenstrom macroglobulinaemia secretes an intact monoclonal IgM with an
    assembled light chain; mu-HCD secretes a free truncated mu chain demonstrable
    only by immunoselection.
  - >-
    Vacuolated marrow plasma cells and the dissociation between very high serum
    free light chains and an absent or trivial SPEP peak favour mu-HCD.
  - >-
    Hyperviscosity, cryoglobulinaemia, and anti-MAG neuropathy favour Waldenstrom
    macroglobulinaemia.
  evidence:
  - reference: PMID:33596645
    reference_title: "Light chain proteinuria revealing mu-heavy chain disease: an atypical presentation of Waldenström macroglobulinemia in two cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Waldenström macroglobulinemia (WM) is a lymphoplasmacytic lymphoma
      secreting monoclonal IgM, mainly κ, which is strongly associated with the
      MYD88 L265P somatic mutation.
    explanation: >-
      Defines Waldenstrom macroglobulinaemia and the shared MYD88 L265P
      association that makes the distinction difficult.
- name: Multiple Myeloma
  disease_term:
    preferred_term: multiple myeloma
    term:
      id: MONDO:0009693
      label: plasma cell myeloma
  description: >-
    Both are monoclonal gammopathies of the plasma-cell/lymphoplasmacytic
    lineage, and mu-HCD in particular can be mistaken for light-chain myeloma
    because it presents with hypogammaglobulinaemia, very high serum free light
    chains, and Bence Jones proteinuria.
  distinguishing_features:
  - >-
    Multiple myeloma secretes an intact monoclonal immunoglobulin or free light
    chains from a marrow plasma-cell clone; HCD secretes a truncated heavy chain
    with no bound light chain.
  - >-
    Lytic bone lesions, hypercalcaemia, and the other CRAB features are myeloma
    findings that HCD does not produce.
  - >-
    The underlying HCD neoplasm is lymphoplasmacytic or MALT-type rather than a
    plasma cell myeloma.
  evidence:
  - reference: PMID:33596645
    reference_title: "Light chain proteinuria revealing mu-heavy chain disease: an atypical presentation of Waldenström macroglobulinemia in two cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Free light chain multiple myeloma was suspected and bone marrow aspiration
      was performed
    explanation: >-
      A worked example in which mu-HCD was initially mistaken for free
      light-chain myeloma.
- name: Monoclonal Gammopathy of Undetermined Significance
  disease_term:
    preferred_term: monoclonal gammopathy of uncertain significance
    term:
      id: MONDO:0004225
      label: monoclonal gammopathy of uncertain significance
  description: >-
    Gamma- and mu-HCD patients without an overt lymphoma may be labelled as MGUS,
    and asymptomatic mu-HCD is managed by watchful waiting exactly as MGUS is.
  distinguishing_features:
  - >-
    MGUS involves an intact monoclonal immunoglobulin with normal light-chain
    pairing, whereas the HCD paraprotein is a truncated heavy chain with no bound
    light chain, demonstrable only by immunoselection.
  - >-
    Making the distinction matters because HCD carries a defined risk of
    progression to overt lymphoma.
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These patients may occasionally be diagnosed with a monoclonal gammopathy
      of undetermined significance (MGUS).
    explanation: >-
      States directly that HCD patients may be misclassified as MGUS.
- name: Chronic Lymphocytic Leukemia
  disease_term:
    preferred_term: chronic lymphocytic leukemia/small lymphocytic lymphoma
    term:
      id: MONDO:0003864
      label: chronic lymphocytic leukemia/small lymphocytic lymphoma
  description: >-
    Mu-HCD almost always arises in a marrow lymphoid neoplasm with CLL/SLL
    features and has historically been described as CLL-like, so CLL/SLL is the
    default alternative diagnosis. A systematic review of published mu-HCD cases
    nevertheless found lymphocytosis to be uncommon, and recurrent MYD88 mutation
    points many cases toward lymphoplasmacytic lymphoma instead.
  distinguishing_features:
  - >-
    CLL/SLL shows peripheral lymphocytosis with a CD5-positive, CD23-positive
    clone and no free heavy chain.
  - >-
    Mu-HCD shows vacuolated marrow plasma cells, frequent Bence Jones
    proteinuria, usually no lymphocytosis, and a free truncated mu chain on
    immunoselection.
  evidence:
  - reference: PMID:35932039
    reference_title: "Mu heavy chain disease with MYD88 L265P mutation: an unusual manifestation of lymphoplasmacytic lymphoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Mu heavy chain disease has been described as similar to chronic
      lymphocytic leukemia; however, the frequency of lymphocytosis in mu heavy
      chain disease has not been previously reported. We reviewed all previously
      published mu heavy chain disease reports and found that lymphocytosis is
      uncommon in the entity.
    explanation: >-
      Establishes both the historical CLL comparison and the evidence that
      distinguishes the two.
- name: Celiac Disease
  disease_term:
    preferred_term: celiac disease
    term:
      id: MONDO:0005130
      label: celiac disease
  description: >-
    The principal non-neoplastic differential for the alpha-HCD malabsorption
    presentation. Both cause chronic diarrhoea, malabsorption, weight loss, and
    small-bowel villous atrophy with a lamina propria lymphoid infiltrate, and
    both involve chronic mucosal antigenic stimulation with an increased risk of
    lymphoid malignancy; celiac disease predominates in Northwestern Europe and
    North America where IPSID is rare, and vice versa.
  distinguishing_features:
  - >-
    Celiac disease responds to gluten withdrawal, whereas alpha-HCD does not
    respond to a gluten-free diet.
  - >-
    Celiac disease shows serological markers (anti-tissue transglutaminase,
    anti-endomysial antibodies) and HLA-DQ2/DQ8, with a polyclonal plasma-cell
    population and intraepithelial lymphocytosis.
  - >-
    Alpha-HCD shows a monoclonal alpha-chain-positive, light-chain-negative
    plasma-cell population on immunohistochemistry and is confirmed by anti-IgA
    immunofixation.
  evidence:
  - reference: PMID:10235185
    reference_title: "Alpha-heavy chain disease, Mediterranean lymphoma, and immunoproliferative small intestinal disease: a review of clinicopathological features, pathogenesis, and differential diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In Middle-Eastern and Mediterranean countries immunoproliferative small
      intestinal disease is endemic, whereas in other parts of the world
      (including Northwestern Europe and North America) celiac sprue, and other
      sprue-like syndromes refractory to dietary gluten withdrawal, predominate.
    explanation: >-
      Frames celiac sprue and IPSID as the geographically complementary causes
      of the same malabsorption syndrome.
  - reference: PMID:10235185
    reference_title: "Alpha-heavy chain disease, Mediterranean lymphoma, and immunoproliferative small intestinal disease: a review of clinicopathological features, pathogenesis, and differential diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All of these syndromes appear to involve chronic stimulation of intestinal
      mucosa-associated lymphoid tissue and are associated with a heightened
      risk of malignant transformation.
    explanation: >-
      Identifies the shared mechanism (chronic MALT stimulation) that makes the
      distinction mechanistically as well as clinically important.
- name: Heavy Chain Deposition Disease
  disease_term:
    preferred_term: heavy chain deposition disease
    term:
      id: MONDO:0019728
      label: heavy chain deposition disease
  description: >-
    The most commonly confused entity, and a genuinely distinct one. Heavy chain
    deposition disease shares the CH1-deleted truncated heavy chain but the
    abnormal chain deposits in tissue - typically producing nodular
    glomerulosclerosis - rather than circulating as a detectable serum or urine
    paraprotein.
  distinguishing_features:
  - >-
    In heavy chain disease the truncated chain is demonstrable in serum or urine;
    in heavy chain deposition disease and heavy chain amyloidosis it is
    demonstrable in tissue.
  - >-
    The clinical picture of heavy chain deposition disease is a monoclonal
    immunoglobulin deposition nephropathy rather than a lymphoproliferative
    syndrome.
  evidence:
  - reference: PMID:32245744
    reference_title: "Heavy Lifting: Nomenclature and Novel Therapy for Gamma Heavy Chain Disease and Other Heavy Chain Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These disorders share the pathognomonic finding of a truncated
      immunoglobulin heavy chain without an associated light chain in the serum
      or urine in the case of heavy chain disease or in the tissues in the case
      of heavy chain deposition disease and heavy chain amyloidosis but are
      clinically distinct entities.
    explanation: >-
      States precisely the serum/urine versus tissue distinction that separates
      heavy chain disease from heavy chain deposition disease.
treatments:
- name: Antimicrobial Therapy for Early Alpha-HCD
  description: >-
    First-line treatment of early-stage alpha-HCD/IPSID, and the therapeutic
    expression of its antigen-driven pathogenesis. Any documented bacterial or
    parasitic gastrointestinal infection is eradicated; empirical treatment with
    metronidazole, ampicillin, or tetracycline is commonly given even without a
    demonstrated organism. A six-month course is recommended, since shorter
    courses relapse. Clinical, laboratory, and histological remission is achieved
    in 33-71% of early-stage patients, though recurrence is frequent. These are
    historical regimen choices and require contemporary susceptibility, safety,
    and antimicrobial-stewardship review.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: antibiotic therapy
    term:
      id: NCIT:C15620
      label: Antibiotic Therapy
    therapeutic_agent:
    - preferred_term: metronidazole
      term:
        id: CHEBI:6909
        label: metronidazole
    - preferred_term: ampicillin
      term:
        id: CHEBI:28971
        label: ampicillin
    - preferred_term: tetracycline
      term:
        id: CHEBI:27902
        label: tetracycline
  target_mechanisms:
  - target: Chronic Enteric Antigenic Stimulation
    treatment_effect: INHIBITS
    description: >-
      Eradicating the driving enteric organism removes the antigenic stimulus
      sustaining the clone, which is why early antigen-dependent disease
      regresses.
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Metronidazole, ampicillin, or tetracycline are the antibiotics of choice
      for this empiric therapy.
    explanation: Names the empirical antimicrobial regimens used in alpha-HCD.
  - reference: PMID:15542584
    reference_title: "Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Early-stage IPSID responds to antibiotics (30%-70% complete remission)."
    explanation: >-
      Quantifies the complete remission rate of early-stage IPSID with
      antibiotics.
- name: Doxorubicin-Containing Combination Chemotherapy
  description: >-
    For alpha-HCD that is refractory to antimicrobials, bulky, or transformed,
    and for aggressive gamma-HCD. CHOP (cyclophosphamide, doxorubicin,
    vincristine, prednisone) is the standard backbone, with rituximab added in
    CD20-positive disease; CHVP and ABV are historical alternatives. Total
    abdominal radiation is an alternative for refractory alpha-HCD. There is no
    randomised trial evidence in HCD; regimens are adapted from
    infection-associated MALT lymphoma and other B-cell neoplasms.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: NCIT:C15632
      label: Chemotherapy
    therapeutic_agent:
    - preferred_term: cyclophosphamide
      term:
        id: CHEBI:4027
        label: cyclophosphamide
    - preferred_term: doxorubicin
      term:
        id: CHEBI:28748
        label: doxorubicin
    - preferred_term: vincristine
      term:
        id: CHEBI:28445
        label: vincristine
    - preferred_term: prednisone
      term:
        id: CHEBI:8382
        label: prednisone
  regimen_term:
    preferred_term: CHOP regimen
    term:
      id: NCIT:C9549
      label: CHOP Regimen
  target_mechanisms:
  - target: Transformation to Aggressive Lymphoma
    treatment_effect: INHIBITS
    description: >-
      Cytotoxic chemotherapy is directed at the transformed high-grade lymphoma
      that antimicrobial therapy cannot control.
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Refractory disease is treated with either total abdominal radiation"
    explanation: >-
      Establishes the escalation pathway for antimicrobial-refractory alpha-HCD.
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CHOP regimen (with rituximab in CD20 - positive cases) shows the best
      results in aggressive/refractory patients.
    explanation: >-
      Identifies CHOP with rituximab as the best-performing regimen in
      aggressive or refractory gamma-HCD.
- name: Rituximab-Based Immunotherapy
  description: >-
    Anti-CD20 monoclonal antibody therapy for CD20-positive gamma-HCD, used alone
    or with chemotherapy. Fludarabine plus rituximab has been reported effective
    in gamma-HCD complicated by pancytopenia.
  therapeutic_modality: MONOCLONAL_ANTIBODY
  treatment_term:
    preferred_term: monoclonal antibody therapy
    term:
      id: NCIT:C15490
      label: Monoclonal Antibody Therapy
    therapeutic_agent:
    - preferred_term: rituximab
      term:
        id: NCIT:C1702
        label: Rituximab
  target_mechanisms:
  - target: Clonal Lymphoplasmacytic B-Cell Expansion
    treatment_effect: INHIBITS
    description: Anti-CD20 depletes the CD20-positive neoplastic B-cell clone.
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Chlorambucil, or melphalan and prednisone, or bortezomib and prednisone ,
      and rituximab in CD20 -positive disease are the treatment of choice for
      plasma cell
    explanation: >-
      Identifies rituximab as treatment of choice for CD20-positive
      plasma-cell-predominant gamma-HCD.
- name: Alkylator and Proteasome-Inhibitor Therapy for Plasma-Cell-Predominant Gamma-HCD
  description: >-
    For gamma-HCD in which the underlying neoplasm is plasma-cell predominant
    rather than a disseminated aggressive lymphoma, the treatments of choice are
    chlorambucil, melphalan plus prednisone, or bortezomib plus prednisone. A
    single-institution series has also reported responses to modern myeloma- and
    lymphoma-derived regimens including CRd (cyclophosphamide, lenalidomide,
    dexamethasone), CyBorD, R-CVP, bendamustine-rituximab, and V-EPOCH.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: NCIT:C15632
      label: Chemotherapy
    therapeutic_agent:
    - preferred_term: chlorambucil
      term:
        id: CHEBI:28830
        label: chlorambucil
    - preferred_term: melphalan
      term:
        id: CHEBI:28876
        label: melphalan
    - preferred_term: prednisone
      term:
        id: CHEBI:8382
        label: prednisone
    - preferred_term: bortezomib
      term:
        id: CHEBI:52717
        label: bortezomib
  target_mechanisms:
  - target: Clonal Lymphoplasmacytic B-Cell Expansion
    treatment_effect: INHIBITS
    description: >-
      Alkylator and proteasome-inhibitor therapy is directed at the
      plasma-cell-predominant clone rather than at an antigenic trigger.
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Chlorambucil, or melphalan and prednisone, or bortezomib and prednisone ,
      and rituximab in CD20 -positive disease are the treatment of choice for
      plasma cell
    explanation: >-
      Names the alkylator and proteasome-inhibitor options as treatment of
      choice for plasma-cell-predominant gamma-HCD.
  - reference: PMID:32245744
    reference_title: "Heavy Lifting: Nomenclature and Novel Therapy for Gamma Heavy Chain Disease and Other Heavy Chain Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Herein we present a review of the literature and 5 consecutive cases at a
      single institution of gamma heavy chain disease and heavy chain deposition
      disease treated with novel agents including regimens of CRd
      (cyclophosphamide, lenalidomide, and dexamethasone), CyBorD
      (cyclophosphamide, bortezomib, and dexamethasone), R-CVP (rituximab,
      cyclophosphamide, vincristine, and dexamethasone), BR (bendamustine and
      rituximab), V-EPOCH (bortezomib, etoposide, prednisone, vincristine,
      cyclophosphamide, and doxorubicin), and autologous hematopoietic stem cell
      transplantation.
    explanation: >-
      A contemporary single-institution series enumerating the novel-agent
      regimens actually used in gamma-HCD.
- name: Autologous Hematopoietic Stem Cell Transplantation
  description: >-
    High-dose therapy with autologous haematopoietic stem cell transplantation
    should be considered for refractory or relapsing disease. Evidence is
    limited to case-level experience; there is no trial-level support in any HCD
    subtype.
  therapeutic_modality: CELL_THERAPY
  treatment_term:
    preferred_term: hematopoietic stem cell transplantation
    term:
      id: NCIT:C15431
      label: Hematopoietic Cell Transplantation
  target_mechanisms:
  - target: Clonal Lymphoplasmacytic B-Cell Expansion
    treatment_effect: INHIBITS
    description: >-
      High-dose conditioning is intended to eradicate the refractory clone, with
      autologous rescue.
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      For patients with a refractory or relapsing disease, high -dose therapy
      with autologous hematopoietic stem cell transplantation should be
      considered.
    explanation: >-
      Recommends autologous HSCT for refractory or relapsing disease. Marked
      PARTIAL because the recommendation is expert opinion without trial-level
      support.
- name: Radiation Therapy
  description: >-
    Radiotherapy has two distinct roles in HCD. In alpha-HCD it is used as total
    abdominal radiation for disease refractory to antimicrobials, as an
    alternative to doxorubicin-containing chemotherapy. In gamma-HCD it is used
    as local radiation for localised extranodal disease, where surgical
    resection is the other option. As with every HCD treatment, the evidence is
    case-level and adapted from related B-cell neoplasms.
  therapeutic_modality: RADIOTHERAPY
  treatment_term:
    preferred_term: radiation therapy
    term:
      id: NCIT:C15313
      label: Radiation Therapy
  target_mechanisms:
  - target: Lymphoplasmacytic Tissue Infiltration
    treatment_effect: INHIBITS
    description: >-
      Radiation is directed at the bulk of infiltrating neoplastic tissue,
      whether diffusely in the abdomen or at a localised extranodal site.
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Refractory disease is treated with either total abdominal radiation"
    explanation: >-
      Establishes total abdominal radiation as an option for
      antimicrobial-refractory alpha-HCD.
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      While surgical resection or radiation therapy have been successfully
      employed in patients with localized extra-nodal disease
    explanation: >-
      Establishes local radiation as a successful option for localised
      extranodal gamma-HCD.
- name: Surgical Resection and Management of Bowel Complications
  description: >-
    Surgery has two roles. In localised extranodal gamma-HCD, surgical resection
    is a definitive option alongside radiation. In alpha-HCD it is
    complication-directed rather than disease-directed: small bowel obstruction,
    perforation, and intussusception arising from enlargement of the
    lymphomatous tissue are the dreadful and potentially fatal local
    complications that require operative management.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  target_mechanisms:
  - target: Lymphoplasmacytic Tissue Infiltration
    treatment_effect: INHIBITS
    description: >-
      In localised extranodal gamma-HCD, resection removes the infiltrating
      neoplastic tissue itself and can be definitive.
  - target: Transformation to Aggressive Lymphoma
    treatment_effect: INHIBITS
    description: >-
      In alpha-HCD, surgery is complication-directed: it relieves the mechanical
      bowel complications produced by the enlarging lymphomatous mass.
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      While surgical resection or radiation therapy have been successfully
      employed in patients with localized extra-nodal disease
    explanation: >-
      Establishes surgical resection as a successful option for localised
      extranodal gamma-HCD.
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Small bowel obstruction, perforat ion, and intussusception that can be
      fatal are the dreadful local complications of enlargement of the
      lymphomatous tissue.
    explanation: >-
      Names the mechanical bowel complications of alpha-HCD that require
      operative management.
- name: Observation and Watchful Waiting
  description: >-
    Appropriate for asymptomatic gamma-HCD without an overt lymphoma, and for
    asymptomatic mu-HCD in which a monoclonal mu chain is detected incidentally.
    Some gamma-HCD patients without overt lymphoma undergo spontaneous remission
    and survive for prolonged periods untreated; in the Mayo series, treatment
    was judged unnecessary in five of 23 patients, and median survival in that
    series was 7.4 years.
  therapeutic_modality: OTHER
  notes: >-
    No treatment_term is asserted. Observation is not a pharmacotherapy,
    procedure, or behavioural intervention, and no active-surveillance term
    reachable by this repository's TreatmentActionTerm dynamic enum was
    identified; binding it to NCIT:C15986 (Pharmacotherapy) would be a
    mis-annotation.
  evidence:
  - reference: PMID:12861101
    reference_title: "Gamma-heavy chain disease: review of 23 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      For 5 patients, treatment was not felt to be necessary; 2 patients were
      thought to be too sick for treatment.
    explanation: >-
      Documents that a subset of gamma-HCD patients are appropriately managed
      without treatment.
  - reference: PMID:12861101
    reference_title: "Gamma-heavy chain disease: review of 23 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Median survival was 7.4 years."
    explanation: >-
      Provides the survival benchmark against which observation is judged
      reasonable in gamma-HCD.
- name: Nutritional and Supportive Care
  description: >-
    Correction of malnutrition, electrolyte disturbance (hypocalcaemia,
    hypokalaemia, hypomagnesaemia), hypoalbuminaemia, and vitamin and mineral
    deficiency is essential in alpha-HCD, in which severe malnutrition and
    cachexia are recognised causes of death alongside infection and mechanical
    bowel complications.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: NCIT:C15447
      label: Dietary Intervention
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other potential causes of death are severe malnutrition and subsequent
      cachexia, as well as infectious complications.
    explanation: >-
      Establishes malnutrition and cachexia as causes of death, motivating
      nutritional support as a treatment component.
progression:
- phase: Early antigen-dependent phase
  subtype: Alpha-HCD
  notes: >-
    Mucosal, non-bulky disease with a plasma-cell-rich lamina propria infiltrate.
    This is the therapeutic window: 33-71% of early-stage patients achieve
    clinical, laboratory, and histological remission on prolonged antimicrobial
    therapy.
  evidence:
  - reference: PMID:15542584
    reference_title: "Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Early-stage IPSID responds to antibiotics (30%-70% complete remission)."
    explanation: >-
      Defines the antibiotic-responsive early phase and quantifies its remission
      rate.
- phase: Transformed lymphomatous phase
  subtype: Alpha-HCD
  notes: >-
    Progression to lymphoplasmacytic and immunoblastic lymphoma invading the
    bowel wall and mesenteric nodes, with possible distant metastasis. Requires
    chemotherapy or radiation; death results from progressive lymphoma,
    obstruction, perforation, intussusception, cachexia, or infection.
  evidence:
  - reference: PMID:15542584
    reference_title: "Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Most untreated IPSID patients progress to lymphoplasmacytic and
      immunoblastic lymphoma invading the intestinal wall and mesenteric lymph
      nodes, and may metastasize to a distant organ.
    explanation: Defines the transformed phase and its anatomic extent.
- phase: Heterogeneous gamma-HCD course
  subtype: Gamma-HCD
  notes: >-
    Prognosis is highly variable and depends on the associated neoplasm.
    Occasional spontaneous remissions occur in patients with no overt lymphoma,
    who may survive for long periods untreated; treated localised lymphoma
    usually achieves sustained complete clinical and immunologic remission;
    gamma-HCD with systemic lymphoma may be either aggressive and rapidly
    progressive or indolent. Median survival in the Mayo series was 7.4 years.
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Occasional spontaneous remissions have been reported in patients with no
      overt lymphoma, who are nonetheless expec ted to undergo a prolonged
      survival without treatment.
    explanation: >-
      Documents the indolent, sometimes spontaneously remitting end of the
      gamma-HCD spectrum.
  - reference: PMID:12861101
    reference_title: "Gamma-heavy chain disease: review of 23 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Median survival was 7.4 years."
    explanation: >-
      Provides the survival benchmark for gamma-HCD from the largest published
      single-institution series.
- phase: Mu-HCD course
  subtype: Mu-HCD
  notes: >-
    Reported median overall survival is approximately two years, with a very
    wide range. This figure is probably an underestimate, because the truncated
    mu chain is frequently missed on serum protein electrophoresis and
    indolent cases go unrecognised.
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Reported median overall survival is approximately two years"
    explanation: Provides the survival benchmark for mu-HCD.
epidemiology:
- name: Geographic and demographic distribution
  description: >-
    Alpha-HCD is concentrated in Mediterranean, North African, and Middle Eastern
    populations of low socioeconomic background and presents in the second and
    third decades with a slight male predominance. Gamma-HCD presents between 51
    and 68 years with a marked female predominance. Mu-HCD occurs predominantly
    in older Caucasian men, with a median age of 58 years. These distributions
    may partly reflect ascertainment and publication bias; no modern
    population-based incidence estimate exists for any subtype.
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      is most prevalent during the second and third decades of life, with a
      slight male predominance, typically affects the gastrointestinal system and
      rarely the respiratory tract.
    explanation: >-
      Documents the age distribution and sex ratio of alpha-HCD and its organ
      tropism.
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The disease occurs predominantly in Caucasian males, with a median age of
      58 years at diagnosis.
    explanation: Documents the demographic distribution of mu-HCD.
discussions:
- discussion_id: hcd_ch1_membrane_form_oncogenic_driver
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Is the CH1-deleted heavy chain merely a secretory-escape by-product, or is
    its membrane form an oncogenic driver that sustains the clone through
    antigen-independent B-cell receptor signalling?
  attaches_to:
  - "pathophysiology#Antigen-Independent B-Cell Receptor Aggregation"
  rationale: >-
    The distinction determines whether the CH1 lesion is a diagnostic marker or a
    therapeutic target, and whether antimicrobial therapy alone can be curative
    once the lesion is established. It would also explain why a subset of
    alpha-HCD progresses despite eradication of the driving organism. The
    proposal currently rests on suggestion in a review rather than direct
    demonstration in human HCD tissue.
  proposed_experiments:
  - experiment_id: hcd_single_cell_bcr_tonic_signalling
    name: Single-cell BCR and transcriptomic profiling of HCD clones
    description: >-
      Profile HCD clones at single-cell resolution alongside matched
      lymphoplasmacytic and MALT lymphoma controls, testing whether the HCD clone
      shows tonic, ligand-independent BCR pathway activation.
    decision_criterion: >-
      Selective enrichment of BCR-pathway activation signatures in HCD clones
      relative to light-chain-competent controls would support the driver model.
  - experiment_id: hcd_ch1_deleted_construct_aggregation
    name: Engineered CH1-deleted heavy chain constructs in B-cell lines
    description: >-
      Express CH1-deleted heavy chain constructs in B-cell lines and assay
      directly for antigen-independent receptor aggregation and downstream
      signalling.
    decision_criterion: >-
      Demonstration of spontaneous receptor clustering and downstream signalling
      in the absence of antigen would establish the mechanism in a controlled
      system.
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In addition, recent work suggests that the altered heavy chain, which
      forms part of the transmembrane B -cell receptor, may facilitate antigen
      -independent aggregation and
    explanation: >-
      Documents the state of the art: the mechanism is offered as a suggestion,
      not a demonstration, which is what leaves the gap open.
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      down-stream signaling by the receptor, thereby conferring a growth
      advantage to neoplastic cells.
    explanation: >-
      The continuation of the same sentence across a PDF page break in the
      cached review, carrying the growth-advantage claim itself. Quoted as a
      separate item because the page break makes a single contiguous quote
      impossible.
- discussion_id: hcd_population_incidence_unknown
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    What is the true population incidence of each heavy chain disease subtype,
    and how much of the reported geographic and sex skew is ascertainment bias?
  attaches_to:
  - "pathophysiology#Clonal Lymphoplasmacytic B-Cell Expansion"
  rationale: >-
    Every published figure is a cumulative literature case count (more than 400
    alpha, about 130 gamma, 30-40 mu), not a rate. Mu-HCD is explicitly suspected
    to be under-ascertained because the truncated chain is missed on serum
    protein electrophoresis, so its reported median survival of about two years
    is probably an underestimate. Without denominators, neither prognosis nor
    treatment effect can be estimated reliably.
  proposed_experiments:
  - experiment_id: hcd_international_registry
    name: International HCD registry with centralised confirmation
    description: >-
      Establish a multinational registry with centralised mass-spectrometric and
      immunofixation confirmation of every submitted case and contemporary
      outcome capture.
    decision_criterion: >-
      Denominator-based incidence estimates and outcome curves that are stable
      across contributing regions.
  - experiment_id: hcd_reflex_immunoselection_ascertainment
    name: Reflex immunoselection in discordant monoclonal gammopathies
    description: >-
      Apply systematic reflex immunoselection in laboratories reporting
      monoclonal gammopathies with discordant heavy-chain and light-chain
      quantitation, to estimate how many HCD cases current practice misses.
    decision_criterion: >-
      A measurable yield of previously unrecognised free heavy chains would
      quantify the ascertainment shortfall.
  evidence:
  - reference: PMID:29326807
    reference_title: "Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It is the most common of the three HCDs, with more than 400 cases
      described in the literature since its initial description in 1968.
    explanation: >-
      Illustrates that the best available epidemiological figures are cumulative
      literature case counts rather than population rates.
- discussion_id: hcd_campylobacter_causality
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Is Campylobacter jejuni causal in alpha-HCD/IPSID, or a marker of the poor
    sanitation and polymicrobial enteric colonisation that constitute the real
    antigenic drive?
  attaches_to:
  - "pathophysiology#Chronic Enteric Antigenic Stimulation"
  rationale: >-
    The C. jejuni association is well documented and antibiotic responsiveness is
    consistent with an antigen-driven mechanism, but reviewers explicitly note
    controversy about the organism's pathogenetic role, and contemporary cases
    have found several concomitant enteric pathogens rather than C. jejuni alone.
    Resolving this determines whether targeted eradication or broad
    decolonisation is the rational therapy.
  proposed_experiments:
  - experiment_id: hcd_ipsid_metagenomics
    name: Metagenomic sequencing of IPSID small-bowel biopsies
    description: >-
      Sequence the small-bowel microbiome of IPSID patients and geographically
      matched controls to test whether C. jejuni is specifically enriched
      relative to overall enteric microbial burden.
    decision_criterion: >-
      Specific enrichment of C. jejuni beyond the general increase in enteric
      burden would support a causal role.
  - experiment_id: hcd_targeted_eradication_cohort
    name: Organism-specific eradication versus histological remission
    description: >-
      Prospectively correlate documented organism-specific eradication with
      histological remission versus persistence in a multicentre IPSID cohort.
    decision_criterion: >-
      Remission tracking C. jejuni clearance specifically, rather than broad
      antimicrobial exposure, would support causality.
  evidence:
  - reference: PMID:29372346
    reference_title: Heavy Chain Disease of the Small Bowel.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A link between Campylobacter jejuni infection and IPSID has been
      established, but there is controversy as to the role played by this
      organism in disease pathogenesis.
    explanation: >-
      States the controversy explicitly, which is the gap this discussion
      records.
notes: >-
  Modelling decisions. (1) The CH1 mechanism is modelled as an explicit five-node
  causal chain - somatic IGH deletion, loss of CH1 and failure of light-chain
  pairing, escape from BiP-dependent ER quality control, secretion of the
  truncated chain, and the excess free light chains that follow in mu-HCD -
  because it is the single lesion that unifies three clinically dissimilar
  diseases. (2) Conformance to `tumor_promoting_inflammation` is claimed only at
  the module's `Chronic Inflammatory Stimulus` node, for the alpha-HCD enteric
  infection and gamma-HCD autoimmune triggers. Conformance to the module's
  `Pro-Tumorigenic Inflammatory Microenvironment` node was deliberately NOT
  claimed: that node is defined by tumour-associated macrophages, neutrophils,
  and mast cells secreting growth and pro-angiogenic factors, and no such
  myeloid-microenvironment evidence exists for HCD. (3) The Ria 2018 review names
  the ER chaperone "HSP78"; this is a naming slip for BiP/GRP78 (HSPA5), and the
  chaperone identity in this entry is taken from the primary sources (Vanhove
  2001, Feige 2009, Vergneault 2021) rather than from the review. (4) Heavy chain
  deposition disease (MONDO:0019728) and heavy chain amyloidosis are curated here
  only as differential diagnoses; they share the CH1 lesion but deposit in tissue
  rather than circulating, and are separate entities. (5) The cached full text of
  PMID:33596645 renders Greek mu as the Latin letter "m" throughout (m-HCD,
  m-heavy chain); snippets quoted from it preserve that rendering. (6) The ICD-O
  morphology assignment uses `Lymphoma` because the closed enum has no value for
  ICDO:9762/3 (heavy chain disease); see the `classifications.notes`. (7)
  Nosological tension, recorded rather than resolved: MONDO places
  MONDO:0019464 under MONDO:0004959 plasma cell neoplasm, and `parents` records
  that placement faithfully. The primary literature disagrees - Ria 2018 states
  "Each HCD appears to represent an unusual variant of a type of lymphoma, and
  none of them can be defined a true plasma cell neoplasms" - and Wahner-Roedler
  & Kyle likewise classify the HCDs as non-Hodgkin lymphoma variants. The
  `categories` list and the ICD-O assignment therefore follow the literature
  (lymphoplasmacytic/lymphoma), while `parents` follows MONDO. This is a
  candidate MONDO placement issue rather than a curation error in this entry.
  (8) Villous atrophy is deliberately curated twice: as a `histopathology`
  finding (the microscopic observation, bound to NCIT:C38731) and as a
  `phenotypes` entry (bound to HP:0011473), because `histopathology` entries are
  not nodes in the causal graph and the infiltration -> villous atrophy ->
  malabsorption chain would otherwise dangle.

📚

References & Deep Research

References

2

PMID:29326807

Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update.

No top-level findings curated for this source.

PMID:16026747

Heavy chain diseases.

No top-level findings curated for this source.

Deep Research

1

Falcon ▸

Heavy-Chain Disease: Disease-Characteristics Research Report

Edison Scientific Literature 14 citations 2026-08-01T05:07:22.730754

Heavy-Chain Disease: Disease-Characteristics Research Report

Executive summary

Heavy-chain diseases (HCDs) are three exceptionally rare, acquired B-cell neoplasms that secrete a monoclonal immunoglobulin heavy chain lacking an associated light chain: α-HCD (IgA; usually immunoproliferative small-intestinal disease/IPSID), γ-HCD (IgG; Franklin disease), and μ-HCD (IgM). They are not inherited antibody deficiencies, camelid “heavy-chain-only antibodies,” or heavy-chain deposition disease, a separate monoclonal immunoglobulin deposition nephropathy. The strongest modern synthesis located was Ria, Dammacco, and Vacca, published 1 January 2018, DOI 10.4084/MJHID.2018.011. It states: “The heavy chain diseases (HCDs) are rare B-cell malignancies characterized by the production of a monoclonal immunoglobulin heavy chain without an associated light chain.” (ria2018heavychaindiseasesand pages 1-2)

The evidence base consists mainly of historical cohorts, pathology series, and case reports. Recent 2023–2024 literature remains case-based; no HCD-specific prospective interventional trial, validated molecular-risk model, or standardized treatment guideline was identified. The review’s central expert conclusion remains: “No standardized therapies are available for the HCDs, because of their rarity.” (ria2018heavychaindiseasesand pages 4-6)

1. Disease information

Definition, category, and identifiers

Category: rare acquired mature B-cell/lymphoplasmacytic neoplasm; monoclonal gammopathy; α-HCD/IPSID is an extranodal marginal-zone lymphoma of mucosa-associated lymphoid tissue.
Preferred umbrella name: heavy-chain disease.
Subtypes/synonyms:
α-heavy-chain disease, alpha-chain disease, IgA HCD, IPSID, immunoproliferative small-intestinal disease, Mediterranean lymphoma.
γ-heavy-chain disease, gamma-chain disease, IgG HCD, Franklin disease.
μ-heavy-chain disease, mu-chain disease, IgM HCD.
Ontology suggestions: MONDO’s precise current identifier should be verified directly against the live MONDO release before ingestion; recommended concepts are heavy chain disease, alpha heavy chain disease, gamma heavy chain disease, and mu heavy chain disease. MeSH concept: Heavy Chain Disease. ICD coding is generally nested under immunoproliferative neoplasms rather than providing robust subtype-specific clinical granularity; verify against the jurisdiction/version in use.
Data provenance: published information is aggregated at disease level from case reports and small retrospective/prospective series—not patient-specific EHR data in this report.

Historical reporting totals were >400 α-HCD cases since 1968, approximately 130 γ-HCD cases, and only 30–40 μ-HCD cases. These are literature case counts, not prevalence estimates. (ria2018heavychaindiseasesand pages 1-2, ria2018heavychaindiseasesand pages 2-4)

Subtype / synonyms	Immunoglobulin product	Typical demographic and organ sites	Hallmark phenotype / pathology	Diagnostic signature	Treatment	Prognosis / statistics
α-heavy-chain disease (α-HCD); immunoproliferative small intestinal disease (IPSID); Mediterranean lymphoma	Truncated monoclonal IgA heavy chain without associated light chain (ria2018heavychaindiseasesand pages 1-2, ria2018heavychaindiseasesand pages 2-4)	Approx. historical case count: >400 reported since 1968; most prevalent in 2nd-3rd decades, slight male predominance; mainly Mediterranean, North African, Middle Eastern populations of low socioeconomic background; primarily proximal small bowel (duodenum/jejunum), rarely respiratory tract (ria2018heavychaindiseasesand pages 1-2, ria2018heavychaindiseasesand pages 2-4)	Malabsorption syndrome with weight loss, diarrhea, abdominal discomfort, growth retardation, amenorrhea, alopecia; advanced disease may show ascites/anasarca. Histology is extranodal marginal zone/MALT lymphoma with lamina propria lymphoplasmacytic infiltrate, villous atrophy, ± lymphoepithelial lesions; associated bowel infection by Campylobacter jejuni or Helicobacter pylori may occur (ria2018heavychaindiseasesand pages 1-2, ria2018heavychaindiseasesand pages 2-4)	Serum electrophoresis may be normal, hypogammaglobulinemic, or show a broad band in α2/β region; anti-IgA immunofixation positivity is mandatory; abnormal α chains may be found in jejunal/gastric fluids or small amounts in urine; endoscopy often shows infiltrative or nodular proximal small-bowel lesions (ria2018heavychaindiseasesand pages 2-4, ria2018heavychaindiseasesand pages 4-6)	Eradicate documented GI infection; empiric metronidazole, ampicillin, or tetracycline often used for 6 months. Refractory disease: total abdominal radiation or doxorubicin-containing chemotherapy (CHOP, CHVP, ABV); surgery mainly for complications (ria2018heavychaindiseasesand pages 4-6, ria2018heavychaindiseasesand pages 6-7)	33-71% of early-stage patients achieve clinical/laboratory/histologic remission with antimicrobials, but recurrences are frequent. Multi-drug chemotherapy: 64% complete remission, 67% 5-year overall survival. Untreated disease can progress locally then systemically; fatal complications include obstruction, perforation, intussusception, malnutrition/cachexia, infection (ria2018heavychaindiseasesand pages 4-6, ria2018heavychaindiseasesand pages 6-7)
γ-heavy-chain disease (γ-HCD); Franklin disease	Truncated monoclonal IgG heavy chain without associated light chain (ria2018heavychaindiseasesand pages 1-2, ria2018heavychaindiseasesand pages 4-6)	Approx. historical case count: ~130 reported; age at diagnosis 51-68 years with female predominance; common sites include bone marrow, spleen, lymph nodes, and extranodal sites such as skin, thyroid, salivary glands, GI tract, conjunctiva (ria2018heavychaindiseasesand pages 1-2, ria2018heavychaindiseasesand pages 4-6)	Often linked to lymphoplasmacytic neoplasm (83-91%); 25% have autoimmune disease (especially rheumatoid arthritis). Clinical patterns include disseminated lymphoma with constitutional symptoms (57-66%), generalized lymphadenopathy/splenomegaly/hepatomegaly (50%), or localized medullary/extramedullary disease (~25%). Histology is heterogeneous with mixed lymphocytes, plasmacytoid lymphocytes, plasma cells, sometimes immunoblasts/eosinophils/histiocytes and occasional Reed-Sternberg-like cells (ria2018heavychaindiseasesand pages 1-2, ria2018heavychaindiseasesand pages 2-4, ria2018heavychaindiseasesand pages 4-6)	Serum electrophoresis may be normal or show a β-region monoclonal band; anti-IgG immunofixation positivity without light chains is mandatory. Abnormal γ chains are often detectable in urine due to low molecular weight/dimerization. Lab clues include cytopenias, Coombs-positive hemolysis, thrombocytopenia, circulating plasmacytoid cells/plasma cells (ria2018heavychaindiseasesand pages 2-4, ria2018heavychaindiseasesand pages 4-6)	Management tailored to symptoms, autoimmune disease, and lymphoma burden. Options include chlorambucil, melphalan + prednisone, bortezomib + prednisone, rituximab for CD20+ disease; CHOP ± rituximab for aggressive/refractory cases; fludarabine + rituximab reported effective in pancytopenic disease. Localized extranodal disease may be treated with surgery or radiation; asymptomatic patients without lymphoma may be observed (ria2018heavychaindiseasesand pages 6-7, ria2018heavychaindiseasesand pages 4-6)	Course is heterogeneous. Some patients without overt lymphoma have spontaneous remissions and prolonged survival without treatment; treated localized lymphoma often reaches sustained complete remission. Systemic lymphoma may be aggressive or indolent. Median survival 7.4 years (range 1 month to >2 decades) in the Mayo series (ria2018heavychaindiseasesand pages 6-7, ria2018heavychaindiseasesand pages 4-6)
μ-heavy-chain disease (μ-HCD)	Truncated monoclonal IgM heavy chain; neoplastic cells often also produce monoclonal light chains, usually κ, that fail to assemble with the truncated heavy chain (ria2018heavychaindiseasesand pages 2-4, ria2018heavychaindiseasesand pages 4-6)	Approx. historical case count: 30-40 reported; predominantly Caucasian males, median age 58 years; mainly bone marrow, often with features resembling CLL/SLL; splenomegaly frequent, hepatomegaly in ~25%, superficial lymphadenopathy in 40% (ria2018heavychaindiseasesand pages 2-4)	Usually a lymphoid neoplasm with CLL/SLL-like features. Characteristic marrow morphology shows plasma cells with prominent cytoplasmic vacuoles admixed with small round lymphocytes. Reported associations include recurrent pulmonary infections, portal hypertension, pancytopenia, SLE, DLBCL of the breast, MDS, carpal tunnel syndrome, systemic amyloidosis (ria2018heavychaindiseasesand pages 2-4, ria2018heavychaindiseasesand pages 4-6)	Serum electrophoresis generally normal or shows a broad monoclonal band; anti-μ immunofixation positive and anti-κ/anti-λ negative confirms the heavy-chain component. Bence Jones proteinuria is frequent because excess light chains are produced but do not assemble; hypoproliferative anemia is the commonest lab abnormality (ria2018heavychaindiseasesand pages 2-4, ria2018heavychaindiseasesand pages 4-6)	Because of rarity, data are limited. Watch-and-wait for asymptomatic patients with detectable monoclonal μ chains. If underlying malignancy develops: CHOP, CVP, single-agent fludarabine, or cyclophosphamide have been used (ria2018heavychaindiseasesand pages 6-7)	Reported median overall survival ~2 years, ranging from <1 month to >10 years; likely underestimated because monoclonal μ chains are often missed on electrophoresis. Rare spontaneous remission reported (ria2018heavychaindiseasesand pages 6-7)

Table: This table compares the three classic heavy-chain disease subtypes using only data extracted from the Ria 2018 full text. It is useful for quickly distinguishing epidemiology, pathology, diagnostic hallmarks, treatments, and available outcome statistics in these very rare disorders.

2. Etiology and risk/protective factors

Causal factors

HCD is an acquired clonal disorder, not a recognized Mendelian disease. The defining molecular lesions are somatically acquired deletions, insertions, and point mutations in rearranged immunoglobulin heavy-chain genes, usually removing much of the constant-1 (CH1) domain required for light-chain binding. The lesions arise in the context of somatic diversification of a mature B-cell clone. (ria2018heavychaindiseasesand pages 1-2)

α-HCD/IPSID: chronic mucosal antigenic stimulation is the leading model. It is associated with poverty and poor sanitation in Mediterranean, North African, and Middle Eastern populations. Enteric bacteria or parasites—including Campylobacter jejuni and sometimes Helicobacter pylori—have been detected in affected patients. The landmark C. jejuni association was reported by Lecuit et al., New England Journal of Medicine 2004, DOI 10.1056/NEJMoa031887. Association and antibiotic responsiveness support an antigen-driven mechanism, but neither organism is demonstrated to be necessary or sufficient in every case. (ria2018heavychaindiseasesand pages 2-4, ria2018heavychaindiseasesand pages 8-9)

γ-HCD: autoimmune disease is an important clinical context. Approximately 25% have rheumatoid arthritis or, less often, Sjögren syndrome, systemic lupus erythematosus, vasculitis, myasthenia gravis, or autoimmune cytopenia; autoimmunity may precede HCD by years. A lymphoplasmacytic neoplasm is present in 83–91%. (ria2018heavychaindiseasesand pages 1-2)

μ-HCD: no consistent environmental or infectious cause is established. It most often accompanies a CLL/SLL-like marrow neoplasm. (ria2018heavychaindiseasesand pages 2-4)

Risk and protective factors

Supported risk contexts: low socioeconomic conditions/enteric infection for α-HCD; older age, female sex, autoimmune disease, and lymphoplasmacytic neoplasia for γ-HCD; older Caucasian male demographic and CLL/SLL-like neoplasia for μ-HCD. Demographic enrichment must not be interpreted as causal.
Genetic susceptibility: no validated germline causal variant, GWAS locus, penetrance estimate, founder mutation, carrier frequency, or modifier gene is established specifically for HCD.
Protective factors: no validated protective allele, diet, medication, or lifestyle intervention exists. Improved sanitation is biologically and epidemiologically plausible for reducing α-HCD, but has not been quantified in controlled prevention studies. (ria2018heavychaindiseasesand pages 4-6)
Gene–environment interaction: a plausible but unquantified model is chronic microbial antigen exposure acting on mucosal B cells that subsequently acquire clone-defining IGH lesions. No formal HCD-specific G×E study was identified.

3. Phenotypes

α-HCD/IPSID

Onset is usually in the second or third decade, with slight male predominance. It is chronic and often insidious. Hallmark manifestations are diarrhea, abdominal discomfort, nausea/vomiting, malabsorption, weight loss, growth retardation, amenorrhea, and alopecia. Advanced disease can cause ascites, anasarca, clubbing, tetany, obstruction, perforation, or intussusception. Laboratory abnormalities include hypochromic anemia, hypoalbuminemia, hypocalcemia, hypokalemia, hypomagnesemia, vitamin/mineral deficiency, and increased intestinal alkaline phosphatase. Rare respiratory α-HCD produces dyspnea, hypoxemia, diffuse infiltrates, and restrictive pulmonary physiology. (ria2018heavychaindiseasesand pages 2-4, ria2018heavychaindiseasesand pages 1-2)

Suggested HPO annotations include Diarrhea (HP:0002014), Malabsorption (HP:0002024), Weight loss (HP:0001824), Abdominal pain (HP:0002027), Anemia (HP:0001903), Hypoalbuminemia (HP:0003073), Ascites (HP:0001541), Generalized edema (HP:0000969), Intestinal obstruction (HP:0005214), Lymphadenopathy (HP:0002716), Hepatomegaly (HP:0002240), Splenomegaly (HP:0001744), and Growth delay (HP:0001510). Exact ontology IDs should be validated in the target HPO release.

γ-HCD

Age at diagnosis is typically 51–68 years, with female predominance. Disseminated lymphoma with fever, malaise, and weight loss occurs in 57–66%; generalized lymphadenopathy, hepatomegaly, or splenomegaly occurs in about 50%; approximately 25% have localized medullary or extramedullary disease. Cytopenias, normocytic anemia, Coombs-positive autoimmune hemolytic anemia, thrombocytopenia, and circulating plasmacytoid lymphocytes may occur. Skin, thyroid, salivary gland, gastrointestinal tract, and conjunctiva can be involved. (ria2018heavychaindiseasesand pages 2-4, ria2018heavychaindiseasesand pages 1-2)

Suggested HPO terms: Fever (HP:0001945), Fatigue (HP:0012378), Weight loss, Lymphadenopathy, Hepatomegaly, Splenomegaly, Autoimmune hemolytic anemia (HP:0001890), Thrombocytopenia (HP:0001873), Pancytopenia (HP:0001876), and Arthritis (HP:0001369).

μ-HCD

Median diagnosis age is about 58 years; reported patients are predominantly Caucasian men. Hypoproliferative anemia is the commonest laboratory abnormality. Splenomegaly is frequent, superficial lymphadenopathy occurs in 40%, and hepatomegaly in about 25%. Marrow plasma cells with prominent cytoplasmic vacuoles are characteristic. Rare associations include recurrent pulmonary infection, portal hypertension, pancytopenia, SLE, myelodysplasia, amyloidosis, and other lymphomas. (ria2018heavychaindiseasesand pages 2-4, ria2018heavychaindiseasesand pages 4-6)

Suggested HPO terms: Anemia, Splenomegaly, Lymphadenopathy, Hepatomegaly, Recurrent respiratory infections (HP:0002205), Pancytopenia, and Abnormality of bone marrow cell morphology (HP:0012145).

Quality of life

No HCD-specific EQ-5D, SF-36, PROMIS, or validated quality-of-life study was identified. Nevertheless, chronic diarrhea, severe malnutrition, abdominal complications, constitutional symptoms, cytopenias, infection, and chemotherapy predict substantial functional burden. This is clinical inference, not a measured HCD-specific utility estimate.

4. Genetic and molecular information

The relevant loci are the rearranged immunoglobulin heavy-chain genes at IGH, chromosome 14q32.33: principally IGHA1/IGHA2, IGHG subclass genes, or IGHM, depending on subtype. These are clone-specific somatic rearrangements/structural defects, not constitutional pathogenic variants suitable for Mendelian ClinVar classification. Consequently, germline allele frequencies in gnomAD and ACMG carrier classifications are generally not applicable.

The altered chains contain deletions, insertions, or point mutations that typically disrupt CH1. In normal cells, an unpaired heavy chain binds the endoplasmic-reticulum chaperone BiP/GRP78 (HSPA5 in modern nomenclature; the review uses “HSP78”) and is retained/degraded. CH1-defective chains fail to bind both light chain and chaperone, escape proteasomal quality control, and are secreted into serum or urine. A membrane form may aggregate and signal without antigen, conferring clonal growth advantage. (ria2018heavychaindiseasesand pages 1-2)

No recurrent disease-defining cytogenetic translocation, somatic mutation panel, validated modifier gene, methylation signature, or HCD-specific pathogenic-variant catalogue was identified. Molecular testing of clonality or the abnormal IG transcript can support difficult cases, but routine diagnosis remains protein- and pathology-based.

5. Environmental and infectious information

For α-HCD, poor sanitation and chronic intestinal infection are the principal environmental contexts. C. jejuni is the best-supported organism; parasites and H. pylori have also been reported. The causal chain proposed from human clinical/pathological evidence is: chronic enteric antigen exposure → sustained mucosal B-cell/plasma-cell stimulation → emergence/selection of a monoclonal IGHA-abnormal clone → IPSID/MALT-type infiltration → villous atrophy and malabsorption → progressive lymphoma in untreated disease. (ria2018heavychaindiseasesand pages 2-4, ria2018heavychaindiseasesand pages 4-6, ria2018heavychaindiseasesand pages 8-9)

No reproducible association with smoking, alcohol, occupational toxins, radiation, or pollution is established. There is no evidence that HCD is contagious or zoonotic.

6. Mechanism and pathophysiology

Upstream events

Mature B-cell/plasmacytic clone acquires an abnormal rearranged heavy-chain gene.
CH1 loss or disruption prevents light-chain assembly and ER chaperone retention.
Truncated heavy chain is secreted; possible autonomous B-cell-receptor aggregation promotes survival/proliferation. (ria2018heavychaindiseasesand pages 1-2)

Downstream tissue mechanisms

α-HCD: monoclonal α-chain-positive plasma cells and marginal-zone-like B cells infiltrate small-intestinal lamina propria, producing villous atrophy and sometimes lymphoepithelial lesions. Malabsorption then causes protein, electrolyte, vitamin, and mineral deficiencies. Continued expansion can lead to bulky or transformed lymphoma and mechanical bowel complications. (ria2018heavychaindiseasesand pages 2-4)
γ-HCD: heterogeneous lymphoplasmacytic infiltration affects marrow, lymph nodes, spleen, and extranodal MALT-type sites; autoimmune inflammation may be upstream, concurrent, or downstream, but directionality is unresolved. (ria2018heavychaindiseasesand pages 4-6)
μ-HCD: a CLL/SLL-like marrow clone produces truncated μ chains, often alongside unassembled κ light chains; marrow infiltration causes anemia/cytopenias. (ria2018heavychaindiseasesand pages 4-6)

Suggested GO biological-process terms include B-cell receptor signaling pathway (GO:0050853), immunoglobulin production (GO:0002377), somatic hypermutation of immunoglobulin genes, B-cell proliferation (GO:0042100), plasma-cell differentiation (GO:0002317), response to bacterium (GO:0009617), and regulation of proteasomal protein catabolic process. Suggested cellular components are endoplasmic reticulum lumen (GO:0005788), proteasome complex (GO:0000502), B-cell receptor complex (GO:0019815), and extracellular region (GO:0005576).

Suggested Cell Ontology populations are B cell (CL:0000236), plasma cell (CL:0000786), lymphocyte of B lineage, marginal-zone B cell, and plasmacytoid lymphocyte. Exact IDs for narrower cell classes should be checked in the current CL release.

No validated HCD-specific transcriptomic, proteomic, metabolomic, lipidomic, single-cell, spatial-transcriptomic, multi-omic, or CRISPR-screen signature was identified. Clinical immunofixation is a targeted protein assay, not comprehensive proteomics.

7. Anatomical structures affected

α-HCD: duodenum and jejunum are primary; more distal bowel, abdominal lymphatics, and rarely respiratory tract/pharyngeal mucosa are involved. Suggested UBERON concepts: small intestine (UBERON:0002108), duodenum (UBERON:0002114), jejunum (UBERON:0002115), intestinal mucosa, lamina propria, and lung (UBERON:0002048).
γ-HCD: bone marrow, spleen, lymph nodes, skin, thyroid, salivary gland, gastrointestinal tract, and conjunctiva.
μ-HCD: primarily bone marrow, with spleen, liver, and lymph nodes secondarily involved.

Subcellular compartments include the ER/proteasome during heavy-chain quality control, the plasma membrane BCR, cytoplasm of plasma cells, and extracellular serum/urine. Lateralization is not characteristic. (ria2018heavychaindiseasesand pages 2-4, ria2018heavychaindiseasesand pages 4-6, ria2018heavychaindiseasesand pages 1-2)

8. Temporal development

α-HCD usually begins insidiously in young adulthood. Untreated disease can progress from mucosal/local disease to systemic lymphoma; early antigen-dependent disease is most antibiotic-responsive. γ-HCD ranges from an indolent monoclonal gammopathy or localized lesion to rapidly progressive disseminated lymphoma. μ-HCD is similarly variable but generally occurs in later adulthood. Rare spontaneous remission is documented in γ- and μ-HCD; treatment-induced durable remission is most likely in localized γ-HCD. (ria2018heavychaindiseasesand pages 6-7, ria2018heavychaindiseasesand pages 4-6)

No universally accepted HCD staging system exists. For IPSID, historical pathological staging has been used, while overt lymphoma should be staged according to the corresponding lymphoma classification. The clinically important intervention window is early α-HCD before bulky or transformed disease, when prolonged antimicrobial treatment can induce histological as well as clinical remission.

9. Inheritance, epidemiology, and population

HCD is sporadic and acquired. Autosomal/X-linked inheritance, penetrance, anticipation, germline mosaicism, founder variants, consanguinity, carrier frequency, and reproductive genetic risk are not applicable based on present evidence.

No reliable population incidence or prevalence per 100,000 exists. Historical case totals are the most defensible numbers: >400 α-HCD, ~130 γ-HCD, and 30–40 μ-HCD. α-HCD is geographically concentrated in Mediterranean, North African, and Middle Eastern regions and lower-socioeconomic populations; γ-HCD has female predominance at ages 51–68; μ-HCD predominantly affects older men. (ria2018heavychaindiseasesand pages 1-2, ria2018heavychaindiseasesand pages 2-4)

These distributions may reflect ascertainment and publication bias. Modern population-based estimates are a major unmet need.

10. Diagnostics

Recommended workflow

Clinical suspicion: malabsorption/young endemic-region patient; unexplained lymphoplasmacytic lymphoma plus autoimmune disease; or CLL/SLL-like marrow disease with unusual paraprotein.
Serum protein electrophoresis plus serum and urine immunofixation. Electrophoresis can be normal, and therefore cannot exclude HCD.
Demonstrate an isotype-specific heavy chain—anti-IgA, anti-IgG, or anti-μ reactivity—without corresponding κ or λ light chain. Two-dimensional immunoelectrophoresis is historically useful. (ria2018heavychaindiseasesand pages 2-4, ria2018heavychaindiseasesand pages 4-6)
Quantitative immunoglobulins, serum free light chains, CBC, chemistry, albumin, calcium/magnesium/potassium, nutritional assessment, and urine protein studies.
Tissue biopsy with morphology, immunohistochemistry/immunofluorescence, and flow cytometry. α-HCD requires upper endoscopy and multiple duodenal/jejunal biopsies; infiltrative and nodular patterns are most characteristic. Search biopsy/stool for bacteria and parasites. (ria2018heavychaindiseasesand pages 2-4)
CT or PET/CT and marrow biopsy as indicated to define lymphoma distribution. Molecular B-cell clonality studies may support ambiguous cases.

α-HCD electrophoresis may be normal, hypogammaglobulinemic, or show a broad α2/β-region band. γ-HCD commonly hides in the β region and its low-molecular-weight dimers are often detectable in urine. μ-HCD may have normal electrophoresis; Bence-Jones proteinuria is frequent because separate κ chains may be produced. (ria2018heavychaindiseasesand pages 2-4, ria2018heavychaindiseasesand pages 4-6)

Pathology and differential diagnosis

α-HCD resembles MALT lymphoma with α-chain-positive/light-chain-negative plasma cells and marginal-zone cells. Differentials include celiac disease, tropical sprue, giardiasis, common variable immunodeficiency enteropathy, Crohn disease, intestinal tuberculosis, conventional MALT lymphoma, enteropathy-associated T-cell lymphoma, and diffuse large B-cell lymphoma.

γ-HCD can mimic lymphoplasmacytic lymphoma, marginal-zone lymphoma, plasma-cell neoplasm, Hodgkin lymphoma, or peripheral T-cell lymphoma because Reed–Sternberg-like cells and polymorphous infiltrates may occur. μ-HCD overlaps CLL/SLL and Waldenström macroglobulinemia; the decisive feature is free truncated μ heavy chain without assembled light chain. (ria2018heavychaindiseasesand pages 4-6)

Genetic testing: WES/WGS, germline panels, chromosomal microarray, mitochondrial testing, and repeat-expansion testing are not routine or validated. Targeted IG rearrangement sequencing may be used in specialist investigation but does not replace immunofixation and biopsy.

Screening: no population, newborn, carrier, or cascade screening is recommended.

11. Outcome and prognosis

For early α-HCD, antimicrobial therapy produces clinical, laboratory, and histological remission in 33–71%, although recurrence is frequent. Historical multidrug chemotherapy achieved 64% complete remission and 67% five-year overall survival. Fatal pathways include progressive lymphoma, bowel obstruction/perforation/intussusception, severe malnutrition/cachexia, and infection. (ria2018heavychaindiseasesand pages 6-7, ria2018heavychaindiseasesand pages 4-6)

γ-HCD prognosis depends on the associated neoplasm. Localized treated disease can enter sustained complete remission; systemic disease may be aggressive or indolent. A Mayo Clinic series reported median survival of 7.4 years, ranging from one month to more than two decades. (ria2018heavychaindiseasesand pages 6-7)

Reported μ-HCD median survival is approximately two years, ranging from under one month to over ten years, but this likely underestimates survival because monoclonal μ chains are often missed. (ria2018heavychaindiseasesand pages 6-7)

No validated molecular prognostic biomarker or contemporary multivariable risk calculator exists. Adverse clinical factors are advanced/systemic lymphoma, transformation, severe malnutrition, cytopenias, infection, and refractory disease.

12. Treatment and current applications

Treatment is adapted from infection-associated MALT lymphoma and related B-cell neoplasms rather than derived from randomized HCD trials.

α-HCD

Eradicate identified bacterial or parasitic infection and correct nutrition/electrolytes.
Historical empiric regimens include metronidazole, ampicillin, or tetracycline for approximately six months; shorter courses relapse more often. These historical choices require current susceptibility, safety, and antimicrobial-stewardship review. (ria2018heavychaindiseasesand pages 4-6)
Persistent, advanced, or transformed disease: doxorubicin-containing chemotherapy such as CHOP, with lymphoma-directed anti-CD20 therapy where biologically appropriate. CHVP and ABV are historical regimens. Radiation is occasionally used; surgery is reserved mainly for obstruction, perforation, intussusception, bleeding, or diagnostic need. (ria2018heavychaindiseasesand pages 6-7, ria2018heavychaindiseasesand pages 4-6)

γ-HCD

Asymptomatic, non-lymphomatous disease: observation can be appropriate.
Treat associated autoimmune disease according to standard disease-specific guidance.
Plasma-cell-predominant disease: historical chlorambucil or melphalan/prednisone; bortezomib/prednisone has been used.
CD20-positive/aggressive disease: rituximab-containing therapy, commonly R-CHOP; fludarabine–rituximab has case-report support. Localized extranodal disease may receive radiation or surgery. (ria2018heavychaindiseasesand pages 6-7)

μ-HCD

Watchful waiting for an asymptomatic patient with detectable μ chain.
If symptomatic lymphoma develops: reported regimens include CHOP, CVP, fludarabine, or cyclophosphamide. Evidence is limited to very small numbers. (ria2018heavychaindiseasesand pages 6-7)

Suggested NCIt intervention concepts include Antibiotic Therapy, Metronidazole, Ampicillin, Tetracycline, CHOP Regimen, Rituximab, Bortezomib, Fludarabine, Radiation Therapy, Surgical Procedure, Hematopoietic Stem Cell Transplantation, Best Supportive Care, and Active Surveillance; exact NCIt codes should be resolved against the current release. Relevant chemical ontology concepts include ampicillin (CHEBI:28971), metronidazole (CHEBI:6909), and tetracycline (CHEBI:27902), with release verification advised.

No HCD-specific gene therapy, RNA therapy, CAR-T protocol, approved precision biomarker, pharmacogenomic recommendation, or registered disease-specific prospective trial was identified in the searches. High-dose therapy/autologous transplantation has been considered for refractory or relapsed α-HCD, but is not supported by trial-level evidence. (ria2018heavychaindiseasesand pages 6-7)

13. Prevention

Primary prevention: no proven intervention. Sanitation, safe food/water, and prompt treatment of enteric infection are plausible for α-HCD but have not been shown to prevent HCD prospectively.
Secondary prevention: no asymptomatic population screening. In symptomatic high-risk settings, early endoscopy, biopsy, and immunofixation may prevent delay and permit antibiotic-responsive treatment.
Tertiary prevention: eradicate infection, restore nutrition, monitor electrolytes and albumin, vaccinate appropriately for immunocompromised patients, prevent/treat infection, and surveil for lymphoma progression, transformation, bowel complications, and treatment toxicity.
No HCD vaccine, chemoprophylaxis, genetic counseling indication, prenatal diagnosis, or preimplantation testing applies.

14. Other species and natural disease

No well-established naturally occurring veterinary counterpart of human α-, γ-, or μ-HCD was identified, and no zoonotic transmission exists. Immunoglobulin heavy-chain orthologues are widely conserved, but naturally occurring heavy-chain-only antibodies in camelids are normal physiology and not homologous disease. C. jejuni has animal reservoirs, but human IPSID is not itself transmissible from animals.

Suggested taxa for mechanistic context—not natural HCD annotation—include Homo sapiens (NCBI Taxon 9606), Campylobacter jejuni (Taxon 197), and Helicobacter pylori (Taxon 210), with strain-level identifiers used where available.

15. Model organisms and research gaps

No validated mouse, rat, zebrafish, invertebrate, organoid, or iPSC model was identified that recapitulates the full human disease: clone-specific truncated heavy-chain secretion, relevant tissue tropism, chronic infection/autoimmunity, and lymphoma evolution. General B-cell lymphoma lines, engineered CH1-deleted immunoglobulin constructs, intestinal organoids with immune co-culture, and infection models could interrogate individual mechanisms, but they are reductionist rather than faithful HCD models.

Priority research needs are: an international registry with contemporary incidence and outcomes; centralized mass-spectrometric/immunofixation confirmation; paired tumor-normal long-read IGH sequencing; microbial metagenomics in IPSID; single-cell BCR/transcriptomic profiling; standardized response criteria; and prospective antibiotic-versus-lymphoma-directed treatment studies.

Evidence-quality and recency assessment

The principal quantitative evidence remains historical because HCD is exceptionally rare. Key primary sources include Lecuit et al. on C. jejuni–associated IPSID, DOI 10.1056/NEJMoa031887; Bieliauskas et al.’s 13-case γ-HCD pathology series, DOI 10.1097/PAS.0b013e318240590a; and the Turkish five-year IPSID cohort cited in the 2018 review. (ria2018heavychaindiseasesand pages 8-9)

A 2024 report of gastrointestinal α-HCD with persistent C. jejuni colonization and refractory giardiasis—DOI 10.14309/crj.0000000000001467—illustrates that infection-associated, diagnostically difficult IPSID persists, but a single case cannot update population-level efficacy estimates. The absence of robust 2023–2024 cohorts, trials, omics studies, and quality-of-life datasets is itself an important finding: current management remains expert, pathology-driven, and individualized rather than guideline-standardized.

References

(ria2018heavychaindiseasesand pages 1-2): Roberto Ria, Franco Dammacco, and Angelo Vacca. Heavy-chain diseases and myeloma-associated fanconi syndrome: an update. Mediterranean Journal of Hematology and Infectious Diseases, 10:2018011, Jan 2018. URL: https://doi.org/10.4084/mjhid.2018.011, doi:10.4084/mjhid.2018.011. This article has 19 citations.
(ria2018heavychaindiseasesand pages 4-6): Roberto Ria, Franco Dammacco, and Angelo Vacca. Heavy-chain diseases and myeloma-associated fanconi syndrome: an update. Mediterranean Journal of Hematology and Infectious Diseases, 10:2018011, Jan 2018. URL: https://doi.org/10.4084/mjhid.2018.011, doi:10.4084/mjhid.2018.011. This article has 19 citations.
(ria2018heavychaindiseasesand pages 2-4): Roberto Ria, Franco Dammacco, and Angelo Vacca. Heavy-chain diseases and myeloma-associated fanconi syndrome: an update. Mediterranean Journal of Hematology and Infectious Diseases, 10:2018011, Jan 2018. URL: https://doi.org/10.4084/mjhid.2018.011, doi:10.4084/mjhid.2018.011. This article has 19 citations.
(ria2018heavychaindiseasesand pages 6-7): Roberto Ria, Franco Dammacco, and Angelo Vacca. Heavy-chain diseases and myeloma-associated fanconi syndrome: an update. Mediterranean Journal of Hematology and Infectious Diseases, 10:2018011, Jan 2018. URL: https://doi.org/10.4084/mjhid.2018.011, doi:10.4084/mjhid.2018.011. This article has 19 citations.
(ria2018heavychaindiseasesand pages 8-9): Roberto Ria, Franco Dammacco, and Angelo Vacca. Heavy-chain diseases and myeloma-associated fanconi syndrome: an update. Mediterranean Journal of Hematology and Infectious Diseases, 10:2018011, Jan 2018. URL: https://doi.org/10.4084/mjhid.2018.011, doi:10.4084/mjhid.2018.011. This article has 19 citations.

Artifacts

Edison artifact artifact-00

Ask OpenScientist

OpenScientist Report

Classifications

Subtypes

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Histopathology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Environmental Factors

Biochemical Markers

Diagnosis

Progression

Prevalence

Epidemiology

Infectious Agent

Differential Diagnoses

Source YAML

References & Deep Research

References

Deep Research

Heavy-Chain Disease: Disease-Characteristics Research Report

Executive summary

1. Disease information

Definition, category, and identifiers

2. Etiology and risk/protective factors

Causal factors

Risk and protective factors

3. Phenotypes

α-HCD/IPSID

γ-HCD

μ-HCD

Quality of life

4. Genetic and molecular information

5. Environmental and infectious information

6. Mechanism and pathophysiology

Upstream events

Downstream tissue mechanisms

7. Anatomical structures affected

8. Temporal development

9. Inheritance, epidemiology, and population

10. Diagnostics

Recommended workflow

Pathology and differential diagnosis

11. Outcome and prognosis

12. Treatment and current applications

α-HCD

γ-HCD

μ-HCD

13. Prevention

14. Other species and natural disease

15. Model organisms and research gaps

Evidence-quality and recency assessment

Artifacts